<?xml version="1.0"?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset>
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Endocrinol Metab</journal-id>
      <journal-id journal-id-type="iso-abbrev">Indian J Endocrinol Metab</journal-id>
      <journal-id journal-id-type="publisher-id">IJEM</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Endocrinology and Metabolism</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2230-8210</issn>
      <issn pub-type="epub">2230-9500</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26904464</article-id>
      <article-id pub-id-type="pmc">4743391</article-id>
      <article-id pub-id-type="publisher-id">IJEM-20-9</article-id>
      <article-id pub-id-type="doi">10.4103/2230-8210.172273</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Diabetes insipidus: The other diabetes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kalra</surname>
            <given-names>Sanjay</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zargar</surname>
            <given-names>Abdul Hamid</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jain</surname>
            <given-names>Sunil M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sethi</surname>
            <given-names>Bipin</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chowdhury</surname>
            <given-names>Subhankar</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Singh</surname>
            <given-names>Awadhesh Kumar</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">5</xref>
          <xref ref-type="aff" rid="aff7">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thomas</surname>
            <given-names>Nihal</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Unnikrishnan</surname>
            <given-names>A. G.</given-names>
          </name>
          <xref ref-type="aff" rid="aff9">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thakkar</surname>
            <given-names>Piya Ballani</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Malve</surname>
            <given-names>Harshad</given-names>
          </name>
          <xref ref-type="aff" rid="aff11">10</xref>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <italic>Bharti Hospital and BRIDE, Karnal, Haryana, India</italic>
      </aff>
      <aff id="aff2">
        <label>1</label>
        <italic>Department of Endocrinology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India</italic>
      </aff>
      <aff id="aff3">
        <label>2</label>
        <italic>Managing Director, TOTALL Diabetes Hormone Institute, Indore, Madhya Pradesh, India</italic>
      </aff>
      <aff id="aff4">
        <label>3</label>
        <italic>Consultant Endocrinologist, CARE Hospitals, Hyderabad, Telangana, India</italic>
      </aff>
      <aff id="aff5">
        <label>4</label>
        <italic>Department of Endocrinology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India</italic>
      </aff>
      <aff id="aff6">
        <label>5</label>
        <italic>GD Diabetes Institute, Kolkata, West Bengal, India</italic>
      </aff>
      <aff id="aff7">
        <label>6</label>
        <italic>Sun Valley Diabetes and Endocrine Research Centre, Guwahati, Assam, India</italic>
      </aff>
      <aff id="aff8">
        <label>7</label>
        <italic>Department of Endocrinology, Diabetes and Metabolism and Vice-Principal (Research), Christian Medical College, Vellore, Tamil Nadu, India</italic>
      </aff>
      <aff id="aff9">
        <label>8</label>
        <italic>Chellaram Diabetes Institute, Pune, Maharashtra, India</italic>
      </aff>
      <aff id="aff10">
        <label>9</label>
        <italic>Bombay Hospital and Medical Research Centre, Mumbai, Maharashtra, India</italic>
      </aff>
      <aff id="aff11">
        <label>10</label>
        <italic>Lead Medical, Asia Pacific region, Ferring Pharmaceuticals Pvt. Ltd., Mumbai, Maharashtra, India</italic>
      </aff>
      <author-notes>
        <corresp id="cor1"><bold>Corresponding Author:</bold> Dr. Harshad Malve, Ferring Pharmaceuticals Pvt. Ltd., 24<sup>th</sup> Floor, Sunshine Towers, Senapati Bapat Marg, Dadar (West), Mumbai - 400 013, Maharashtra, India. E-mail: <email xlink:href="dr.harshad.malve@gmail.com">dr.harshad.malve@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2016</year>
      </pub-date>
      <volume>20</volume>
      <issue>1</issue>
      <fpage>9</fpage>
      <lpage>21</lpage>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Endocrinology and Metabolism</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Diabetes insipidus (DI) is a hereditary or acquired condition which disrupts normal life of persons with the condition; disruption is due to increased thirst and passing of large volumes of urine, even at night. A systematic search of literature for DI was carried out using the PubMed database for the purpose of this review. Central DI due to impaired secretion of arginine vasopressin (AVP) could result from traumatic brain injury, surgery, or tumors whereas nephrogenic DI due to failure of the kidney to respond to AVP is usually inherited. The earliest treatment was posterior pituitary extracts containing vasopressin and oxytocin. The synthetic analog of vasopressin, desmopressin has several benefits over vasopressin. Desmopressin was initially available as intranasal preparation, but now the oral tablet and melt formulations have gained significance, with benefits such as ease of administration and stability at room temperature. Other molecules used for treatment include chlorpropamide, carbamazepine, thiazide diuretics, indapamide, clofibrate, indomethacin, and amiloride. However, desmopressin remains the most widely used drug for the treatment of DI. This review covers the physiology of water balance, causes of DI and various treatment modalities available, with a special focus on desmopressin.</p>
      </abstract>
      <kwd-group>
        <kwd>Antidiuretic hormone</kwd>
        <kwd>desmopressin</kwd>
        <kwd>polydipsia</kwd>
        <kwd>polyuria</kwd>
        <kwd>vasopressin</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-1">
      <title>I<sc>NTRODUCTION</sc></title>
      <p>Diabetes insipidus (DI) is part of a group of hereditary or acquired polyuria and polydipsia diseases. It is associated with inadequate arginine vasopressin (AVP) or antidiuretic hormone (ADH) secretion or renal response to AVP, resulting in hypotonic polyuria and a compensatory/underlying polydipsia.[<xref rid="ref1" ref-type="bibr">1</xref>] Polyuria (&gt;50mL/kg), dilute urine (osmolality &lt;300 mOsm/L), and increased thirst (water intake of up to 20 L/day) are characteristic of DI.[<xref rid="ref2" ref-type="bibr">2</xref>] The kidneys pass large amounts of water irrespective of the body's hydration state.[<xref rid="ref3" ref-type="bibr">3</xref>] Untreated DI can cause hypovolemia, dehydration, and electrolyte imbalances.[<xref rid="ref4" ref-type="bibr">4</xref>] This article reviews the physiology, causes, and treatment of DI.</p>
    </sec>
    <sec id="sec1-2">
      <title>R<sc>EVIEW</sc> M<sc>ETHODS</sc></title>
      <p>A search of literature on the causes, physiology, and treatment options for DI was carried out using the PubMed database. Only English language articles were included in this review.</p>
    </sec>
    <sec id="sec1-3">
      <title>P<sc>ATHOPHYSIOLOGY OF</sc> W<sc>ATER</sc> B<sc>ALANCE</sc></title>
      <p>DI can be caused by two fundamentally different defects: Inadequate/impaired secretion of AVP from the posterior pituitary gland and impaired/insufficient renal response to ADH.[<xref rid="ref3" ref-type="bibr">3</xref>] AVP, a neurohypophyseal nonapeptide, regulates body water and osmotic homeostasis.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>] The AVP-neurophysin II gene (<italic>AVP-NPII</italic>) encodes AVP, which is synthesized in the supraoptic and paraventricular nuclei of the hypothalamus as a precursor complex of AVP, NPII, and glycopeptides copeptin and is released as AVP from neurons in the posterior pituitary. AVP and its protein carrier, NPII, are released by calcium-dependent exocytosis.[<xref rid="ref6" ref-type="bibr">6</xref>] AVP release may occur due to nonosmotic stimuli also including orthostatic hypotension or emetic reflexes (manifested in nausea and vomiting).[<xref rid="ref5" ref-type="bibr">5</xref>]</p>
      <p>The AVP system [<xref ref-type="fig" rid="F1">Figure 1</xref>] maintains water balance based on serum osmolality and arterial blood volume via the vasopressin-2-receptor (V2R).[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] AVP activates V2R at the basolateral membrane of the principal cells in the distal convoluted tubule and collecting duct of the kidney. This activates protein kinase A which in turn phosphorylates aquaporin 2 (AQP2) water channels in the intracellular vesicles. Exocytic insertion of AQP2 vesicles into the cell membrane follows, and the collecting duct becomes water permeable, thus concentrating the urine.[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>]</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>The arginine vasopressin system. cAMP: Cyclic adenosine monophosphate, V2R: Vasopressin-2-receptor, ADH: Antidiuretic hormone, AVP: Arginine vasopressin, Gs: G proteins, PKA: Protein kinase A</p>
        </caption>
        <graphic xlink:href="IJEM-20-9-g001"/>
      </fig>
    </sec>
    <sec id="sec1-4">
      <title>E<sc>PIDEMIOLOGY OF</sc> D<sc>IABETES</sc> I<sc>NSIPIDUS</sc></title>
      <p>DI is a rare disease, with a prevalence of 1:25,000.[<xref rid="ref6" ref-type="bibr">6</xref>] DI can present at any age, and the prevalence is equal among males and females. The age of presentation depends on the etiology.[<xref rid="ref8" ref-type="bibr">8</xref>] Less than 10% of DI is hereditary. X-linked nephrogenic DI (NDI) accounts for 90% of cases of congenital NDI and occurs with a frequency of 4&#x2013;8/1 million male live births. Autosomal NDI accounts for approximately 10% of the remaining cases.[<xref rid="ref6" ref-type="bibr">6</xref>]</p>
    </sec>
    <sec id="sec1-5">
      <title>T<sc>YPES OF</sc> D<sc>IABETES</sc> I<sc>NSIPIDUS</sc></title>
      <sec id="sec2-1">
        <title>Central diabetes insipidus</title>
        <p>Central DI (CDI) or neurogenic DI is the most common form of DI, occurring in both the sexes equally and at any age. It is caused by inadequate synthesis/release of AVP, often secondary to surgery or head injury which causes traumatic injury to the hypothalamus or posterior pituitary gland[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref>] and destruction/degeneration of neurons originating in the supraoptic and paraventricular nuclei of the hypothalamus.[<xref rid="ref6" ref-type="bibr">6</xref>] Symptoms of DI manifest after 80&#x2013;90% of the magnocellular neurons in the hypothalamus are damaged.[<xref rid="ref1" ref-type="bibr">1</xref>] Damage to the proximal part of the hypothalamo-neurohypophyseal region kills more neurons than do injuries to the distal region. However, proximal injuries account for 30&#x2013;40% of posttraumatic and postoperative CDI, while distal injuries account for 50&#x2013;60% of cases.[<xref rid="ref3" ref-type="bibr">3</xref>] The etiology of CDI is summarized in <xref ref-type="table" rid="T1">Table 1</xref>. Acquired CDI is more common than congenital CDI, and about 25% of adult CDI cases are idiopathic.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref6" ref-type="bibr">6</xref>]</p>
        <table-wrap id="T1" position="float">
          <label>Table 1</label>
          <caption>
            <p>Etiology of CDI</p>
          </caption>
          <graphic xlink:href="IJEM-20-9-g002"/>
        </table-wrap>
        <p>Children with acute injury to the nervous system and CDI have a high mortality.[<xref rid="ref9" ref-type="bibr">9</xref>] Traumatic brain injury (TBI) is associated with high mortality and acute and chronic morbidity. TBI is usually due to road traffic accidents and falls. The direct mechanical impact or the acceleration-deceleration effect of car crashes lead to dysfunction of the hypothalamic-pituitary axis. Trauma may lead to ischemia, hypoxia, alterations of cerebral vascularization/metabolism, and increased intracranial pressure, thus causing pituitary damage.[<xref rid="ref10" ref-type="bibr">10</xref>] Among patients admitted to the surgical intensive care unit or level 1 trauma center for severe head injuries, CDI occurred in 12.5% of patients with blunt head injuries and 40.9% of patients with penetrating head injuries. Glasgow Coma Scale &#x2264;8, cerebral edema, and an abbreviated injury score &gt;3 were independently associated with development of CDI. However, CDI itself independently led to an almost 4-fold increase in the risk of death.[<xref rid="ref11" ref-type="bibr">11</xref>]</p>
        <p>Among Taiwanese children aged 3 months to 18 years, central nervous system (CNS) infection was a common cause of CDI than blunt head injury (35.2% vs. 18.5%), but the development of CDI within the first 2 days of acute CNS injury resulted in a 5-fold higher risk of mortality.[<xref rid="ref9" ref-type="bibr">9</xref>] In a larger study, the incidence of CDI after TBI was 18%, and 71.4% of 818 pediatric patients were declared brain dead after CDI diagnosis. A higher mortality was associated with CDI which developed during the first 2 days after head injury.[<xref rid="ref12" ref-type="bibr">12</xref>]</p>
        <p>Pituitary surgery also results in CDI, with a wide range of incidence (1&#x2013;67%).[<xref rid="ref13" ref-type="bibr">13</xref>] Minimally invasive surgery has a low incidence of postoperative CDI (transient CDI 13.6% and permanent CDI 2.7%).[<xref rid="ref14" ref-type="bibr">14</xref>] Abnormalities in the secretion of AVP usually begin during the intraoperative period.[<xref rid="ref6" ref-type="bibr">6</xref>] The incidence of immediate postoperative DI was higher among patients undergoing surgery by a traditional method than by the endoscopic transsphenoidal method (36% vs. 15%). The incidence of long-term DI did not vary significantly between the groups.[<xref rid="ref15" ref-type="bibr">15</xref>] CDI that developed postoperatively causes 22% of cases in Indian children, and these cases were diagnosed at a later age (6.9 &#xB1; 4.7 years) compared to patients with histiocytosis and CNS malformations (3.7 &#xB1; 1.5 years and 0.4 &#xB1; 0.1 years, respectively). Compared to those with histiocytosis as a cause, more patients with postoperative CDI had a short stature (92.3% vs. 9.1%).[<xref rid="ref16" ref-type="bibr">16</xref>]</p>
        <p>Tumors have been reported as a cause of CDI, with intracranial tumors accounting for 23% of CDI cases among children and adults in one study.[<xref rid="ref17" ref-type="bibr">17</xref>] Tumor-associated CDI was not diagnosed in children aged &lt;5 years.[<xref rid="ref18" ref-type="bibr">18</xref>] Germ cell tumors and Langerhans cell histiocytosis (LCH) accounted for 60% of CDI cases in Taiwanese children, and histiocytosis accounted for 18.6% of cases in Indian children.[<xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref19" ref-type="bibr">19</xref>] LCH as a cause of CDI has been associated with better survival.[<xref rid="ref17" ref-type="bibr">17</xref>]</p>
        <p>Vascular damage to the CNS has been linked to CDI though the pathophysiology is not completely understood. Magnetic resonance imaging (MRI) studies indicated that abnormal blood supply to the posterior pituitary is associated with what is often termed as &#x201C;idiopathic&#x201D; CDI.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref20" ref-type="bibr">20</xref>] Infections such as cryptococcal meningitis, encephalitis, tuberculosis, tuberculous meningitis, and neurosarcoidosis also contribute to acquired CDI cases.[<xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr">23</xref><xref rid="ref24" ref-type="bibr">24</xref><xref rid="ref25" ref-type="bibr">25</xref>]</p>
        <p>Congenital CDI is a small contributor in the etiology of CDI. Nonetheless, more than 60 gene mutations in the <italic>AVP-NPII</italic> gene have been identified, most of which are in the <italic>NPII</italic> gene.[<xref rid="ref26" ref-type="bibr">26</xref>] In a study of familial CDI, mutations in exon 2 of <italic>AVP</italic> were detected in two Turkish families, but the age of onset differed (&lt;1 year in one family [G45C mutation] and at 4&#x2013;7 years in another family [C98X mutation]).[<xref rid="ref27" ref-type="bibr">27</xref>]</p>
        <p>Wolfram or DIDMOAD syndrome (autosomal recessive neurodegenerative disorder resulting in CDI, deafness, optic atrophy, and diabetes mellitus [DM]) is considered a differential diagnosis of CDI that developed in the neonatal period.[<xref rid="ref28" ref-type="bibr">28</xref>] Mutations have been detected at nucleotide 997 in exon 8 (A997G) and an insertion in exon 8 of wolframin (WFS1) gene, which results in early-onset CDI in children.[<xref rid="ref29" ref-type="bibr">29</xref>] Wolfram syndrome often results in DI and type 1 DM in children. However, an interesting first case of coexistence of CDI and type 2 DM has been reported in a 56-year-old man though no common cause could be determined.[<xref rid="ref30" ref-type="bibr">30</xref>]</p>
      </sec>
      <sec id="sec2-2">
        <title>Nephrogenic diabetes insipidus</title>
        <p>NDI results from the failure of the kidney to respond to AVP. Urine production in patients with NDI is typically 12 L/day. Children usually present with the inherited form whereas adults present with the acquired form of NDI [<xref ref-type="table" rid="T2">Table 2</xref>].[<xref rid="ref31" ref-type="bibr">31</xref>] In most cases (90%), inherited NDI is an X-linked condition caused by a loss-of-function mutation in the <italic>V2R</italic> gene. It is rarely due to mutations in the <italic>AQP2</italic> gene (10%).[<xref rid="ref7" ref-type="bibr">7</xref>] V2R is predominantly expressed in the distal convoluted tubule and renal collecting tubes, and it responds to AVP thus concentrating the urine.[<xref rid="ref7" ref-type="bibr">7</xref>]</p>
        <table-wrap id="T2" position="float">
          <label>Table 2</label>
          <caption>
            <p>Etiology of nephrogenic diabetes insipidus</p>
          </caption>
          <graphic xlink:href="IJEM-20-9-g003"/>
        </table-wrap>
        <p>In a nationwide survey of NDI patients in Japan, 143/173 patients (82.7%) had congenital NDI whereas the remaining (17.3%) had acquired NDI. Mutations in <italic>V2R</italic> were more common (74.7%) than mutations in <italic>AQP2</italic> (9.2%).[<xref rid="ref32" ref-type="bibr">32</xref>] In a study of two unrelated Thai children with NDI, the R181C mutation in <italic>V2R</italic> caused complete NDI whereas the M311V mutation caused mild NDI (V2R retained partial activity).[<xref rid="ref33" ref-type="bibr">33</xref>]</p>
        <p>Drug-induced NDI is most commonly due to lithium, followed by foscarnet and clozapine.[<xref rid="ref34" ref-type="bibr">34</xref>] Lithium is used to treat mood disorders and is associated with renal injury including impaired urine-concentrating ability. Lithium enters the collecting duct principal cells predominantly via epithelial sodium channels (ENaC). Excess lithium reduces sodium reabsorption. Lithium inhibits AVP-stimulated translocation of cytoplasmic AQP2 to the apical membrane, thus delivering hypo-osmotic fluid. Long-term exposure to lithium may down-regulate <italic>AQP2</italic> gene expression.[<xref rid="ref35" ref-type="bibr">35</xref><xref rid="ref36" ref-type="bibr">36</xref>] Lithium-induced NDI has been reported in adults and geriatric patients.[<xref rid="ref37" ref-type="bibr">37</xref><xref rid="ref38" ref-type="bibr">38</xref><xref rid="ref39" ref-type="bibr">39</xref>]</p>
      </sec>
      <sec id="sec2-3">
        <title>Primary polydipsia</title>
        <p>Primary polydipsia (PP) results from excessive fluid intake practiced over an extended period. Persons with PP have a defective thirst mechanism or increased the thirst sensation (dipsogenic DI). Patients with an unknown motive for polydipsia are frequently associated with psychiatric disorders (psychogenic polydipsia),[<xref rid="ref1" ref-type="bibr">1</xref>] caused by schizophrenia, compulsive behavior, or stress reduction. PP also occurs in psychiatric patients to reduce the effect of anticholinergic drugs.[<xref rid="ref40" ref-type="bibr">40</xref>] Phenothiazine administration causes the sensation of a dry mouth and may result in PP.[<xref rid="ref4" ref-type="bibr">4</xref>] Excessive fluid consumption resulted in decreased serum osmolality and suppressed release of AVP. Patients exhibit characteristics of DI though pituitary and renal functions are not compromised.[<xref rid="ref1" ref-type="bibr">1</xref>] Dipsogenic DI can be caused by chronic meningitis, granulomatous diseases, multiple sclerosis, or other diffuse pathology of the brain.[<xref rid="ref41" ref-type="bibr">41</xref>] Cranial MRI is essential to distinguish PP from CDI.[<xref rid="ref1" ref-type="bibr">1</xref>]</p>
      </sec>
      <sec id="sec2-4">
        <title>Gestational diabetes insipidus</title>
        <p>Gestational DI occurs in about 1 in 30,000 pregnancies[<xref rid="ref42" ref-type="bibr">42</xref>] as a result of degradation of AVP by the enzyme, cysteine aminopeptidase.[<xref rid="ref1" ref-type="bibr">1</xref>] Vasopressinase levels are typically higher in pregnant women (up to 300 times higher), more so in twin pregnancies.[<xref rid="ref43" ref-type="bibr">43</xref>] However, hormone levels are often normal, suggesting that pregnancy unmasks a subtle underlying deficiency of AVP.[<xref rid="ref1" ref-type="bibr">1</xref>] Gestational DI typically presents in the third trimester[<xref rid="ref43" ref-type="bibr">43</xref>] and spontaneously resolves about 2&#x2013;3 weeks postpartum, but diagnosis to reveal any underlying pathology is necessary.[<xref rid="ref1" ref-type="bibr">1</xref>] It is usually underdiagnosed since polyuria during pregnancy is considered normal and does not cause complications.[<xref rid="ref44" ref-type="bibr">44</xref>]</p>
      </sec>
      <sec id="sec2-5">
        <title>Diagnosis of diabetes insipidus</title>
        <p>Onset of CDI can be abrupt (due to insult to the body) or gradual (due to tumor or idiopathic causes). The age of onset and the severity of the disease can differ among patients who have congenital disease.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref6" ref-type="bibr">6</xref>]</p>
        <p>The primary symptoms of DI include persistent polyuria (producing 8&#x2013;16 L of dilute urine a day) and polydipsia (intake of up to 20 L fluid per day). Other symptoms are dizziness, weakness, nocturia, fatigue, and signs of dehydration (fever, dry skin and mucus membranes, weight loss, poor skin turgor). Hypotension and tachycardia with decreased right atrial and pulmonary artery occlusion pressures and an altered level of consciousness may occur. Young children may present with severe dehydration, vomiting, constipation, fever, irritability, sleep disturbances, retardation of growth, and failure to thrive. Mental retardation can be caused by repeated and unrecognized dehydration.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref6" ref-type="bibr">6</xref>]</p>
        <p>The diagnostic algorithm of CDI and NDI is described in <xref ref-type="fig" rid="F2">Figure 2</xref>. The ability of the CNS to produce AVP and of the kidney to respond to it is measured by the water deprivation test (Hare-Hickey test) and desmopressin challenge test. A 24-h urine volume is used to confirm polyuria. During water deprivation, hourly measurements of body weight and urine osmolality are made, until 2&#x2013;3 samples vary by &lt;30 mOsm/kg (or &lt;10%), or until the patient loses 5% of his/her body weight. Serum ADH is then measured and ADH/desmopressin (5 units) is injected. Urine osmolality is measured 30&#x2013;60 min after this.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref41" ref-type="bibr">41</xref>] The test is discontinued if the patient loses &gt;5% of his/her body weight and/or plasma Na<sup>+</sup> exceeds 143 mEq/L and/or urine osmolality increases to normal. Response to the administration of desmopressin distinguishes between CDI and NDI. The interpretation of the water deprivation test is described in <xref ref-type="table" rid="T3">Table 3</xref>.[<xref rid="ref6" ref-type="bibr">6</xref>]</p>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Diagnostic flowchart for central and nephrogenic diabetes insipidus. AVP: Arginine vasopressin, Posm: Plasma osmolality, Uosm: Urine osmolality</p>
          </caption>
          <graphic xlink:href="IJEM-20-9-g004"/>
        </fig>
        <table-wrap id="T3" position="float">
          <label>Table 3</label>
          <caption>
            <p>Interpretation of the water deprivation test and the desmopressin challenge test in the diagnosis of diabetes insipidus</p>
          </caption>
          <graphic xlink:href="IJEM-20-9-g005"/>
        </table-wrap>
        <p>Findings suggestive of PP include the history of psychiatric disease, fluctuating symptoms and gradual onset of polydipsia, posterior pituitary bright spot and normal thickness of the pituitary stalk, and hyponatremia after a therapeutic trial with desmopressin.[<xref rid="ref1" ref-type="bibr">1</xref>]</p>
      </sec>
      <sec id="sec2-6">
        <title>New diagnostic markers</title>
        <p>Endogenous vasopressin measurement is an important test to differentiate between CDI and NDI. Copeptin (the C-terminal glycoprotein of the AVP prohormone) can be considered a stable surrogate for endogenous plasma AVP. AVP is unstable, largely attached to platelets and is rapidly cleared. The small size of AVP makes estimation difficult.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref45" ref-type="bibr">45</xref>] In one study, copeptin levels were found to be &lt;2.5 pmol/L in all patients with CDI, suggesting that it could be used to distinguish CDI from PP and NDI.[<xref rid="ref46" ref-type="bibr">46</xref>]</p>
      </sec>
    </sec>
    <sec id="sec1-6">
      <title>T<sc>REATMENT OF</sc> D<sc>IABETES</sc> I<sc>NSIPIDUS</sc></title>
      <p>Treatment of DI varies for central or nephrogenic forms. The available medications are described in <xref ref-type="table" rid="T4">Table 4</xref>.</p>
      <table-wrap id="T4" position="float">
        <label>Table 4</label>
        <caption>
          <p>Summary of drugs used for the treatment of diabetes insipidus</p>
        </caption>
        <graphic xlink:href="IJEM-20-9-g006"/>
      </table-wrap>
      <sec id="sec2-7">
        <title>Carbamazepine</title>
        <p>Carbamazepine is an anticonvulsant and psychotropic drug used to treat epilepsy or intellectual disabilities. It may stimulate the release of vasopressin from the pituitary gland and act directly on renal tubules. Carbamazepine increased water absorption in the absence of AVP <italic>in vitro</italic>. The effect was cyclic adenosine monophosphate (cAMP)-dependent. In rats, carbamazepine increased water permeability and absorption in the inner medullary collecting duct, acted directly on the V2R-protein G complex and increased <italic>AQP2</italic> expression.[<xref rid="ref47" ref-type="bibr">47</xref>] Meinders <italic>et al</italic>., studied six CDI patients treated with 200&#x2013;800 mg carbamazepine daily. All patients had a reduction in urinary water output (from 8&#x2013;16 L/day to 1.9&#x2013;6 L/day) and an increase in urine osmolality (from 60&#x2013;120 mOsm/kg to 150&#x2013;532 mOsm/kg). AVP levels were undetectable in DI patients and healthy subjects, suggesting that carbamazepine did not stimulate the release of, or inhibit the breakdown of AVP.[<xref rid="ref48" ref-type="bibr">48</xref>]</p>
        <p>Hyponatremia has been detected in 4.8&#x2013;40% of patients receiving carbamazepine for neurological disorders[<xref rid="ref47" ref-type="bibr">47</xref><xref rid="ref49" ref-type="bibr">49</xref><xref rid="ref50" ref-type="bibr">50</xref>] and among patients receiving it for back pain.[<xref rid="ref51" ref-type="bibr">51</xref>] Prolonged carbamazepine treatment has been linked to reduction in antidiuretic activity possibly due to auto-induction of carbamazepine.[<xref rid="ref52" ref-type="bibr">52</xref>]</p>
      </sec>
      <sec id="sec2-8">
        <title>Chlorpropamide</title>
        <p>The antidiuretic drug, chlorpropamide, decreases the clearance of solute-free water if the neurohypophysis has the residual secretory capacity and normalizes plasma osmolality.[<xref rid="ref53" ref-type="bibr">53</xref>] Chlorpropamide administered to children and adults (125&#x2013;1000 mg daily) reduced urine output from 5.4&#x2013;10.7 L/day to &lt;2 L/day. Maximal diuresis was achieved in 3&#x2013;4 days, and the effect was dose-dependent.[<xref rid="ref54" ref-type="bibr">54</xref>]</p>
        <p>Chlorpropamide may enhance the neurohypophyseal secretion of vasopressin, have a vasopressin-like effect or potentiate the effect of minute amounts of vasopressin which persist in DI.[<xref rid="ref54" ref-type="bibr">54</xref><xref rid="ref55" ref-type="bibr">55</xref>] Chlorpropamide may potentiate vasopressin-induced water transport through activation of renal tubular adenylyl cyclase which generates cAMP rather than affecting water movement.[<xref rid="ref55" ref-type="bibr">55</xref>]</p>
      </sec>
      <sec id="sec2-9">
        <title>Clofibrate</title>
        <p>Clofibrate is a hypolipidemic agent which stimulates ADH production in patients with partial CDI.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref56" ref-type="bibr">56</xref>] Clofibrate treatment (500 mg every 6 h) significantly reduced the mean urine clearance from 280 mL/h to 141 mL/h, and the mean free water clearance from 158 mL/h to 10 mL/h in 6 cases of DI. Urine osmolality increased from 152 mOsm/kg to 317 mOsm/kg, with a concomitant decrease in urinary ADH excretion in 4/6 patients. There was a significant antidiuretic activity even in patients who were water-loaded.[<xref rid="ref56" ref-type="bibr">56</xref>]</p>
        <p>Chlorpropamide treatment causes a greater reduction in mean urine volume (59% vs. 47%), and higher urine osmolality compared to clofibrate treatment. However, clofibrate significantly reduces free water clearance. Furthermore, chlorpropamide can cause serious hypoglycemia, unlike clofibrate.[<xref rid="ref57" ref-type="bibr">57</xref>] Clofibrate is generally safe, but there have been reports of clofibrate-induced myopathy.[<xref rid="ref58" ref-type="bibr">58</xref>] It is likely that hypothyroidism coexisting in patients with secondary DI may precipitate the development of clofibrate-induced myopathy.[<xref rid="ref58" ref-type="bibr">58</xref>]</p>
      </sec>
      <sec id="sec2-10">
        <title>Thiazide diuretics</title>
        <p>Thiazide diuretics can be used to treat both NDI and CDI.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref59" ref-type="bibr">59</xref>] They act at the distal convoluted tubule and inhibit cotransport of sodium and chloride. Prolonged administration reduces extracellular fluid volume, allowing water and sodium reabsorption at the proximal tubules. Ultimately, there is reduction of urine output.[<xref rid="ref59" ref-type="bibr">59</xref>] An animal model of lithium-induced NDI demonstrated that chronic hydrochlorothiazide treatment up-regulates NCC and ENa C, which enhances sodium reabsorption along the distal segments of the nephron.[<xref rid="ref60" ref-type="bibr">60</xref>]</p>
        <p>Treatment with chlorothiazide (5&#x2013;10 mg/kg/day) or hydrochlorothiazide (1&#x2013;2 mg/kg/day) was effective and safe, with hospitalization for hypernatremia required in only 1/13 patients.[<xref rid="ref61" ref-type="bibr">61</xref>] Treatment with chlorothiazide or hydrochlorothiazide reduced water intake by 23&#x2013;40% in children with NDI.[<xref rid="ref62" ref-type="bibr">62</xref>] The combination of amiloride and hydrochlorothiazide was superior to hydrochlorothiazide alone and prevented urinary potassium loss, hypokalemia, and alkalosis.[<xref rid="ref63" ref-type="bibr">63</xref>] Though hydrochlorothiazide decreases urine volume by up to 50% in pregnant, the risks of hypokalemia and hypovolemia cause it to be used sparingly in gestational DI.[<xref rid="ref43" ref-type="bibr">43</xref>]</p>
      </sec>
      <sec id="sec2-11">
        <title>Indapamide</title>
        <p>Indapamide is an antihypertensive, diuretic drug which could be considered as an alternative drug for mild CDI.[<xref rid="ref8" ref-type="bibr">8</xref>] The molecular structure is similar to hydrochlorothiazide and chlorpropamide. As with thiazides, the activity of indapamide may be due to proximal tubular water reabsorption.[<xref rid="ref64" ref-type="bibr">64</xref>] The first report on the use of indapamide (at 2.5 mg/day) for DI demonstrated a reduction in the 24-h urinary volume (from 5&#x2013;16 L to 2.3&#x2013;9.2 L) in 3 patients with CDI.[<xref rid="ref65" ref-type="bibr">65</xref>]</p>
        <p>Among patients with treatment-na&#xEF;ve CDI, there was a smaller reduction in mean urine output volume (48.49% &#xB1; 10.69% vs. 40.56% &#xB1; 9.7%) in patients receiving indapamide compared to those receiving chlorpropamide. Urine osmolality increased in all nine patients receiving indapamide and in 7/11 patients receiving chlorpropamide, while serum osmolality decreased in 4/9 and 7/11 patients, respectively. Chlorpropamide was discontinued due to hypoglycemia in 2 patients while there were no adverse effects among patients receiving indapamide.[<xref rid="ref64" ref-type="bibr">64</xref>]</p>
      </sec>
      <sec id="sec2-12">
        <title>Indomethacin</title>
        <p>Indomethacin is a nonsteroidal anti-inflammatory drug which has antidiuretic action.[<xref rid="ref4" ref-type="bibr">4</xref>] Weinstock and Moses reported that indomethacin effectively treated NDI that persisted after lithium therapy was discontinued. When used along with desmopressin, there was a marked decrease in polyuria.[<xref rid="ref66" ref-type="bibr">66</xref>] A patient who did not respond to desmopressin, thiazides, and amiloride for the treatment of lithium-induced NDI, responded immediately to indomethacin treatment with a reduction in urine volume from 24 L/day to 12 L/day, and ultimately to 2 L/day.[<xref rid="ref67" ref-type="bibr">67</xref>] Indomethacin successfully treated streptozocin-induced NDI, with a rapid correction in polyuria that was independent of the glomerular filtration rate.[<xref rid="ref68" ref-type="bibr">68</xref>] Indomethacin may impair renal function[<xref rid="ref66" ref-type="bibr">66</xref>] and have severe adverse effects such as gastrointestinal bleeding, hyperkalemia, hypernatremia, and elevated creatinine.[<xref rid="ref4" ref-type="bibr">4</xref>]</p>
      </sec>
      <sec id="sec2-13">
        <title>Amiloride</title>
        <p>Amiloride is a diuretic that is useful in the treatment of lithium-induced NDI. It reduces transcellular lithium transport, intracellular lithium concentration and lithium-induced inactivation of GSK-3-x&#x3B2;. Blocking of ENaC with amiloride reduces the lithium-induced down-regulation of <italic>AQP2</italic> expression and protects the cellular composition of the collecting duct.[<xref rid="ref69" ref-type="bibr">69</xref>] In a study of the effect of amiloride versus placebo on lithium-induced NDI, amiloride administered for 6 weeks increased maximal urine osmolality and AQP2 excretion.[<xref rid="ref35" ref-type="bibr">35</xref>]</p>
      </sec>
      <sec id="sec2-14">
        <title>Desmopressin</title>
        <p>Vasopressin was first used to treat CDI in 1913, using posterior pituitary extracts containing oxytocin and vasopressin. Pitressin (vasopressin tannate in oil) became available for clinical use in the 1930s and was the principal drug for the treatment of DI almost until the 1970s when desmopressin was introduced. Substitution of the 8<sup>th</sup> residue of vasopressin with the D-isomer of arginine diminished the pressor effect of vasopressin.[<xref rid="ref70" ref-type="bibr">70</xref><xref rid="ref71" ref-type="bibr">71</xref>] This synthetic analog of vasopressin, 1-deamino-8-D-AVP(DDAVP), or desmopressin, has increased and prolonged antidiuretic effect, decreased vasoconstrictive and oxytocic effects, reduced side effects (hyponatremia and convulsions), and enhanced resistance to vasopressinase. It is convenient to administer, being available as an intranasal spray, oral tablet, and orally disntegrating tablet (ODT).[<xref rid="ref70" ref-type="bibr">70</xref><xref rid="ref71" ref-type="bibr">71</xref><xref rid="ref72" ref-type="bibr">72</xref>]</p>
      </sec>
      <sec id="sec2-15">
        <title>Pharmacokinetics</title>
        <p>Desmopressin formulations include intranasal spray, oral tablet, and orally disintegrating tablet (ODT)/oral lyophilisate/melt. Due to safety issues, desmopressin intranasal spray is no longer approved by the United States Food and Drug Administration. This led to withdrawal of the spray and switch to the tablet or melt formulation in a majority of countries; however, the spray continues to be available in India.[<xref rid="ref73" ref-type="bibr">73</xref>] The pharmacokinetic properties or oral DDAVP among adult patients with CDI uncontrolled on intranasal DDAVP are described in <xref ref-type="table" rid="T5">Table 5</xref>.[<xref rid="ref74" ref-type="bibr">74</xref>]</p>
        <table-wrap id="T5" position="float">
          <label>Table 5</label>
          <caption>
            <p>Pharmacokinetic properties of the oral and intranasal forms of desmopressin in adults with CDI</p>
          </caption>
          <graphic xlink:href="IJEM-20-9-g007"/>
        </table-wrap>
        <p>The antidiuretic activity of the various formulations is described in <xref ref-type="fig" rid="F3">Figure 3</xref>. The mean urine osmolality at 4 h was only marginally higher for the intranasal compared to the oral formulation. There was no significant difference in the mean urine flow rates for up to 8 h. Increasing the dose of desmopressin from 200 to 400 mg did not significantly increase the maximal antidiuretic activity.[<xref rid="ref74" ref-type="bibr">74</xref>] Among children with CDI, free water clearance decreased rapidly with both intranasal (10&#x2013;20 &#x3BC;g) and oral (200&#x2013;400 &#x3BC;g) formulations. Doses of the oral formulation were approximately 20 times greater than those for the nasal formulation.[<xref rid="ref75" ref-type="bibr">75</xref>]</p>
        <fig id="F3" position="float">
          <label>Figure 3</label>
          <caption>
            <p>(a) Plasma 1-deamino-8-D-arginine-vasopressin concentrations (<italic>n</italic> = 9), (b) urine osmolality, and (c) urine flow rate at varying intervals after the administration of intranasal or oral desmopressin in 10 adult patients with central diabetes insipidus</p>
          </caption>
          <graphic xlink:href="IJEM-20-9-g008"/>
        </fig>
        <p>Large individual variations in the absorption of orally administered desmopressin have been reported in studies with adults[<xref rid="ref74" ref-type="bibr">74</xref>] and children.[<xref rid="ref75" ref-type="bibr">75</xref>] In healthy, overhydrated adults who were administered intravenous desmopressin (30&#x2013;500 ng), the increase in plasma desmopressin and urine osmolality was proportional to the dose. C<sub>max</sub> occurred at or within 15 min of the end of a 2-h infusion though the individual C<sub>max</sub> varied over a 2-fold or 3-fold range. Urine osmolality increases were 350 mOsm/kg in the 60 ng group and 700 mOsm/kg in the 500 ng group. The individual variation in time required for a given level of plasma desmopressin to exert its maximum antidiuretic effect could be due to individual differences in the kinetics of one or more intracellular mechanisms that promote the reabsorption of solute-free water by principal cells in renal collecting tubules.[<xref rid="ref76" ref-type="bibr">76</xref>]</p>
        <p>The gender difference in the activity of desmopressin has been reported in a study of ODT desmopressin for nocturia and among healthy volunteers. At lower doses (25 &#x3BC;g), the decrease in nocturia was larger for women than men. Among patients aged &gt;50 years, women had 2-fold greater decreases in serum sodium levels than men, at doses of 25&#x2013;50 &#x3BC;g, but a 5-fold greater risk of hyponatremia at 50 &#x3BC;g. Overall, sensitivity to the antidiuretic effect of desmopressin with females was higher than males.[<xref rid="ref77" ref-type="bibr">77</xref>]</p>
      </sec>
      <sec id="sec2-16">
        <title>Oral tablet formulation of desmopressin</title>
        <p>Oral tablets have advantages over the intranasal formulation as they can be used easily in infants, elderly patients and patients with visual disturbances and chronic rhinitis. Desmopressin is absorbed unaltered from the gastrointestinal tract after oral administration.[<xref rid="ref78" ref-type="bibr">78</xref>] Fukuda <italic>et al</italic>., studied the use of oral desmopressin (100 &#x3BC;g) in patients with CDI (age 17&#x2013;36 years) switching from the intranasal formulation. Plasma concentrations of desmopressin peaked (14.7 &#xB1; 5.4 pg/mL) at 90 min, and then decreased gradually in the subsequent 3 h. Urine volumes decreased 1 h after administration, with diuretic activity remaining low from 3 h to 6 h after administration. Urine osmolality increased progressively from 1 h after administration, reaching a maximum at 4 h (732 &#xB1; 21 mOsm/kg).[<xref rid="ref78" ref-type="bibr">78</xref>] Promising results for the oral formulation emerged from a similar study involving a switch from intranasal to oral formulation. Both formulations controlled urine volume (1958 &#xB1; 758 vs. 1720 &#xB1; 378 mL, respectively) and corrected urine specific gravity to normal (1101 &#xB1; 6 vs. 1101 &#xB1; 4, respectively). While the spray had a more rapid onset of action and a longer duration of action, the tablet was more available and much more easily consumed according to patients (<italic>P</italic> = 0.00067). The dose equivalence ratio for intranasal to 100 &#x3BC;g oral desmopressin was 1:18.[<xref rid="ref79" ref-type="bibr">79</xref>]</p>
        <p>The long-term use of oral desmopressin has been evaluated. The mean ratio of oral to intranasal doses required to maintain antidiuretic activity was 19 &#xB1; 2 (range 15&#x2013;30). Daily urine volumes were well-maintained (mean volume 1739 &#xB1; 68 mL/day, range 1500&#x2013;1930 mL/day) and urine osmolality was 275&#x2013;899 mOsm/kg. Importantly, there was no adverse reaction or loss of desmopressin activity over the study period. The oral formulation was as effective as the intranasal formulation in controlling CDI over a 5-year period and was a safe treatment modality.[<xref rid="ref78" ref-type="bibr">78</xref>]</p>
        <p>A study on oral desmopressin in children with CDI determined that doses of 100&#x2013;400 &#x3BC;g achieved a mean antidiuretic activity of 8 h. The antidiuretic activity was dose-dependent. The effect on urine osmolality is described in <xref ref-type="fig" rid="F4">Figure 4</xref>. Most patients were discharged from hospital with an initial dose of 100&#x2013;400 &#x3BC;g thrice daily. The activity of desmopressin correlated with body weight (<italic>r</italic> = 0.61, <italic>P</italic> &lt; 0.05). There were no adverse reactions to any dosage of desmopressin and no significant changes in body weight, blood pressure, or heart rate. During a follow-up period of 6 months, the mean daily oral dose was 550 &#x3BC;g while the mean intranasal dose was 25 &#x3BC;g. Higher initial intranasal doses corresponded to higher oral dose requirements (<italic>r</italic> = 0.79, <italic>P</italic> &lt; 0.5). Oral desmopressin was considered safe and efficacious in the management of CDI in children in the long-term.[<xref rid="ref80" ref-type="bibr">80</xref>]</p>
        <fig id="F4" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Effect of single rising doses of oral desmopressin on urine osmolality in the seven pediatric patients in the study</p>
          </caption>
          <graphic xlink:href="IJEM-20-9-g009"/>
        </fig>
        <p>A case of gestational DI was successfully treated with desmopressin (vasopressinase resistant) but not AVP (vasopressinase sensitive). Subcutaneous administration resulted in a prompt decrease in oral fluid intake (85 mL/h) and urine output (66 mL/h) and an increase in urine osmolality (656 mOsm/L). Subsequent treatment with intravenous and intranasal forms also controlled the symptoms, and desmopressin was weaned gradually from 6 weeks postpartum while her condition resolved.[<xref rid="ref81" ref-type="bibr">81</xref>] A large study in Sweden found that the use of desmopressin during pregnancy was not a risk to infants since the duration of pregnancy and infant birth weight were not affected by the treatment.[<xref rid="ref82" ref-type="bibr">82</xref>]</p>
      </sec>
      <sec id="sec2-17">
        <title>New formulation of desmopressin: Orally disintegrating tablet</title>
        <p>The ODT formulation of desmopressin was launched in 2005 for the treatment of nocturnal enuresis. It is a wafer-like formulation which dissolves instantly in the mouth with no need for water,[<xref rid="ref70" ref-type="bibr">70</xref>] thus avoiding the ingestion of extra fluids and overcoming difficulties related to swallowing tablets.[<xref rid="ref83" ref-type="bibr">83</xref>] It is advantageous over the intranasal formulation which requires cold storage for long-term stability. Absorption of intranasal desmopressin may be erratic due to changes in nasal mucosa due to atrophy, scarring, congestion, or discharge.[<xref rid="ref84" ref-type="bibr">84</xref>]</p>
        <p>The efficacy of switching to from the intranasal to the ODT formulation was demonstrated in a recent multicenter, open-label, dose-titration study in CDI patients. After 4 weeks of ODT treatment, there was no significant difference between the 24-h urine volume, hourly diuresis rate [<xref ref-type="fig" rid="F5">Figure 5</xref>], urine specific gravity, and urine osmolality compared to the baseline values. More patients had urine osmolality and specific gravity within the normal range [<xref ref-type="fig" rid="F5">Figure 5c</xref>]. Patients received desmopressin ODT 120&#x2013;360 &#x3BC;g/day in either two or three doses. Treatment-emergent adverse effects were seen in 11 patients, and hyponatremia was the most common adverse effect. The ratio of ODT to intranasal desmopressin dose was 24. Desmopressin ODT achieved sufficient antidiuretic control compared to intranasal therapy and was well-tolerated over long-term treatment. Individual titration of dosing is important as 6 patients in the study required dose modification due to altered urine volume or sodium levels.[<xref rid="ref83" ref-type="bibr">83</xref>]</p>
        <fig id="F5" position="float">
          <label>Figure 5</label>
          <caption>
            <p>Changes in (a) 24-h urine volume and (b) hourly diuresis rate and (c) urine osmolality over time</p>
          </caption>
          <graphic xlink:href="IJEM-20-9-g010"/>
        </fig>
        <p>The ODT formulation was safe and effective in adults with CDI switching from intranasal spray/drops to 60 &#x3BC;g ODT desmopressin. The mean daily dosage of the formulations and the laboratory characteristics are described in <xref ref-type="table" rid="T6">Table 6</xref>. The ratio of nasal to ODT desmopressin dose was 17.0 &#xB1; 7.6 in all patients, 11.7 &#xB1; 6.5 in the nasal spray group, and 21.0 &#xB1; 5.5 in the nasal drop group. The difference between the ratio for the drop and spray groups was statistically significant. Prior dosage of intranasal desmopressin significantly correlated with the required ODT dose. No events of hyponatremia or water toxicity were reported.[<xref rid="ref84" ref-type="bibr">84</xref>]</p>
        <table-wrap id="T6" position="float">
          <label>Table 6</label>
          <caption>
            <p>Characteristics of the two formulations of desmopressin</p>
          </caption>
          <graphic xlink:href="IJEM-20-9-g011"/>
        </table-wrap>
        <p>The potential of desmopressin ODT in very young infants with CDI was recently described. A preterm male infant was administered 60 &#x3BC;g desmopressin ODT, resulting in an increase in urine osmolality within 3 h. The bioavailability of desmopressin was maintained over time, but several dose adjustments were required due to variability in urine output and body weight. After 125 days, 60 &#x3BC;g desmopressin ODT was administered daily, together with a normal fluid intake, resulting in stable random sodium concentrations. In a full-term female infant, 15 &#x3BC;g of desmopressin ODT increased the urine osmolality to &gt;400 mOsm/kg within 3 h of administration and the effect was maintained for 12 h. By the age of 12 months, DI was managed with 45 &#x3BC;g/day desmopressin ODT.[<xref rid="ref70" ref-type="bibr">70</xref>]</p>
        <p>Quality of life (QOL) has been assessed using the Peds QL and the Adult Hypopituitarism Questionnaire, but neither is specific for CDI. A new tool, the Nagasaki DI Questionnaire, included 10 questions directly related to CDI symptoms and two questions about the consistency of the effect of and the patient's satisfaction with desmopressin has recently been tested. Patients receiving intranasal spray were either switched to desmopressin ODT or continued the nasal spray. Newly diagnosed patients were treated with desmopressin ODT. The frequency of hyponatremia was lower during ODT than intranasal treatment (13.3% vs. 21.1%), but clinical significance was lacking. Changing from intranasal to ODT desmopressin improved the overall QOL, except the frequency of urination in the daytime. Among patients with newly diagnosed CDI, there were improvements in QOL for each question, without statistical difference.[<xref rid="ref85" ref-type="bibr">85</xref>]</p>
        <p>Pharmacovigilance data show that hyponatremia is very rare (&lt;1 in 10,000). The lower risk of hyponatremia for the oral formulations makes them preferable over nasal sprays.[<xref rid="ref86" ref-type="bibr">86</xref>] The pros and cons of the different formulations of desmopressin are listed in <xref ref-type="table" rid="T7">Table 7</xref>.</p>
        <table-wrap id="T7" position="float">
          <label>Table 7</label>
          <caption>
            <p>Advantages and disadvantages of various formulations of desmopressin</p>
          </caption>
          <graphic xlink:href="IJEM-20-9-g012"/>
        </table-wrap>
      </sec>
    </sec>
    <sec id="sec1-7">
      <title>G<sc>UIDELINES FOR THE</sc> M<sc>ANAGEMENT OF</sc> D<sc>IABETES</sc> I<sc>NSIPIDUS</sc></title>
      <p>The book, Medicine Update Volume 23, published by the Association of Physicians of India in 2013, had a theme of &#x201C;Practical Indian Guidelines and Protocols for all the Common Diseases.&#x201D; It described an algorithm for diagnosis of polyuria [<xref ref-type="fig" rid="F6">Figure 6</xref>].[<xref rid="ref41" ref-type="bibr">41</xref>] The Indian Society for Paediatric and Adolescent Endocrinology has enlisted instructions for patients on desmopressin treatment. These include:[<xref rid="ref87" ref-type="bibr">87</xref>]</p>
      <fig id="F6" position="float">
        <label>Figure 6</label>
        <caption>
          <p>Diagnostic flowchart for polyuria. DM: Diabetes mellitus, CKD: Chronic kidney disease, ADH: Antidiuretic hormone, RF: Renal function, NDI: Nephrogenic diabetes insipidus, CDI: Central diabetes insipidus, MRI: Magnetic resonance imaging</p>
        </caption>
        <graphic xlink:href="IJEM-20-9-g013"/>
      </fig>
      <p>
<list list-type="bullet"><list-item><p>Never change dosage of medicine without the advice of doctor</p></list-item><list-item><p>Give next dose of desmopressin only when the effect of the previous day's dose has finished, and the patient begins passing urine frequently for at least 2 h</p></list-item><list-item><p>On days of cold and stuffy nose, the effectiveness of the desmopressin is low, so the patient will pass larger amount of urine. Give oral fluids according to thirst. Do not try to double the dose of desmopressin</p></list-item><list-item><p>On days of fever, loose motions, and vomiting, desmopressin should be continued. Extraoral fluids should be given according to thirst</p></list-item><list-item><p>If the patient becomes unconscious, consult a local doctor immediately.</p></list-item></list>
</p>
    </sec>
    <sec id="sec1-8">
      <title>S<sc>UMMARY</sc></title>
      <p>DI is a disorder that can be debilitating. It is important to identify the etiology of DI to be able to treat is appropriately. Since its introduction in 1972, desmopressin has been demonstrated as a safe and effective drug for the management of DI in several short-term and long-term studies. Newer preparations including oral and ODT formulations are advantageous over nasal preparations as they are useful in patients who are elderly, mentally, or physically handicapped or have chronic rhinitis. Desmopressin continues to be a valuable drug after more than 35 years since its introduction and provides an effective therapeutic option for DI.</p>
      <sec id="sec2-18">
        <title>Financial support and sponsorship</title>
        <p>Nil.</p>
      </sec>
      <sec id="sec2-19">
        <title>Conflicts of interest</title>
        <p>Dr. Harshad Malve is working as a Lead Medical, Asia Pacific region with Ferring Pharmaceuticals Pvt. Ltd.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>R<sc>EFERENCES</sc></title>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fenske</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Allolio</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Clinical review: Current state and future perspectives in the diagnosis of diabetes insipidus: A clinical review</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2012</year>
          <volume>97</volume>
          <fpage>3426</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="pmid">22855338</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grace</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Balachandran</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Preethy</surname>
            </name>
            <name>
              <surname>Menon</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic central diabetes insipidus</article-title>
          <source>Indian J Med Sci</source>
          <year>2011</year>
          <volume>65</volume>
          <fpage>452</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">23511046</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Makaryus</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>McFarlane</surname>
              <given-names>SI</given-names>
            </name>
          </person-group>
          <article-title>Diabetes insipidus: Diagnosis and treatment of a complex disease</article-title>
          <source>Cleve Clin J Med</source>
          <year>2006</year>
          <volume>73</volume>
          <fpage>65</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="pmid">16444918</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crawford</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Water world, part 2: Understanding diabetes insipidus in adults</article-title>
          <source>Nurs Crit Care</source>
          <year>2012</year>
          <volume>7</volume>
          <fpage>12</fpage>
          <lpage>6</lpage>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Juul</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Bichet</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>N&#xF8;rgaard</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors</article-title>
          <source>Am J Physiol Renal Physiol</source>
          <year>2014</year>
          <volume>306</volume>
          <fpage>F931</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">24598801</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Iorgi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Napoli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Allegri</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Olivieri</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bertelli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gallizia</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diabetes insipidus &#x2013; Diagnosis and management</article-title>
          <source>Horm Res Paediatr</source>
          <year>2012</year>
          <volume>77</volume>
          <fpage>69</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">22433947</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garc&#xED;a Casta&#xF1;o</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>P&#xE9;rez de Nanclares</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Madariaga</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Aguirre</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chocron</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Madrid</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Novel mutations associated with nephrogenic diabetes insipidus. A clinical-genetic study</article-title>
          <source>Eur J Pediatr</source>
          <year>2015</year>
          <volume>174</volume>
          <fpage>1373</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">25902753</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saifan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nasr</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sharma Acharya</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Perrera</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Faddoul</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diabetes insipidus: A challenging diagnosis with new drug therapies</article-title>
          <source>ISRN Nephrol 2013</source>
          <year>2013</year>
          <fpage>797620</fpage>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Hsia</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Hung</surname>
              <given-names>PC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Central diabetes insipidus in children with acute brain insult</article-title>
          <source>Pediatr Neurol</source>
          <year>2011</year>
          <volume>45</volume>
          <fpage>377</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">22114999</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Capatina</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Paluzzi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Karavitaki</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Diabetes insipidus after traumatic brain injury</article-title>
          <source>J Clin Med</source>
          <year>2015</year>
          <volume>4</volume>
          <fpage>1448</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="pmid">26239685</pub-id>
        </element-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hadjizacharia</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Beale</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Inaba</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Demetriades</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Acute diabetes insipidus in severe head injury: A prospective study</article-title>
          <source>J Am Coll Surg</source>
          <year>2008</year>
          <volume>207</volume>
          <fpage>477</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">18926448</pub-id>
        </element-citation>
      </ref>
      <ref id="ref12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alharfi</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Morrison</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Central diabetes insipidus in pediatric severe traumatic brain injury</article-title>
          <source>Pediatr Crit Care Med</source>
          <year>2013</year>
          <volume>14</volume>
          <fpage>203</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">23314181</pub-id>
        </element-citation>
      </ref>
      <ref id="ref13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schreckinger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Szerlip</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mittal</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Diabetes insipidus following resection of pituitary tumors</article-title>
          <source>Clin Neurol Neurosurg</source>
          <year>2013</year>
          <volume>115</volume>
          <fpage>121</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">22921808</pub-id>
        </element-citation>
      </ref>
      <ref id="ref14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sigounas</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Sharpless</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Senior</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Ewend</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>Predictors and incidence of central diabetes insipidus after endoscopic pituitary surgery</article-title>
          <source>Neurosurgery</source>
          <year>2008</year>
          <volume>62</volume>
          <fpage>71</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">18300893</pub-id>
        </element-citation>
      </ref>
      <ref id="ref15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shah</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Har-El</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Diabetes insipidus after pituitary surgery: Incidence after traditional versus endoscopic transsphenoidal approaches</article-title>
          <source>Am J Rhinol</source>
          <year>2001</year>
          <volume>15</volume>
          <fpage>377</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">11777244</pub-id>
        </element-citation>
      </ref>
      <ref id="ref16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bajpai</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kabra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Menon</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>Central diabetes insipidus: Clinical profile and factors indicating organic etiology in children</article-title>
          <source>Indian Pediatr</source>
          <year>2008</year>
          <volume>45</volume>
          <fpage>463</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">18599930</pub-id>
        </element-citation>
      </ref>
      <ref id="ref17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Varan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Atas</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Aydin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Yal&#xE7;in</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Aky&#xFC;z</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kutluk</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evaluation of patients with intracranial tumors and central diabetes insipidus</article-title>
          <source>Pediatr Hematol Oncol</source>
          <year>2013</year>
          <volume>30</volume>
          <fpage>668</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="pmid">23988090</pub-id>
        </element-citation>
      </ref>
      <ref id="ref18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maghnie</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cosi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Genovese</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Manca-Bitti</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zecca</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Central diabetes insipidus in children and young adults</article-title>
          <source>N Engl J Med</source>
          <year>2000</year>
          <volume>343</volume>
          <fpage>998</fpage>
          <lpage>1007</lpage>
          <pub-id pub-id-type="pmid">11018166</pub-id>
        </element-citation>
      </ref>
      <ref id="ref19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Tung</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>MZ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical characteristics of central diabetes insipidus in Taiwanese children</article-title>
          <source>J Formos Med Assoc</source>
          <year>2013</year>
          <volume>112</volume>
          <fpage>616</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">23916565</pub-id>
        </element-citation>
      </ref>
      <ref id="ref20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maghnie</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Altobelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Di Iorgi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Genovese</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Meloni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Manca-Bitti</surname>
              <given-names>ML</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Idiopathic central diabetes insipidus is associated with abnormal blood supply to the posterior pituitary gland caused by vascular impairment of the inferior hypophyseal artery system</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2004</year>
          <volume>89</volume>
          <fpage>1891</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">15070961</pub-id>
        </element-citation>
      </ref>
      <ref id="ref21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woredekal</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Recurrent central diabetes insipidus secondary to cryptococcal meningitis</article-title>
          <source>J Assoc Acad Minor Phys</source>
          <year>1998</year>
          <volume>9</volume>
          <fpage>22</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">9585672</pub-id>
        </element-citation>
      </ref>
      <ref id="ref22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawamoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hatanaka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Imakita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tamaki</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Central diabetes insipidus in an HHV6 encephalitis patient with a posterior pituitary lesion that developed after tandem cord blood transplantation</article-title>
          <source>Intern Med</source>
          <year>2013</year>
          <volume>52</volume>
          <fpage>1107</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="pmid">23676599</pub-id>
        </element-citation>
      </ref>
      <ref id="ref23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Domiciano</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>de Carvalho</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Macedo</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Laurindo</surname>
              <given-names>IM</given-names>
            </name>
          </person-group>
          <article-title>Central diabetes insipidus induced by tuberculosis in a rheumatoid arthritis patient</article-title>
          <source>Acta Reumatol Port</source>
          <year>2010</year>
          <volume>35</volume>
          <fpage>232</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">20711095</pub-id>
        </element-citation>
      </ref>
      <ref id="ref24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mishra</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Agrawal</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>Partial central diabetes insipidus following tuberculous meningitis</article-title>
          <source>J Assoc Physicians India</source>
          <year>1993</year>
          <volume>41</volume>
          <fpage>757</fpage>
          <pub-id pub-id-type="pmid">8005943</pub-id>
        </element-citation>
      </ref>
      <ref id="ref25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Non</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Brito</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Anastasopoulou</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Neurosarcoidosis-associated central diabetes insipidus masked by adrenal insufficiency</article-title>
          <source>BMJ Case Rep 2015</source>
          <year>2015</year>
          <fpage>pii</fpage>
          <fpage>Bcr2014206390</fpage>
        </element-citation>
      </ref>
      <ref id="ref26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Fost</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>van Trotsenburg</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>van Santen</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Endert</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>van den Elzen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kamsteeg</surname>
              <given-names>EJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Familial neurohypophyseal diabetes insipidus due to a novel mutation in the arginine vasopressin-neurophysin II gene</article-title>
          <source>Eur J Endocrinol</source>
          <year>2011</year>
          <volume>165</volume>
          <fpage>161</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">21498630</pub-id>
        </element-citation>
      </ref>
      <ref id="ref27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turkkahraman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Saglar</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Karaduman</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mergen</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>AVP-NPII gene mutations and clinical characteristics of the patients with autosomal dominant familial central diabetes insipidus</article-title>
          <source>Pituitary</source>
          <year>2015</year>
          <volume>18</volume>
          <fpage>898</fpage>
          <lpage>904</lpage>
          <pub-id pub-id-type="pmid">26134705</pub-id>
        </element-citation>
      </ref>
      <ref id="ref28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghirardello</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dusi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Castiglione</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fumagalli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mosca</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Congenital central diabetes insipidus and optic atrophy in a Wolfram newborn: Is there a role for WFS1 gene in neurodevelopment?</article-title>
          <source>Ital J Pediatr</source>
          <year>2014</year>
          <volume>40</volume>
          <fpage>76</fpage>
          <pub-id pub-id-type="pmid">25255707</pub-id>
        </element-citation>
      </ref>
      <ref id="ref29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perrotta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Di Iorgi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ragione</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Scianguetta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Borriello</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Allegri</surname>
              <given-names>AE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early-onset central diabetes insipidus is associated with de novo arginine vasopressin-neurophysin II or Wolfram syndrome 1 gene mutations</article-title>
          <source>Eur J Endocrinol</source>
          <year>2015</year>
          <volume>172</volume>
          <fpage>461</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">25740874</pub-id>
        </element-citation>
      </ref>
      <ref id="ref30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shin</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HJ</given-names>
            </name>
          </person-group>
          <article-title>Polyuria with the concurrent manifestation of Central Diabetes Insipidus (CDI) and type 2 Diabetes Mellitus (DM)</article-title>
          <source>Electrolyte Blood Press</source>
          <year>2012</year>
          <volume>10</volume>
          <fpage>26</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">23508726</pub-id>
        </element-citation>
      </ref>
      <ref id="ref31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bockenhauer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bichet</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus</article-title>
          <source>Nat Rev Nephrol</source>
          <year>2015</year>
          <volume>11</volume>
          <fpage>576</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">26077742</pub-id>
        </element-citation>
      </ref>
      <ref id="ref32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujimoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Okada</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kawashima</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Miyahara</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kawaba</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical overview of nephrogenic diabetes insipidus based on a nationwide survey in Japan</article-title>
          <source>Yonago Acta Med</source>
          <year>2014</year>
          <volume>57</volume>
          <fpage>85</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">25324589</pub-id>
        </element-citation>
      </ref>
      <ref id="ref33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sahakitrungruang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tee</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Rattanachartnarong</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Shotelersuk</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Suphapeetiporn</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>WL</given-names>
            </name>
          </person-group>
          <article-title>Functional characterization of vasopressin receptor 2 mutations causing partial and complete congenital nephrogenic diabetes insipidus in Thai families</article-title>
          <source>Horm Res Paediatr</source>
          <year>2010</year>
          <volume>73</volume>
          <fpage>349</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="pmid">20389105</pub-id>
        </element-citation>
      </ref>
      <ref id="ref34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bendz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Aurell</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced diabetes insipidus: Incidence, prevention and management</article-title>
          <source>Drug Saf</source>
          <year>1999</year>
          <volume>21</volume>
          <fpage>449</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">10612269</pub-id>
        </element-citation>
      </ref>
      <ref id="ref35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bedford</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Weggery</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Joyce</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Leader</surname>
              <given-names>JP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lithium-induced nephrogenic diabetes insipidus: Renal effects of amiloride</article-title>
          <source>Clin J Am Soc Nephrol</source>
          <year>2008</year>
          <volume>3</volume>
          <fpage>1324</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">18596116</pub-id>
        </element-citation>
      </ref>
      <ref id="ref36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Behl</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kotwani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kaur</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Goel</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of prolonged lithium therapy-induced nephrogenic diabetes insipidus</article-title>
          <source>Eur J Pharmacol</source>
          <year>2015</year>
          <volume>755</volume>
          <fpage>27</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="pmid">25746463</pub-id>
        </element-citation>
      </ref>
      <ref id="ref37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Imam</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Hasan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shahid</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Lithium-induced nephrogenic diabetes insipidus</article-title>
          <source>J Pak Med Assoc</source>
          <year>2005</year>
          <volume>55</volume>
          <fpage>125</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">15852752</pub-id>
        </element-citation>
      </ref>
      <ref id="ref38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eustatia-Rutten</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Tamsma</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Meinders</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>
          <article-title>Lithium-induced nephrogenic diabetes insipidus</article-title>
          <source>Neth J Med</source>
          <year>2001</year>
          <volume>58</volume>
          <fpage>137</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">11246113</pub-id>
        </element-citation>
      </ref>
      <ref id="ref39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mukhopadhyay</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gokulkrishnan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mohanaruban</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Lithium-induced nephrogenic diabetes insipidus in older people</article-title>
          <source>Age Ageing</source>
          <year>2001</year>
          <volume>30</volume>
          <fpage>347</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">11509315</pub-id>
        </element-citation>
      </ref>
      <ref id="ref40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kohli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>S</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>A</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Psychogenic polydipsia</article-title>
          <source>Indian J Psychiatry</source>
          <year>2011</year>
          <volume>53</volume>
          <fpage>166</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">21772654</pub-id>
        </element-citation>
      </ref>
      <ref id="ref41">
        <label>41</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Sarma</surname>
              <given-names>KV</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Muruganathan</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Algorithmic approach for the diagnosis of polyuria</article-title>
          <source>Medicine Update</source>
          <year>2013</year>
          <volume>23</volume>
          <publisher-loc>New Delhi</publisher-loc>
          <publisher-name>Jaypee Brothers Medical Publishers (P) Ltd</publisher-name>
          <fpage>311</fpage>
          <lpage>3</lpage>
        </element-citation>
      </ref>
      <ref id="ref42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinberg</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Dinsmoor</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Silver</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <article-title>Severe hydramnios and preterm delivery in association with transient maternal diabetes insipidus</article-title>
          <source>Obstet Gynecol</source>
          <year>2010</year>
          <volume>116</volume>
          <issue>Suppl 2</issue>
          <fpage>547</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">20664450</pub-id>
        </element-citation>
      </ref>
      <ref id="ref43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ananthakrishnan</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Diabetes insipidus in pregnancy: Etiology, evaluation, and management</article-title>
          <source>Endocr Pract</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>377</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">19454377</pub-id>
        </element-citation>
      </ref>
      <ref id="ref44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aleksandrov</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Audibert</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bedard</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Mahone</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Goffinet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kadoch</surname>
              <given-names>IJ</given-names>
            </name>
          </person-group>
          <article-title>Gestational diabetes insipidus: A review of an underdiagnosed condition</article-title>
          <source>J Obstet Gynaecol Can</source>
          <year>2010</year>
          <volume>32</volume>
          <fpage>225</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">20500966</pub-id>
        </element-citation>
      </ref>
      <ref id="ref45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morgenthaler</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>Struck</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bergmann</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin</article-title>
          <source>Clin Chem</source>
          <year>2006</year>
          <volume>52</volume>
          <fpage>112</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">16269513</pub-id>
        </element-citation>
      </ref>
      <ref id="ref46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Fost</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oussaada</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Endert</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Linthorst</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Serlie</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Soeters</surname>
              <given-names>MR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The water deprivation test and a potential role for the arginine vasopressin precursor copeptin to differentiate diabetes insipidus from primary polydipsia</article-title>
          <source>Endocr Connect</source>
          <year>2015</year>
          <volume>4</volume>
          <fpage>86</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">25712898</pub-id>
        </element-citation>
      </ref>
      <ref id="ref47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Bragan&#xE7;a</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Moyses</surname>
              <given-names>ZP</given-names>
            </name>
            <name>
              <surname>Magaldi</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Carbamazepine can induce kidney water absorption by increasing aquaporin 2 expression</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2010</year>
          <volume>25</volume>
          <fpage>3840</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">20525972</pub-id>
        </element-citation>
      </ref>
      <ref id="ref48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meinders</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Cejka</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
          <article-title>The antidiuretic action of carbamazepine in man</article-title>
          <source>Clin Sci Mol Med</source>
          <year>1974</year>
          <volume>47</volume>
          <fpage>289</fpage>
          <lpage>99</lpage>
          <pub-id pub-id-type="pmid">4426163</pub-id>
        </element-citation>
      </ref>
      <ref id="ref49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henry</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Lawson</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Reavey</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Renfrew</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Hyponatraemia during carbamazepine treatment</article-title>
          <source>Br Med J</source>
          <year>1977</year>
          <volume>1</volume>
          <fpage>83</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">832021</pub-id>
        </element-citation>
      </ref>
      <ref id="ref50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Amelsvoort</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bakshi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Devaux</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Schwabe</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Hyponatremia associated with carbamazepine and oxcarbazepine therapy: A review</article-title>
          <source>Epilepsia</source>
          <year>1994</year>
          <volume>35</volume>
          <fpage>181</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">8112243</pub-id>
        </element-citation>
      </ref>
      <ref id="ref51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kamiyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Iseki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kawazoe</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Takishita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fukiyama</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Carbamazepine-induced hyponatremia in a patient with partial central diabetes insipidus</article-title>
          <source>Nephron</source>
          <year>1993</year>
          <volume>64</volume>
          <fpage>142</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">8502320</pub-id>
        </element-citation>
      </ref>
      <ref id="ref52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rad&#xF3;</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Decreased antidiuretic response in diabetes insipidus during prolonged treatment with carbamazepine presumably due to enzym-induction</article-title>
          <source>Endokrinologie</source>
          <year>1976</year>
          <volume>67</volume>
          <fpage>322</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">976207</pub-id>
        </element-citation>
      </ref>
      <ref id="ref53">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hocken</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Longson</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Reduction of free water clearance by chlorporpamide</article-title>
          <source>Br Med J</source>
          <year>1968</year>
          <volume>1</volume>
          <fpage>355</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">5638262</pub-id>
        </element-citation>
      </ref>
      <ref id="ref54">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cushard</surname>
              <given-names>WG</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Beauchamp</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>ND</given-names>
            </name>
          </person-group>
          <article-title>Oral therapy of diabetes insipidus with chlorpropamide</article-title>
          <source>Calif Med</source>
          <year>1971</year>
          <volume>115</volume>
          <fpage>1</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">5563815</pub-id>
        </element-citation>
      </ref>
      <ref id="ref55">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wales</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>Mode of action of chlorpropamide in the treatment of diabetes insipidus</article-title>
          <source>Proc R Soc Med</source>
          <year>1971</year>
          <volume>64</volume>
          <fpage>1070</fpage>
          <lpage>1</lpage>
          <pub-id pub-id-type="pmid">5145326</pub-id>
        </element-citation>
      </ref>
      <ref id="ref56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moses</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Howanitz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>van Gemert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Clofibrate-induced antidiuresis</article-title>
          <source>J Clin Invest</source>
          <year>1973</year>
          <volume>52</volume>
          <fpage>535</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">4685079</pub-id>
        </element-citation>
      </ref>
      <ref id="ref57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>P</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Earll</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Schaaf</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Comparison of clofibrate and chlorpropamide in vasopressin-responsive diabetes insipidus</article-title>
          <source>Metabolism</source>
          <year>1977</year>
          <volume>26</volume>
          <fpage>749</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="pmid">865282</pub-id>
        </element-citation>
      </ref>
      <ref id="ref58">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsukura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chihara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yoshimoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Clofibrate-induced myopathy in patients with diabetes insipidus</article-title>
          <source>Endocrinol Jpn</source>
          <year>1980</year>
          <volume>27</volume>
          <fpage>401</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">7439122</pub-id>
        </element-citation>
      </ref>
      <ref id="ref59">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abraham</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Choong</surname>
              <given-names>CS</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of hydrochlorothiazide and low renal solute feed in neonatal central diabetes insipidus with transition to oral desmopressin in early infancy</article-title>
          <source>Int J Pediatr Endocrinol 2014</source>
          <year>2014</year>
          <fpage>11</fpage>
        </element-citation>
      </ref>
      <ref id="ref60">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Joo</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Na</surname>
              <given-names>KY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl co-transporter, and epithelial sodium channel</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>2836</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">15504936</pub-id>
        </element-citation>
      </ref>
      <ref id="ref61">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al Nofal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lteif</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Thiazide diuretics in the management of young children with central diabetes insipidus</article-title>
          <source>J Pediatr</source>
          <year>2015</year>
          <volume>167</volume>
          <fpage>658</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">26130110</pub-id>
        </element-citation>
      </ref>
      <ref id="ref62">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;doherty</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Rosser</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Slater</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Diabetes insipidus: The influence of chlorothiazide therapy in affected children</article-title>
          <source>Can Med Assoc J</source>
          <year>1962</year>
          <volume>86</volume>
          <fpage>559</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="pmid">14480853</pub-id>
        </element-citation>
      </ref>
      <ref id="ref63">
        <label>63</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alon</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus</article-title>
          <source>Am J Nephrol</source>
          <year>1985</year>
          <volume>5</volume>
          <fpage>9</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">3970081</pub-id>
        </element-citation>
      </ref>
      <ref id="ref64">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tetiker</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ko&#xE7;ak</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of indapamide in central diabetes insipidus</article-title>
          <source>Arch Intern Med</source>
          <year>1999</year>
          <volume>159</volume>
          <fpage>2085</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">10510995</pub-id>
        </element-citation>
      </ref>
      <ref id="ref65">
        <label>65</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ko&#xE7;ak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Karademir</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Tetiker</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Antidiuretic effect of indapamide in central diabetes insipidus</article-title>
          <source>Acta Endocrinol (Copenh)</source>
          <year>1990</year>
          <volume>123</volume>
          <fpage>657</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">2284890</pub-id>
        </element-citation>
      </ref>
      <ref id="ref66">
        <label>66</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weinstock</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Moses</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Desmopressin and indomethacin therapy for nephrogenic diabetes insipidus in patients receiving lithium carbonate</article-title>
          <source>South Med J</source>
          <year>1990</year>
          <volume>83</volume>
          <fpage>1475</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">2123565</pub-id>
        </element-citation>
      </ref>
      <ref id="ref67">
        <label>67</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lam</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Kjellstrand</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Emergency treatment of lithium-induced diabetes insipidus with nonsteroidal anti-inflammatory drugs</article-title>
          <source>Ren Fail</source>
          <year>1997</year>
          <volume>19</volume>
          <fpage>183</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">9044466</pub-id>
        </element-citation>
      </ref>
      <ref id="ref68">
        <label>68</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delaney</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>de Pertuz</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nixon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bourke</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Indomethacin in streptozocin-induced nephrogenic diabetes insipidus</article-title>
          <source>Am J Kidney Dis</source>
          <year>1987</year>
          <volume>9</volume>
          <fpage>79</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="pmid">2949606</pub-id>
        </element-citation>
      </ref>
      <ref id="ref69">
        <label>69</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kortenoeven</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gaeggeler</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Rossier</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Wetzels</surname>
              <given-names>JF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus</article-title>
          <source>Kidney Int</source>
          <year>2009</year>
          <volume>76</volume>
          <fpage>44</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="pmid">19367330</pub-id>
        </element-citation>
      </ref>
      <ref id="ref70">
        <label>70</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Waele</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cools</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Guchtenaere</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Van de Walle</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Raes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Van Aken</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Desmopressin lyophilisate for the treatment of central diabetes insipidus: First experience in very young infants</article-title>
          <source>Int J Endocrinol Metab</source>
          <year>2014</year>
          <volume>12</volume>
          <fpage>e16120</fpage>
          <pub-id pub-id-type="pmid">25745483</pub-id>
        </element-citation>
      </ref>
      <ref id="ref71">
        <label>71</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qureshi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Galiveeti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bichet</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Diabetes insipidus: Celebrating a century of vasopressin therapy</article-title>
          <source>Endocrinology</source>
          <year>2014</year>
          <volume>155</volume>
          <fpage>4605</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">25211589</pub-id>
        </element-citation>
      </ref>
      <ref id="ref72">
        <label>72</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kauli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Laron</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>A vasopressin analogue in treatment of diabetes insipidus</article-title>
          <source>Arch Dis Child</source>
          <year>1974</year>
          <volume>49</volume>
          <fpage>482</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">4850356</pub-id>
        </element-citation>
      </ref>
      <ref id="ref73">
        <label>73</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Guchtenaere</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Van Herzeele</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Raes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dehoorne</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hoebeke</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Van Laecke</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oral lyophylizate formulation of desmopressin: Superior pharmacodynamics compared to tablet due to low food interaction</article-title>
          <source>J Urol</source>
          <year>2011</year>
          <volume>185</volume>
          <fpage>2308</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">21511277</pub-id>
        </element-citation>
      </ref>
      <ref id="ref74">
        <label>74</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lam</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Wat</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Ip</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Pang</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Kumana</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus</article-title>
          <source>Br J Clin Pharmacol</source>
          <year>1996</year>
          <volume>42</volume>
          <fpage>379</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">8877030</pub-id>
        </element-citation>
      </ref>
      <ref id="ref75">
        <label>75</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fjellestad-Paulsen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tubiana-Rufi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Czernichow</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin</article-title>
          <source>Acta Endocrinol (Copenh)</source>
          <year>1987</year>
          <volume>115</volume>
          <fpage>307</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="pmid">3618082</pub-id>
        </element-citation>
      </ref>
      <ref id="ref76">
        <label>76</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Juul</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Erichsen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
          <article-title>Temporal delays and individual variation in antidiuretic response to desmopressin</article-title>
          <source>Am J Physiol Renal Physiol</source>
          <year>2013</year>
          <volume>304</volume>
          <fpage>F268</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="pmid">23136002</pub-id>
        </element-citation>
      </ref>
      <ref id="ref77">
        <label>77</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Juul</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Sandstr&#xF6;m</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Erichsen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>N&#xF8;rgaard</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Gender difference in antidiuretic response to desmopressin</article-title>
          <source>Am J Physiol Renal Physiol</source>
          <year>2011</year>
          <volume>300</volume>
          <fpage>F1116</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="pmid">21367921</pub-id>
        </element-citation>
      </ref>
      <ref id="ref78">
        <label>78</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fukuda</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Hizuka</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Takano</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Oral DDAVP is a good alternative therapy for patients with central diabetes insipidus: Experience of five-year treatment</article-title>
          <source>Endocr J</source>
          <year>2003</year>
          <volume>50</volume>
          <fpage>437</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">14599118</pub-id>
        </element-citation>
      </ref>
      <ref id="ref79">
        <label>79</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larijani</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tabatabaei</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Soltani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Taheri</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pajouhi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bastanhagh</surname>
              <given-names>MH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comparison of desmopressin (DDAVP) tablet and intranasal spray in the treatment of central diabetes insipidus</article-title>
          <source>RJMS</source>
          <year>2004</year>
          <volume>11</volume>
          <fpage>289</fpage>
          <lpage>97</lpage>
        </element-citation>
      </ref>
      <ref id="ref80">
        <label>80</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Westgren</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Wittstr&#xF6;m</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Oral desmopressin in central diabetes insipidus</article-title>
          <source>Arch Dis Child</source>
          <year>1986</year>
          <volume>61</volume>
          <fpage>247</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">3963868</pub-id>
        </element-citation>
      </ref>
      <ref id="ref81">
        <label>81</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wallia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bizhanova</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Goldsmith</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Gossett</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Kopp</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Acute diabetes insipidus mediated by vasopressinase after placental abruption</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2013</year>
          <volume>98</volume>
          <fpage>881</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">23393172</pub-id>
        </element-citation>
      </ref>
      <ref id="ref82">
        <label>82</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>K&#xE4;ll&#xE9;n</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Carlsson</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Bengtsson</surname>
              <given-names>BK</given-names>
            </name>
          </person-group>
          <article-title>Diabetes insipidus and use of desmopressin (Minirin) during pregnancy</article-title>
          <source>Eur J Endocrinol</source>
          <year>1995</year>
          <volume>132</volume>
          <fpage>144</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">7858730</pub-id>
        </element-citation>
      </ref>
      <ref id="ref83">
        <label>83</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Oiso</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Juul</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>N&#xF8;rgaard</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: Results of a multicenter open-label dose-titration study</article-title>
          <source>Endocr J</source>
          <year>2013</year>
          <volume>60</volume>
          <fpage>1085</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="pmid">23811987</pub-id>
        </element-citation>
      </ref>
      <ref id="ref84">
        <label>84</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murakami</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hatoko</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nambu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Matsuo</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yonemitsu</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Desmopressin orally disintegrating tablet in Japanese patients with central diabetes insipidus: A retrospective study of switching from intranasal desmopressin</article-title>
          <source>Endocr J</source>
          <year>2014</year>
          <volume>61</volume>
          <fpage>773</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">24849384</pub-id>
        </element-citation>
      </ref>
      <ref id="ref85">
        <label>85</label>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <name>
              <surname>Nozaki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Akazawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Satoh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sagara</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Horie</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Quality of life in the patients with central diabetes insipidus assessed by Nagasaki Diabetes Insipidus Questionnaire</article-title>
          <source>Endocrine</source>
          <year>2015</year>
          <date-in-citation>Last accessed on 2015 Oct 16</date-in-citation>
          <comment>Epub ahead of print</comment>
          <comment>doi:101007/s12020-015-0637-3</comment>
          <comment>Available from: <uri xlink:type="simple" xlink:href="http://linkspringercom/article/101007%2Fs12020-015-0637-3">http://linkspringercom/article/101007%2Fs12020-015-0637-3</uri></comment>
        </element-citation>
      </ref>
      <ref id="ref86">
        <label>86</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vande Walle</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stockner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Raes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>N&#xF8;rgaard</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Desmopressin 30 years in clinical use: A safety review</article-title>
          <source>Curr Drug Saf</source>
          <year>2007</year>
          <volume>2</volume>
          <fpage>232</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">18690973</pub-id>
        </element-citation>
      </ref>
      <ref id="ref87">
        <label>87</label>
        <element-citation publication-type="webpage">
          <article-title>Instructions for Patient on Desmopressin Treatment for Diabetes Insipidus. Chennai (TN): He Indian Society for Pediatric and Adolescent Endocrinology</article-title>
          <year>c2015</year>
          <date-in-citation>Last accessed on 2015 Jul 27; Last cited on 2015 Jul 27</date-in-citation>
          <comment>Available from: <uri xlink:type="simple" xlink:href="http://www.ispae.org.in/html_pages/diabetes_insipidus.php">http://www.ispae.org.in/html_pages/diabetes_insipidus.php</uri></comment>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Hospital (Lond 1886)</journal-id>
      <journal-id journal-id-type="pmc">hosplond</journal-id>
      <journal-title-group>
        <journal-title>The Hospital</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0267-6478</issn>
      <publisher>
        <publisher-name>Scientific Press</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">29817212</article-id>
      <article-id pub-id-type="pmc">5205736</article-id>
      <article-id pub-id-type="pmc-scan">hosplond73701-0007b</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Hospital Clinics</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Coma in Diabetes Insipidus</article-title>
      </title-group>
      <pub-date pub-type="ppub">
        <day>24</day>
        <month>9</month>
        <year>1904</year>
      </pub-date>
      <volume>36</volume>
      <issue>939</issue>
      <fpage seq="b">445</fpage>
      <lpage>446</lpage>
      <permissions>
        <ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2014-05-29">http://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <floats-group>
    <graphic xlink:href="hosplond73701-0007" id="sp1" content-type="scanned-page" xlink:role="445" position="float" orientation="portrait"/>
    <graphic xlink:href="hosplond73701-0008" id="sp2" content-type="scanned-page" xlink:role="446" position="float" orientation="portrait"/>
  </floats-group>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Diabetes Endocrinol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin Diabetes Endocrinol</journal-id>
      <journal-title-group>
        <journal-title>Clinical Diabetes and Endocrinology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2055-8260</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">30693099</article-id>
      <article-id pub-id-type="pmc">6343255</article-id>
      <article-id pub-id-type="publisher-id">73</article-id>
      <article-id pub-id-type="doi">10.1186/s40842-018-0073-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6674-2611</contrib-id>
          <name>
            <surname>Tan</surname>
            <given-names>Meng H.</given-names>
          </name>
          <address>
            <phone>+1(734) 647-4940</phone>
            <email>mengt@med.umich.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Iyengar</surname>
            <given-names>Ravi</given-names>
          </name>
          <address>
            <email>ravi@iyengars.net</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mizokami-Stout</surname>
            <given-names>Kara</given-names>
          </name>
          <address>
            <email>kmizokam@med.umich.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yentz</surname>
            <given-names>Sarah</given-names>
          </name>
          <address>
            <email>yentzs@med.umich.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>MacEachern</surname>
            <given-names>Mark P.</given-names>
          </name>
          <address>
            <email>markmac@umich.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shen</surname>
            <given-names>Li Yan</given-names>
          </name>
          <address>
            <email>sly1003@126.com</email>
          </address>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Redman</surname>
            <given-names>Bruce</given-names>
          </name>
          <address>
            <email>redmanb@med.umich.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gianchandani</surname>
            <given-names>Roma</given-names>
          </name>
          <address>
            <email>romag@med.umich.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000086837370</institution-id><institution-id institution-id-type="GRID">grid.214458.e</institution-id><institution>Division of Metabolism, Endocrinology &amp; Diabetes, Department of Internal Medicine, </institution><institution>University of Michigan, </institution></institution-wrap>24 Frank Lloyd Wright Drive, Ann Arbor, MI 48106 USA </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0705 3621</institution-id><institution-id institution-id-type="GRID">grid.240684.c</institution-id><institution>Present address: Endocrinology, Rush University Medical Center, </institution></institution-wrap>1725 West Harrison Street, Chicago, IL 60612 USA </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000000086837370</institution-id><institution-id institution-id-type="GRID">grid.214458.e</institution-id><institution>Division of Hematology/Oncology, Department of Internal Medicine, </institution><institution>University of Michigan, </institution></institution-wrap>1500 E. Medical Center Drive, Ann Arbor, MI 48109 USA </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000000086837370</institution-id><institution-id institution-id-type="GRID">grid.214458.e</institution-id><institution>Taubman Health Sciences Library, University of Michigan, </institution></institution-wrap>1135 Catherine Street, Ann Arbor, MI 48109 USA </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.412521.1</institution-id><institution>Affiliated Hospital of QingDao University, </institution></institution-wrap>QingDao, 16 Jiangsu Road, Sinan Qu, Qingdao, Shi, Shandong Sheng China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>1</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>22</day>
        <month>1</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2019</year>
      </pub-date>
      <volume>5</volume>
      <elocation-id>1</elocation-id>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>8</month>
          <year>2018</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>11</month>
          <year>2018</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s). 2019</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p id="Par1">Since 2011 six immune checkpoint inhibitors (ICI) have been approved to treat patients with many advanced solid tumor and hematological malignancies to improve their prognosis. Case reports of their endocrine immune-related adverse events [irAEs]) are increasingly published as more real-world patients with these malignancies are treated with these drugs. They alert physicians of a drug&#x2019;s AEs (which may change during a drug&#x2019;s life cycle) and contribute to post-marketing safety surveillance. Using a modified framework of Arksey and O&#x2019;Malley, we conducted a scoping review of the spectrum and characteristics of ICI-induced endocrinopathies case reports before and after ICIs are marketed.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p id="Par2">In July 2017, we searched, without date and language restrictions, 4 citation databases for ICI-induced endocrinopathies. We also hand-searched articles&#x2019; references, contents of relevant journals, and ran supplemental searches to capture recent reports through January 2018. For this study, a case should have information on type of cancer, type of ICI, clinical presentation, biochemical tests, treatment plus temporal association of ICI initiation with endocrinopathies. Two endocrinologists independently extracted the data which were then summarized and categorized.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p id="Par3">One hundred seventy nine articles reported 451 cases of ICI-induced endocrinopathies - 222 hypopituitarism, 152 thyroid disorders, 66 diabetes mellitus, 6 primary adrenal insufficiencies, 1 ACTH-dependent Cushing&#x2019;s syndrome, 1 hypoparathyroidism and 3 diabetes insipidus cases. Their clinical presentations reflect hormone excess or deficiency. Some were asymptomatic and others life-threatening. One or more endocrine glands could be affected. Polyglandular endocrinopathies could present simultaneously or in sequence. Many occur within 5&#x2009;months of therapy initiation; a few occurred after ICI was stopped. Mostly irreversible, they required long-term hormone replacement. High dose steroids were used when non-endocrine AEs coexisted or as therapy in adrenal insufficiency. There was variability of information in the case reports but all met the study criteria to make a diagnosis.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p id="Par4">The spectrum of ICI-induced endocrinopathies is wide (5 glands affected) and their presentation varied (12 endocrinopathies). Clinical reasoning integrating clinical, biochemical and treatment information is needed to properly diagnose and manage them. Physicians should be vigilant for their occurrence and be able to diagnose, investigate and manage them appropriately at onset and follow-up.</p>
        </sec>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (10.1186/s40842-018-0073-4) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Cancer immunotherapy</kwd>
        <kwd>Immune checkpoint inhibitors (ICI)</kwd>
        <kwd>ICI-induced endocrinopathies</kwd>
        <kwd>Endocrine immune-related AEs</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2019</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par70">Advances in our understanding of the immune response to cancer and mechanisms of immune modulation have been translated to immunotherapy for the treatment of many advanced solid tumor and hematological malignancies. The two most promising advances in cancer immunotherapy are cell-based adoptive therapy modalities and immune regulatory modalities. The immune regulatory modalities currently have a wider therapeutic utility than cell-based therapies. They consist of monoclonal antibodies (mAbs) to proteins known as immune checkpoint regulators - cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1) and programmed death ligand 1 and 2 (PD-L1 and PD-L2) [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p id="Par71">PD-1 and CTLA-4 are found on lymphocytes. PD-L1/L2 are found on many cells, including tumor cells. The typical function of these checkpoint regulator proteins is to diminish the immune response to antigen, acting as a brake on the immune system [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>]. Monoclonal Abs to these checkpoint regulator proteins, known as immune checkpoint inhibitors (ICIs), release the brake that has been placed on the immune system, allowing the patients&#x2019; immune system to attack cancer cells and certain healthy tissues. There are currently 6 ICIs approved for the treatment of many advanced cancers (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Immune checkpoint inhibitors approved by the Food and Drug Administration in USA</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Ipilimumab CTLA-4</th><th>Nivolumab PD-1</th><th>Pembrolizumab PD-1</th><th>Atezolizumab PD-L1</th><th>Avelumab PD-L1</th><th>Durvalumab PD-L1</th></tr></thead><tbody><tr><td colspan="7">Malignancy</td></tr><tr><td>&#x2003;Melanoma</td><td>&#x221A;*(3/2011)</td><td>&#x221A;*(12/2014)</td><td>&#x221A;*(9/2014)</td><td/><td/><td/></tr><tr><td>&#x2003;Non-small cell lung cancer</td><td/><td>&#x221A; (3/2015)</td><td>&#x221A; (10/2015)</td><td>&#x221A; (10/2016)</td><td/><td/></tr><tr><td>&#x2003;Renal cell carcinoma</td><td/><td>&#x221A; (11/2015)</td><td/><td/><td/><td/></tr><tr><td>&#x2003;Hepatocellular carcinoma</td><td/><td>&#x221A; (9/2017)</td><td/><td/><td/><td/></tr><tr><td>&#x2003;Classical Hodgkin&#x2019; s lymphoma</td><td/><td>&#x221A; (5/2016)</td><td>&#x221A; (3/2017)</td><td/><td/><td/></tr><tr><td>&#x2003;Head &amp; neck squamous cell carcinoma4</td><td/><td>&#x221A; (11/2017)</td><td>&#x221A; (8/2016)</td><td/><td/><td/></tr><tr><td>&#x2003;Urothelial Carcinoma</td><td/><td>&#x221A; (2/2017)</td><td>&#x221A; (5/2017)</td><td>&#x221A;*(5/2016)</td><td>&#x221A; (5/2017)</td><td>&#x221A;*(5/2017)</td></tr><tr><td>&#x2003;Colorectal cancer with high msi/mrd</td><td/><td>&#x221A; (8/2017)</td><td/><td/><td/><td/></tr><tr><td>&#x2003;Gastric cancer</td><td/><td/><td>&#x221A; (9/2017)</td><td/><td/><td/></tr><tr><td>&#x2003;Solid tumor with high msi/mrd</td><td/><td/><td>&#x221A; (7/2017)</td><td/><td/><td/></tr><tr><td>&#x2003;Merkel-cell carcinoma</td><td/><td/><td/><td/><td>&#x221A;* (3/2017)</td><td/></tr><tr><td>&#x2003;Bladder Cancer</td><td/><td/><td/><td>&#x221A; (04/2017)</td><td/><td/></tr></tbody></table><table-wrap-foot><p>*First indication approval date by FDA</p></table-wrap-foot></table-wrap></p>
      <p id="Par72">Use of ICIs brings forth a new toxicity called immune-related Adverse Events (irAEs) whose mechanisms and manifestations are quite different from those of cytotoxic chemotherapy, radiation or molecularly targeted agents. These irAEs are inflammatory in nature with potential to affect multiple organ systems. While not occurring in all patients, they are believed to be an autoimmune response that results from the blocking of the normal immune regulatory pathways. Common ICI irAEs include colitis, hepatitis, pneumonitis, dermatitis and endocrinopathies.</p>
      <p id="Par73">While non-endocrine irAEs require cessation of immunotherapy and usually resolve with immunosuppressive therapy [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>], endocrine irAEs, if managed appropriately, do not require cessation of ICIs and are, for the most part, irreversible and require long term management [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Endocrinologists will often be consulted to co-manage these patients and should be familiar with these endocrine irAEs (called ICI-induced endocrinopathies in this paper).</p>
      <p id="Par74">A drug&#x2019;s AE profile may change during its life cycle. Marketed drugs may have previously unreported AEs in real world patients because these patients do not have to meet study entry criteria of clinical trials. In addition, marketed drugs may have rare AEs which surface when many more patients are treated with them. In the United States (US), AEs of marketed drugs are reported by healthcare providers, patients and others directly or indirectly to the Food and Drug Administration (FDA). Healthcare providers may also publish their patient&#x2019;s AEs as case reports in medical journals. Such publications contribute to post-marketing safety surveillance of drugs and alert clinicians to these possible drug AEs.</p>
      <p id="Par75">A 2016 systematic review of case reports of irAEs related to CTLA-4 and PD-1 blockade therapy [<xref ref-type="bibr" rid="CR9">9</xref>] was based on a literature search done in August 2015, four years after the approval of anti-CTLA-4 mAB (ipilimumab) in 2011 and a few months after the approval of anti-PD-1 mAbs (nivolumab and pembrolizumab) in 2014. It included 84 cases of ICI-induced-endocrinopathies &#x2013; 79 with ipilimumab, 2 with pembrolizumab and 3 with nivolumab.</p>
      <p id="Par76">Since that review [<xref ref-type="bibr" rid="CR9">9</xref>], the profiles of ICI-induced endocrinopathies have changed for various reasons: (a) many more advanced cancer patients have been treated with ICIs; (b) the ICIs have been marketed longer; (c) more cancers have been approved for treatment with ICIs; (d) a new subclass of ICI drugs (anti PDL-1 mAbs) was approved in 2016/2017; and (e) rare cases of ICI-induced endocrinopathies have been reported as more patients are treated with these drugs.</p>
      <p id="Par77">In this paper, we report the findings of a scoping review of ICI-induced endocrinopathies case reports based on a literature search conducted in July 2017, 6&#x2009;years after the approval of ipilimumab, 3&#x2009;years after the approval of nivolumab and pembrolizumab, and about a year after the approval of atezolimumab, avelumab and durvalumab. We aim to uncover new knowledge of the changing profiles of ICI-induced endocrinopathies, before and after marketing, as more real-world patients with different advanced cancers are treated with these drugs.</p>
    </sec>
    <sec id="Sec2">
      <title>Method</title>
      <p id="Par78">We used the framework proposed by Arksey and O&#x2019;Malley [<xref ref-type="bibr" rid="CR10">10</xref>] and modified by Levac et al. [<xref ref-type="bibr" rid="CR11">11</xref>] to conduct this scoping review to map out the ICI-induced endocrinopathies.</p>
      <sec id="Sec3">
        <title>Stage 1: Identifying the research questions &#x2013; Purpose</title>
        <p id="Par79">What is the spectrum (extent, range and nature) of ICI-induced endocrinopathies? How and when did they present clinically? What investigations were conducted to support their diagnoses? How were they managed at onset and what were their outcomes?</p>
      </sec>
      <sec id="Sec4">
        <title>Stage 2: Identifying relevant studies- data sources and searches</title>
        <p id="Par80">In July 2017, we searched 4 citation databases for published articles and abstracts of cases of endocrinopathies associated with ICI therapy for cancer. The search was initially developed in 3 Ovid MEDLINE databases (MEDLINE, In-Process &amp; Other Non-Indexed Citations, Epub Ahead of Print) and then optimized for <ext-link ext-link-type="uri" xlink:href="http://embase.com">Embase.com</ext-link>, Cochrane Central Register of Controlled Trials via Wiley Online Library, and Clarivate Analytics Web of Science. The searches were built with a combination of controlled terms (Medical Subject Headings and EMTREE when available), and title or abstracts keywords. No date or language restrictions were included in the searches, but animal studies, editorials, and comments were excluded from review.</p>
        <p id="Par81">Throughout the review process until January 31, 2018 the authors conducted hand-searches of reference lists in articles, reviewed the contents of relevant journals, and ran supplemental searches in Ovid MEDLINE, Embase, and the Cochrane Central Register to capture recently published reports. Duplicate citations were excluded in EndNote X6 (Clarivate Analytics). (All reproducible search strategies are available in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Appendix 1).</p>
      </sec>
      <sec id="Sec5">
        <title>Stage 3: Study selection</title>
        <p id="Par82">For eligibility screening, the citations were categorized by type of endocrinopathy. For this review, a case should have information on the type of cancer, type of ICI used, clinical presentation, biochemical tests&#x2019; results, imaging results (if done), and initial and follow-up treatment.</p>
      </sec>
      <sec id="Sec6">
        <title>Stage 4: Charting the data &#x2013; Data extraction</title>
        <p id="Par83">The citations were distributed to teams of at least 2 endocrinologists to review (pituitary, adrenal and parathyroid, and diabetes insipidus: MHT and LYS; thyroid: RI and MHT; Diabetes mellitus: KMS, RG and MHT). Using a 2-step approach, each team member reviewed the title and abstract to identify potentially eligible relevant citation. Then, the full paper, if available, was retrieved, reviewed and data extracted. Non-English articles were translated with Google Translate.</p>
        <p id="Par84">The reviewers screened all assigned citations independently using a standardized data extraction form (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Appendix 2) to collect data on each case according to the guidelines for AEs publication as recommended by the International Society of Pharmaco-epidemiology and the International Society of Pharmacovigilance to evaluate the quality of case reports [<xref ref-type="bibr" rid="CR12">12</xref>]. They then compared their decisions and resolved any differences by consensus.</p>
      </sec>
      <sec id="Sec7">
        <title>Stage 5: Collating, summarizing and reporting the results</title>
        <p id="Par85">For this review, a case should have information on the type of cancer, type of ICI used, clinical presentation, biochemical tests&#x2019; results, imaging results (if done), and initial and follow-up treatment. When all the above is not reported, the case should have information on 2 of the following: clinical, biochemical and treatment information. To imply association, there should be close temporal relationship between ICI therapy initiation and subsequent development of endocrinopathy. We summarized and categorized the identified ICI-induced endocrinopathies according to the endocrine gland affected, whether it was associated with hyper- or hypofunction of the gland, and whether it involved one or more endocrinopathies (polyglandular endocrinopathies).</p>
      </sec>
    </sec>
    <sec id="Sec8">
      <title>Results</title>
      <p id="Par86">Figure <xref rid="Fig1" ref-type="fig">1</xref> shows the outcomes of the literature search. Of the 1041 citations identified, 218 had ICI-induced endocrinopathies citation with cases with sufficient information for this review. Some of these articles had information on two or more endocrinopathies. Eliminating these duplicates left 179 unique articles (116 papers, 43 abstracts and 20 letters to editor) which reported 451 cases of ICI-induced endocrinopathies that met study criteria for diagnosing the case.<fig id="Fig1"><label>Fig. 1</label><caption><p>PRISMA flow diagram</p></caption><graphic xlink:href="40842_2018_73_Fig1_HTML" id="MO1"/></fig></p>
      <p id="Par87">Five endocrine glands are affected with 12 endocrinopathies:<list list-type="bullet"><list-item><p id="Par88">pituitary (hypopituitarism (multiple or isolated hormone deficiency[ies]), diabetes insipidus, and ACTH-dependent Cushing&#x2019;s syndrome);</p></list-item><list-item><p id="Par89">thyroid (thyrotoxicosis [Graves&#x2019; disease and thyroiditis] and hypothyroidism [primary hypothyroidism and thyrotoxicosis progressing to hypothyroidism]),</p></list-item><list-item><p id="Par90">adrenal (primary adrenal insufficiency),</p></list-item><list-item><p id="Par91">pancreas (type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM)), and</p></list-item><list-item><p id="Par92">parathyroid glands (primary hypoparathyroidism)</p></list-item></list></p>
      <sec id="Sec9">
        <title>Hypophysitis/anterior hypopituitarism</title>
        <p id="Par93">Table <xref rid="Tab2" ref-type="table">2</xref> summarizes the data from the 222 cases of hypophysitis/anterior hypopituitarism [<xref ref-type="bibr" rid="CR13">13</xref>&#x2013;<xref ref-type="bibr" rid="CR96">96</xref>]. (Details of each case are in Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Appendix 3). Of the 222 cases, 220 met the inclusion criteria; the 2 without biochemical tests&#x2019; results had clinical and treatment information.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Cases of immune checkpoint inhibitors-induced hypophysitis and anterior pituitary insufficiency</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Information</th></tr></thead><tbody><tr><td>&#x2003;1. Number of Reports</td><td>84</td></tr><tr><td>&#x2003;2. Cases</td><td>222</td></tr><tr><td>&#x2003;3. Gender</td><td>Males = 145; Females = 62; Not reported = 15</td></tr><tr><td>&#x2003;4. Age (years)</td><td>Median = 61; Mean <underline>+</underline> SD = 60.4 <underline>+</underline> 11.4; Range = 31&#x2013;85</td></tr><tr><td>&#x2003;5. Pertinent medical history</td><td>PHxEndoD: Reported = 12; Not reported = 210<break/>FHxEndoD: Reported = 2; Not reported = 220<break/>PHxAutoD: Reported = 4; Not reported = 218</td></tr><tr><td>&#x2003;6. Type of cancer</td><td>Melanoma = 193; Renal cell carcinoma = 6; Prostate carcinoma = 7; non-small cell lung cancer = 5, lung cancer = 5; papillary thyroid carcinoma =1; mesothelioma =1; not reported = 4</td></tr><tr><td>&#x2003;7. Check point inhibitor<break/>ICI Drug D/C?:</td><td>Ipilimumab = 188; Nivolumab = 13; Tremelilumab = 4; CTLA-4 = 8; Atezolizumab = 2; Ipilimumab + Nivolumab = 3; Nivolumab, then Ipilimumab = 1; Ipilimumab, then Pembrolizumab = 2; Ipilimumab, then Nivomumab = 1.<break/>Yes = 45 No = 17 Not reported = 160</td></tr><tr><td>&#x2003;8. Clinical presentation</td><td>Reflects the hormone(s) affected</td></tr><tr><td>&#x2003;9. Onset (weeks) after first dose</td><td>Median = 12; Mean = 13.8 <underline>+</underline> 10.3; Range 3&#x2013;76</td></tr><tr><td>&#x2003;10. Biochemical tests</td><td>&#x2193;ACTH/cortisol = 183;<break/>&#x2193;TSH/FT4/FT3 = 172;<break/>&#x2193;LH/FSH/T/Estradiol = 137;<break/>&#x2193;PRL = 22; &#x2193;GH/IGF-1 = 22. &#x2191;TSH, &#x2193;FT4,/FT3 = 2</td></tr><tr><td>&#x2003;11. Diagnosis (patients with # hormone deficiencies[def])</td><td>5 deficiency (def) = 7; 4 def = 14; 3 def = 72; 2 def = 47;<break/>One (isolated) def = 36 (31 ACTH, 4 TSH, 1 LH, FSH def).<break/>3 reports with case series account for remainder</td></tr><tr><td>&#x2003;12. Imaging Brain/Pituitary MRI/CT</td><td>Enlarged/Enhanced = 108; Normal 49; Not reported =11; Not done = 11; Sella abnormality = 3; atrophy = 3<break/>3 reports with case series account for remainder</td></tr><tr><td>&#x2003;13. CTCAE grade reported</td><td>Yes = 5; Not reported in 217</td></tr><tr><td>&#x2003;14. Therapy at onset at diagnosis</td><td>High dose steroids = 144; steroids = 62; no steroids = 7; Not reported = 9</td></tr><tr><td>&#x2003;15. Outcome</td><td>219 recovered/discharged (replacement therapy 195 &amp; 24 not reported); 3 deceased.</td></tr></tbody></table></table-wrap></p>
        <p id="Par94">This cohort&#x2019;s median age was 61&#x2009;years. Most (65%) were male (in contrast to mostly females in non-ICI induced autoimmune hypophysitis). The majority (87%) had melanoma. CTLA-4 and PD-1/PD-L1 mAbs were used as monotherapy in 200 and 15 patients respectively with 7 on both. The median onset of clinical presentation was 12&#x2009;weeks (range 3&#x2013;76&#x2009;weeks) after initiation of ICI. Symptoms reflected the associated hormone(s) deficiency(ies) with or without the mass-effect of pituitary enlargement (e.g. headache). In the 176 patients with detailed hormone information, 36 had one hormone deficiency, 47 had two, 72 had three, 14 with four and 7 with five. Secondary adrenal deficiency was present in 83%, secondary hypothyroidism in 77%, and secondary hypogonadism in 53% of patients. Of the 167 patients with pituitary magnetic resonance imaging (MRI)/computerized tomography (CT) scans, 108 showed enlarged/enhanced pituitary. Not all patients with enlarged pituitary presented with headaches and not all who presented with headaches (<italic>n</italic> = 126) had enlarged pituitary. High dose steroid was used as initial therapy in 69%, physiological dose steroid in 29% and no steroid in 2% of patients. When the cases were published, 220 were alive and 2 diseased (cause of death not stated). Of the 220, 184 were on replacement therapy, 32 had no information on discharge medications, and 4 on no replacement medications. During the preapproval and post-marketing periods there were 18 and 204 (166 in the first 4&#x2009;years of marketing) respectively. There were 9 cases of polyglandular endocrinopathies involving anterior hypopituitarism - plus thyroiditis [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR89">89</xref>], plus primary hypothyroidism [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR93">93</xref>], plus Graves&#x2019; disease and T1DM [<xref ref-type="bibr" rid="CR76">76</xref>], and plus T1DM [<xref ref-type="bibr" rid="CR95">95</xref>].</p>
      </sec>
      <sec id="Sec10">
        <title>Thyroid diseases</title>
        <p id="Par95">Table <xref rid="Tab3" ref-type="table">3</xref> summarizes the data from the 152 cases of ICI-induced thyroid disorders (Details of each case [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR97">97</xref>&#x2013;<xref ref-type="bibr" rid="CR138">138</xref>] are in Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Appendix 4).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Cases of immune checkpoint inhibitors-induced thyrotoxicosis and hypothyroidism</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th colspan="2">Thyrotoxicosis</th><th colspan="2">Hypothyroidism</th></tr><tr><th>Graves&#x2019; disease</th><th>Thyroiditis</th><th>Primary hypothyroidism</th><th>Thyrotoxicosis &#x2192; Hypothyroidism</th></tr></thead><tbody><tr><td>Reports</td><td>7 (2 on same case)</td><td>31</td><td>16</td><td>21</td></tr><tr><td>Cases</td><td>6</td><td>67</td><td>29</td><td>50</td></tr><tr><td>Gender</td><td>Males = 4; Females = 2</td><td>Males = 27; Females = 27;<break/>Not reported =13</td><td>Males = 12; Females = 11; Not reported = 6</td><td>Males = 23; Females = 18; Not reported =9</td></tr><tr><td>Age (years)</td><td>Median = 54.5;<break/>Mean <underline>+</underline> SD = 57.3 <underline>+</underline> 7.3<break/>Range = 51&#x2013;67</td><td>Median = 61<break/>Mean <underline>+</underline> SD = 62.1 <underline>+</underline> 12.8<break/>Range = 24&#x2013;88</td><td>Median = 64<break/>Mean <underline>+</underline> SD = 64.1 <underline>+</underline> 7.9<break/>Range = 46&#x2013;85</td><td>Median = 63<break/>Mean <underline>+</underline> SD = 64.1 <underline>+</underline> 10.4<break/>Range = 42&#x2013;86</td></tr><tr><td>Pertinent medical history</td><td>PHx + FHx of ThyD<break/>Reported = 2;<break/>Not reported = 4<break/>PHx + FHx of AutoD<break/>Not reported = 6</td><td>PHx ThyD: Reported 4;<break/>Not reported 63.<break/>FHx ThyD: Reported 3.<break/>Not reported 64.<break/>HxAutoD: Reported 2;<break/>Not reported 65</td><td>PHx ThyD: Reported 5;<break/>Not Reported 24<break/>FHx ThyD: Reported 0;<break/>Not reported 29<break/>HxAutoD: Reported 1;<break/>Not reported 28</td><td>PHx ThyD: Reported 13;<break/>Not reported 37.<break/>FHx ThyD. Reported 2;<break/>Not reported 48.<break/>Hx AutoD: Reported = 1;<break/>Not reported 49.</td></tr><tr><td>Type of cancer</td><td>Melanoma = 6</td><td>Melanoma = 39, NSCLC =9; Breast Ca =1; Lung Ca = 5; RCC = 4; Multiple myeloma = 1; Esophageal Ca = 1; Not reported = 7</td><td>Melanoma = 18; Jaw Sq Ca = 1; Lung Sq Ca =6; RCC = 2; Bladder Ca = 1; Multiple myeloma = 1.</td><td>Melanoma = 29; NSCLC = 8; RCC = 4; Multiple myeloma = 1; breast CA = 1; Lung Ca = 3; Not reported =3.</td></tr><tr><td>Check point inhibitor(s)</td><td>Ipi = 4; Nivo + Ipi = 1,<break/>Tremeli = 1.</td><td>Ipi + bevacizumab = 2; Nivo = 23; Pembro =14; Anti-PD-1 = 6; Ipili = 6; Nivo + Ipili = 7; Ipili+Pembro =1; Ipili, then Pembro = 8.</td><td>Ipi = 2; PDL-1 = 1; Nivo = 15; Ipi, then Pembro = 9; Nivo+Ipi =2.</td><td>Nivo = 17; Pembro = 13; Anti-PD-1 = 6; Ipili = 2; Nivo+Ipili = 7; Ipili then, Pembro = 5.</td></tr><tr><td>ICI Drug D/C?</td><td>Yes = 3; Not reported =3</td><td>Yes = 12; No = 15; Not reported = 40</td><td>Yes =8; No = 5; Not reported = 16</td><td>Yes = 8; No = 14; Not reported = 28</td></tr><tr><td>Clinical presentation</td><td>2 with Graves&#x2019; Eye disease (GED)<break/>4 with thyrotoxicosis</td><td>Hyperthyroidism symptoms = 43; Asymptomatic = 11;<break/>Not reported =13</td><td>Hypothyroid symptoms = 14; Asymptomatic = 3; Not reported =12. DKA = 2; cardiac = 2; adrenal insufficiency = 2</td><td>Many cases do not describe symptoms of hypothyroidism in contrast to symptoms of hyperthyroidism.</td></tr><tr><td>Onset after first dose (weeks)</td><td>Median = 7<break/>Mean <underline>+</underline> SD = 75.8 <underline>+</underline> 166.8 Range 6&#x2013;416</td><td>Median = 6<break/>Mean <underline>+</underline> SD = 7.2 <underline>+</underline> 5.6<break/>Range 3&#x2013;28</td><td>Median = 12<break/>Mena <underline>+</underline> SD = 14.2 <underline>+</underline> 7.1<break/>Range 7&#x2013;36</td><td>Median = 6<break/>Mean <underline>+</underline> SD = 7.2 <underline>+</underline> 3.4<break/>Range 3&#x2013;15</td></tr><tr><td>Biochemical tests</td><td>All have +ve TRAb/TSI;<break/>4 have +ve TPO/TG Ab<break/>2 have NL TSH, FT4 (Graves&#x2019; Eye Disease)<break/>4 &#x2193;TSH,&#x2191;FT4, &#x2191;FT3</td><td>All had &#x2193;TSH, &#x2191;FT4 &amp;/FT3. 47 had reported TPO/TG Ab; 20 + ve.<break/>22 pts. had reported TRAb/TSI; all &#x2013;ve.</td><td>All had &#x2191;TSH, &#x2193;FT4. TPO/TG Ab reported in 14: all +ve.<break/>4 had &#x2193;ACTH &amp; cortisol.<break/>2 had &#x2191;Glu, +ve GAD65 Ab, &amp; &#x2193; C-peptide, pH. &amp; &#x2191;A1c</td><td>All had &#x2193;TSH, 46&#x2191;FT4 /FT3 initially, 3 NL FT4<break/>19 cases had &#x2191;TSH &amp;&#x2193;FT4/ FT3.<break/>TPO/TG Ab reported in 28: 19 + ve; TRAb/TSI in 21:1 + ve.33 cases stated just as hypothyroid.</td></tr><tr><td>Diagnosis</td><td>2 Graves&#x2019; eye disease<break/>4 Graves&#x2019; disease</td><td>3 cases described as &#x201C;thyroid storm&#x201D;.<break/>44 had symptoms of hyperthyroidism.<break/>9 were asymptomatic.<break/>11 symptoms not reported</td><td>Primary hypothyroidism (biochemically) in all.<break/>14 had symptoms of hypothyroidism.</td><td>19 cases had primary hypothyroidism with &#x2191;TSH &amp; &#x2193;FT4/FT3.<break/>Others stated to be hypothyroid with no tests results.</td></tr><tr><td>Imaging<break/>MRI, RAI uptake</td><td>2 enlarged extraocular muscles; 1 &#x2191;thyroid perfusion,1 &#x2191;RAI uptake. 1 MRI pituitary NL; 1 Not reported.</td><td>11 had &#x2193;uptake on thyroid scan; 2 had &#x2191;uptake on PET scan; 14 had thyroid US various findings; 31 not reported.</td><td>Thyroid US in 7&#x2013;1 swollen gland, 6 heterogeneous echo-structure. PET scan in 5 (&#x2191;uptake in 3). Not reported in 16.</td><td>Not reported during hypothyroid state.</td></tr><tr><td>CTCAE grade reported</td><td>Not reported in all;.</td><td>Grade 2 = 1 and not reported. = 66</td><td>Not reported in all 29.</td><td>Grade 2 in one;<break/>Not reported in 48.</td></tr><tr><td>Therapy at onset at diagnosis</td><td>3 high dose steroids; 4 had anti-thyroid drugs(1 had LT4)</td><td>36 no treatment for hyperthyroidism;<break/>8 on steroid (1 colitis; 3 adrenal insufficiency; 4 not reported); 16 on &#x3B2;-blockers; 8 had anti-thyroid drugs; 3 had iodine solutions (thyroid storm);<break/>3 not reported.</td><td>LT4 = 26; No LT4 = 1;<break/>LT4 Not reported in 2.<break/>Steroids = 3; Insuli<italic>n</italic> = 2.</td><td>39 on LT4. 11 not reported.</td></tr><tr><td>Outcome</td><td>All improved; 2 on LT4 (1 had thyroidectomy; 1 became hypothyroid).</td><td>42 required LT4; 17 no LT4; 8 not reported.</td><td>23 0n LT4; 3 subclinical hypothyroid; 2 not reported; 1 deceased.</td><td>44 on LT4. LT4 not reported in 6.</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec11">
        <title>Thyrotoxicosis</title>
        <p id="Par96">Of the 73 thyrotoxicosis cases, 6 had Graves&#x2019; disease and 67 had thyroiditis. All had decreased thyroid stimulating hormone (TSH) and elevated free thyroxine (FT4)/free triiodothyronine (FT3) in addition to the clinical and treatment information. Those with Graves&#x2019; disease also had positive thyrotropin receptor Ab (TRAb) or Thyroid Stimulating Immunoglobulin (TSI). Both groups may or may not have positive thyroid peroxidase (TPO) and/or thyroglobulin (TG) Ab. For those who had radioisotope thyroid scans, Graves&#x2019; disease patients had increased uptake and thyroiditis patients had decreased uptake.</p>
        <sec id="Sec12">
          <title>Graves&#x2019; disease</title>
          <p id="Par97">This cohort&#x2019;s median age was 54&#x2219;5&#x2009;years. Four of the 6 patients were male. All had metastatic melanoma. Ipilimumab was used in 5/6 patients, 4 as monotherapy and 1 with Nivolumab. The median onset of clinical presentation was 7&#x2009;weeks after initiation of ICI (range = 6&#x2013;416). Symptoms ranged from Graves&#x2019; eye disease [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>] to hyperthyroidism. High dose steroid was used as initial therapy in 3 cases and anti-thyroid drugs in 4 cases. All improved and 2 were on replacement thyroxine (1 had thyroidectomy and the other became hypothyroid). Two cases were reported before ipilimumab approval and 3 post-marketing. One case used tremelimumab which has not been approved yet. One case of polyglandular endocrinopathy had Graves&#x2019; disease followed by T1DM and anterior hypopituitarism [<xref ref-type="bibr" rid="CR76">76</xref>].</p>
        </sec>
        <sec id="Sec13">
          <title>Thyroiditis</title>
          <p id="Par98">This cohort&#x2019;s median age was 61&#x2009;years. In those with identified gender, 53% were female. The majority (61%) had metastatic melanoma. Anti-PD-1 mAbs were used in 60/67 patients, monotherapy in 44 and with/after Ipilimumab in 8 and 8 respectively. The median onset of symptoms was 6&#x2009;weeks after initiation of ICI (range = 3&#x2013;28). Clinical presentation ranged from no symptoms to thyroid storm [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. High dose steroid was used as initial therapy in 6 patients (2 of these cases had concomitant adrenal insufficiency), anti-thyroid drugs in 6, &#x3B2;-blockers in 15 and iodide solution in 3. Of the 67 patients with follow-up information, 46 needed thyroxine replacement. During the pre-approval and post-marketing periods there were 2 and 65 reported respectively. There were 7 cases of polyglandular endocrinopathies involving thyroiditis - plus anterior hypopituitarism [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]; plus primary adrenal insufficiency [<xref ref-type="bibr" rid="CR126">126</xref>]; plus pituitary adrenocorticotrophic hormone (ACTH)-dependent Cushing&#x2019;s syndrome and anterior hypopituitarism [<xref ref-type="bibr" rid="CR127">127</xref>]; plus hypoparathyroidism [<xref ref-type="bibr" rid="CR122">122</xref>]; and plus type 1 diabetes mellitus [<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR130">130</xref>].</p>
        </sec>
      </sec>
      <sec id="Sec14">
        <title>Hypothyroidism</title>
        <p id="Par99">Of the 79 cases of hypothyroidism, 29 had primary hypothyroidism and 50 had hypothyroidism preceded by transient hyperthyroidism. Primary hypothyroidism cases had elevated TSH and decreased FT4/FT3. In those with hyperthyroidism progressing to hypothyroidism, TSH (when reported) was high in 19 cases. The remaining 31 were stated to have hypothyroidism with clinical and/or treatment information.</p>
        <sec id="Sec15">
          <title>Primary hypothyroidism</title>
          <p id="Par100">This cohort&#x2019;s median age was 64&#x2009;years. In those with identified gender, 52% were male. Sixty-two percent had metastatic melanoma. As monotherapy anti-PD-1/PDL-1 mAbs were used in 16; with ipilimumab 11 (in sequence in 9 and combined 2) and ipilimumab monotherapy 2. The median onset of symptoms was 12&#x2009;weeks after ICI initiation (range = 7&#x2013;36). Symptoms ranged from mild to severe myxedema coma [<xref ref-type="bibr" rid="CR133">133</xref>]. Levothyroxine (LT4) was started in 26, no LT4 in 1 and 2 not reported. Steroids were used as initial therapy in 3 because of concomitant adrenal insufficiency and insulin was used in 2 to treat diabetes mellitus. In follow-up, 23 needed LT4 replacement, 5 not reported, and I died (cause unknown). During the pre-approval and post-marketing periods 1 and 28 cases were reported respectively. There were 6 cases of polyglandular endocrinopathies involving primary hypothyroidism - plus anterior hypopituitarism [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR93">93</xref>] and plus diabetes mellitus [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR134">134</xref>].</p>
        </sec>
        <sec id="Sec16">
          <title>Thyrotoxicosis progressing to hypothyroidism</title>
          <p id="Par101">This cohort&#x2019;s median age was 63&#x2009;years. In those with identified gender, 56% were male. The majority (59%) had melanoma. Anti-PD-1/ PDL-1 mAbs were used in 48 patients - monotherapy in 36, after ipilimumab in 5 and in combination with ipilimumab in 7. The median onset of symptoms was 6&#x2009;weeks after hyperthyroidism (range 3&#x2013;15). Many patients were stated to be hypothyroid without clinical information on symptoms. At onset of symptoms 39 patients were prescribed LT4. In follow-up, 44 needed LT4 replacement, and LT4 replacement was not reported in 6 patients. All 50 cases were reported in post-marketing period. There were 7 cases of polyglandular endocrinopathies involving hyperthyroidism progressing to hypothyroidism - plus anterior hypopituitarism [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR123">123</xref>];plus primary adrenal insufficiency (PAI) [<xref ref-type="bibr" rid="CR126">126</xref>]; plus pituitary ACTH-dependent Cushing&#x2019;s syndrome [<xref ref-type="bibr" rid="CR127">127</xref>]; plus hypoparathyroidism [<xref ref-type="bibr" rid="CR122">122</xref>]; and plus T1DM [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR128">128</xref>].</p>
        </sec>
      </sec>
      <sec id="Sec17">
        <title>Diabetes mellitus</title>
        <p id="Par102">Table <xref rid="Tab4" ref-type="table">4</xref> summarizes the data from the 66 cases of ICI-induced diabetes mellitus. (Details of each case [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR139">139</xref>&#x2013;<xref ref-type="bibr" rid="CR185">185</xref>] are in Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Appendix 5). All met the inclusion criteria.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Cases of Immune Checkpoint Inhibitors Induced Diabetes Mellitus</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Information</th></tr></thead><tbody><tr><td>Reports</td><td>55</td></tr><tr><td>Cases</td><td>66</td></tr><tr><td>Gender</td><td>Males = 42; Females = 24</td></tr><tr><td>Age (years)</td><td>Median = 63.5; Mean &#xB1; SD = 62 &#xB1; 13.2; Range = 28&#x2013;84</td></tr><tr><td>Pertinent medical history</td><td>PHx diabetes: Reported = 36; Not reported = 30<break/>FHx diabetes: Reported 27; Not reported = 39<break/>Hx AutoD: Reported = 15; Not reported = 51</td></tr><tr><td>Type of cancer (all metastatic)</td><td>Melanoma = 30; Non-small cell lung cancer = 10; Renal cell carcinoma = 7; Lung cancer = 11; Urothelial carcinoma = 2, Small cell jaw cancer = 1, Small cell tonsillar cancer = 1; Small cell maxillary sinus cancer = 1; Hodgkin&#x2019;s lymphoma = 1, Cholangiocarcinoma = 1, Not reported = 1</td></tr><tr><td>Check point inhibitor<break/>Drug D/C?:</td><td>Pembro = 13; Nivo = 32; Nivo + Ipi = 6; Pembro + Ipi = 1; Ipi, then Pembro = 5;<break/>Ipi, then Nivo = 3; Avelu + Utomi = 1; Atezo = 2; Unnamed PDL-1 = 2; Ipi = 1<break/>Yes = 22, No = 15, Ipi stopped/Pembro continued = 1, Not reported = 28</td></tr><tr><td>Clinical presentation</td><td>DKA = 43; Hyperglycemia = 20; Not reported = 3</td></tr><tr><td>Onset (weeks) after first dose</td><td>Median = 7, Mean &#xB1; SD = 11.7 &#xB1; 11.7 Range 1&#x2013;52</td></tr><tr><td>Biochemical tests</td><td>&#x2191;Glucose = 57; &#x2191;A1c = 49; &#x2191;&#x3B2;-OHB = 10<break/>&#x2193;pH = 35; &#x2193;C-pep = 48</td></tr><tr><td>Antibody evaluation</td><td>Any antibodies (GAD65, IA2, ZnT8, IAA) positive = 34 (51.5%)<break/>Antibodies negative = 27 (41%)<break/>Antibodies not reported = 5 (7.5%)</td></tr><tr><td>Pancreatic imaging</td><td>CT with &#x2193; volume or atrophy = 3, CT with pancreatitis = 1; MRI with diffuse inflammatio<italic>n</italic> = 1</td></tr><tr><td>CTCAE severity grade reported</td><td>Yes = 4; Not reported = 62</td></tr><tr><td>Therapy at onset at diagnosis in addition to insulin</td><td>Metformin =1, Glimepiride = 1,glyburide = 1; Diet = 2, High dose steroids* = 10</td></tr><tr><td>Outcome</td><td>Remained insulin-dependent = 52, Recovered = 1,<break/>Not reported = 13</td></tr></tbody></table><table-wrap-foot><p>*Treatment dose steroids as part of chemotherapy regimen (n = 2), treatment of other autoimmune manifestation (<italic>n</italic> = 3), to reverse autoimmune diabetes (n = 2), to decrease insulin resistance (n = 1); for adrenal insufficiency (n = 2)</p></table-wrap-foot></table-wrap></p>
        <p id="Par103">Diagnosis of T1DM was based on clinical (onset, clinical symptoms, immediate and subsequent insulin therapy) and biochemical (glucose, ketone bodies, islet antibodies, acidotic state) data. Any case with positive islet antibody(ies) is diagnosed as T1DM based on the presumed underlying autoimmune nature. In cases where islet antibodies were negative or not reported, we diagnosed them to have T1DM based on their presentation with diabetic ketoacidosis (DKA) in a previously normoglycemic patient, new onset severe hyperglycemia with a low C-peptide in a patient without known diabetes, new insulin requirement in a patient with known T2DM; and anyone with &#x201C;fulminant&#x201D; T1DM.</p>
        <p id="Par104">This cohort&#x2019;s median age was 63&#x2009;years. Most (64%) were male and the majority (45%) had metastatic melanoma. The ICIs used were anti-PD-I mAbs (<italic>n</italic> = 45); anti-PD-L1 mAbs (<italic>n</italic> = 5); anti- PD-1 mAbs + anti-CTLA-4 mAb (<italic>n</italic> = 7); anti-CTLA-4 mAb then Anti-PD-1 mAbs (<italic>n</italic> = 8); anti CTLA-4 mAb (<italic>n</italic> = 1). The median onset of clinical presentation was 7.5&#x2009;weeks after initiation of ICI (range = 1&#x2013;52&#x2009;weeks). Sixty-five had T1DM based on our diagnostic criteria (see above) and one probably had T2DM (had duodenopancreatectomy and did not require insulin to treat mild hyperglycemia) [<xref ref-type="bibr" rid="CR178">178</xref>]. There were 4 cases with T2DM before ICI therapy and who developed T1DM based on a new insulin requirement when on ICI [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR171">171</xref>].</p>
        <p id="Par105">In the T1DM cohort, 43 presented in DKA and 20 with marked hyperglycemia. In the DKA group 12, mostly from Japan, were described to have fulminant T1DM [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR152">152</xref>&#x2013;<xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR168">168</xref>&#x2013;<xref ref-type="bibr" rid="CR170">170</xref>]. Islet-related Abs (Glutamic acid decarboxylase 65(GAD 65), Islet Antigen 2 (IA2), Insulin auto-antibody (IAA) or Zinc Transporter 8 (ZnT8) Ab were positive in 51.5% (<italic>n</italic> = 34), negative in 41% (<italic>n</italic> = 27) and not reported in 7.5% (<italic>n</italic> = 5). At onset of clinical presentation, high dose steroid was used in 10, cases, insulin infusion in 60, oral glucose-lowering medications initially continued in 4, with 2 no information on treatment. All 66 patients recovered from their hyperglycemia with treatment - 53 remained insulin dependent and the outcomes of 13 were not reported. One patient, initially requiring insulin, discontinued insulin on day 81 after pembrolizumab was discontinued [<xref ref-type="bibr" rid="CR142">142</xref>]. All the cases using anti-PD-1 mAbs were reported post-marketing, most 2&#x2013;3&#x2009;years after their approval in 2014. There were 6 cases of polyglandular endocrinopathies involving T1DM - plus anterior hypopituitarism [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR95">95</xref>], plus anterior hypopituitarism + Graves&#x2019; disease [<xref ref-type="bibr" rid="CR76">76</xref>], plus, thyroiditis [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR130">130</xref>], plus primary hypothyroidism [<xref ref-type="bibr" rid="CR132">132</xref>], and plus hyperthyroidism progressing to hypothyroidism [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR130">130</xref>].</p>
      </sec>
      <sec id="Sec18">
        <title>Primary adrenal insufficiency, ACTH-dependent Cushing&#x2019;s syndrome, hypoparathyroidism, and diabetes insipidus</title>
        <p id="Par106">Table <xref rid="Tab5" ref-type="table">5</xref> summarizes the data from 6 cases of PAI, 1 of pituitary ACTH-dependent Cushing&#x2019;s syndrome, 1 of primary hypoparathyroidism and 3 of diabetes insipidus following ICI therapy. (Details of cases [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR186">186</xref>&#x2013;<xref ref-type="bibr" rid="CR189">189</xref>] are in Additional file <xref rid="MOESM6" ref-type="media">6</xref>: Appendix 6). All met the criteria for inclusion in this review.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Cases of Immune Checkpoint Inhibitors Induced Primary Adrenal Insufficiency, Cushing&#x2019;s Disease, Hypoparathyroidism and Diabetes Insipidus</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Primary adrenal insufficiency</th><th>ACTH-dependent Cushing&#x2019;s syndrome</th><th>Hypoparathyroidism</th><th>Diabetes Insipidus</th></tr></thead><tbody><tr><td>Reports No.</td><td>6</td><td>1</td><td>1</td><td>3</td></tr><tr><td>Cases No.</td><td>6</td><td>1</td><td>1</td><td>3</td></tr><tr><td>Gender</td><td>Male = 3; Female = 2;<break/>Not reported =1</td><td>Female = 1</td><td>Male = 1</td><td>Male = 3</td></tr><tr><td>Age (years)</td><td>Median = 52; Mean <underline>+</underline> SD = 51.2 + 4.7 Range 43&#x2013;56</td><td>53</td><td>73</td><td>Median = 62; Mean <underline>+</underline> SD = 61.7 <underline>+</underline> 11.5 Range = 50&#x2013;73</td></tr><tr><td>Pertinent medical history</td><td>PHx EndoD: NR = 6<break/>FHx EndoD: NR = 6<break/>HX AutoD: NR = 6</td><td>PHx EndoD: NR<break/>FHx EndoD: NR<break/>Hx AutoD: NR</td><td>PHx EndoD: NR<break/>FHx EndoD: NR<break/>Hx AutoD: No</td><td>PHx EndoD: NR = 3<break/>FHx EndoD: NR = 3<break/>Hx AutoD: NR = 3</td></tr><tr><td>Type of cancer (all metastatic)</td><td>Melanoma = 3; RCC = 1; Lung adenoCa = 1; NSCLC = 1</td><td>Melanoma</td><td>Melanoma</td><td>Prostate Ca = 1;<break/>Melanoma = 1;<break/>Merkel cell Ca = 1.</td></tr><tr><td>Check point inhibitor(s)</td><td>Ipilimumab =2; Nivolumab =3; Pembrolizumab =1</td><td>Ipilumumab + Nivolumab</td><td>Nivolumab +Ipilimumab</td><td>C1: Ipilimumab.<break/>C2: Ipilimumab<break/>C3: Avelumab</td></tr><tr><td>ICI Drug D/C?</td><td>Yes = 1; Not reported = 5</td><td>Yes = 1 at 12 wks.</td><td>Not reported =1</td><td/></tr><tr><td>Clinical presentation</td><td>Fatigue, weight loss, anorexia, nausea, vomiting, headache, etc</td><td>Anorexia, weakness</td><td>Paresthesia, weakness, etc</td><td>C1: Polydipsia, polyuria<break/>C2: Polydipsia, polyuria<break/>C3: Polydipsia, polyuria.</td></tr><tr><td>Onset (weeks) after 1st dose</td><td>Median = 10 Mean <underline>+</underline> SD =14.92 + 14 Range = 1.5&#x2013;36</td><td>14 wks</td><td>6 wks</td><td>Median = 12; Mean <underline>+</underline> SD = 3 + 16; Range = 3&#x2013;16</td></tr><tr><td>Biochemical tests</td><td>&#x2191;ACTH in 5; &#x2193;cortisol in 4; Synactin test +ve &amp; + ve adrenal Ab in 1 without cortisol.<break/>In 1 cosyntropin stimulation test was negative and pt. had enlarged adrenal glands preceded by secondary adrenal \insufficiency.</td><td>9wks: slight &#x2191; in cortisol;<break/>12 wks: &#x2191;ACTH, &#x2191;cortisol, &#x2191;[cortisol]<sub>u.</sub> Abnormal low dose dexamethasone suppression test.<break/>16 wks: &#x2193;ACTH, cortisol. 6wks: &#x2193;TSH, &#x2191;FT4, FT3. Then &#x2193;TSH, FT4, FT3. &#x2193;LH, estradiol. Normal PRL.</td><td>&#x2193;Calcium, undetectable PTH, &#x2191; phosphate<sub>4</sub>,<break/>&#x2193;vitamin D, magnesium<break/>7wks: &#x2193;TSH, &#x2191;FT4, FT3, then &#x2193;TSH, FT4, FT3.</td><td>C1: &#x2193;ACTH, cortisol, TSH, FT4, FT3, LH &amp; FSH. Normal glucose.<break/>C2: &#x2193;ACTH, cortisol, TSH, FT4, FT3, LH &amp; FSH. Normal glucose. Water deprivation test: partial diabetes insipidus<break/>C3: &#x2191;[sodium],[osmolality]<sub>s</sub>, &#x2193;[osmolality]<sub>u</sub>.<break/>Normal glucose</td></tr><tr><td>Diagnosis</td><td>Primary adrenal insufficiency</td><td>Cushing&#x2019;s disease, then 2<sup>o</sup> adrenal insufficiency. Thyroiditis, then<break/>hypothyroidism.<break/>2<sup>o</sup> hypogonadism.</td><td>Primary hypoparathyroidism</td><td>Diabetes insipidus</td></tr><tr><td>Imaging MRI/CT</td><td>MRI brain: 2 normal &amp; 2 enlarged pituitary.<break/>Abd CT scan: atrophied adrenals; enlarged in 1</td><td>MRI pituitary at 12 wks: enlarged</td><td>EKG: prolonged QT interval</td><td>MRI pituitary: Normal in all</td></tr><tr><td>CTCAE grade reported</td><td>Severity not reported in all:</td><td>Not reported</td><td>Not reported;</td><td>Not reported in all.</td></tr><tr><td>Therapy at onset at diagnosis</td><td>iv steroids in 4.<break/>Oral steroids in 2. Florinef in 2</td><td>Wk5: LT4<break/>Wk16: HCT &amp; LT4.</td><td>iv calcium gluconate, then oral vitamin D &amp; Ca carbonate. LT4.</td><td>C1: High dose steroidsC2: HCT, LT4 &amp; desmopressin. C3: Desmopressin</td></tr><tr><td>Outcome</td><td>5 discharged on steroids.<break/>1 NR.</td><td>HCT &amp; LT4.</td><td>Calcium carbonate + calcitriol<break/>LT4.</td><td>C1: NR. C2: HCT, LT4 &amp; desmopressin; C3: Desmopressin D/C</td></tr></tbody></table></table-wrap></p>
        <sec id="Sec19">
          <title>Primary adrenal insufficiency [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR186">186</xref>&#x2013;<xref ref-type="bibr" rid="CR188">188</xref>]</title>
          <p id="Par107">This cohort&#x2019;s median age was 52&#x2009;years. In those with identified gender, 60% were male. Of the 6 patients, 3 had metastatic melanoma. Anti-PD-1 mAbs were used in 4/6 patients as monotherapy. Ipilimumab was used in 2 patients. The median onset of symptoms was 10&#x2009;weeks after ICI initiation (range = 1.5&#x2013;36). High dose steroid was used as initial therapy in 4 and physiological steroids in 2 cases. All recovered clinically with treatment and were on replacement oral hydrocortisone with two [<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR186">186</xref>] also on fludrocortisone. The patient reported in [<xref ref-type="bibr" rid="CR188">188</xref>] received iv prednisolone which contains some mineralocorticoid effect but at discharge fludrocortisones was not mentioned. One case [<xref ref-type="bibr" rid="CR34">34</xref>] initially had secondary adrenal insufficiency (SAI) but was found to have enlarged adrenals at week 16 after ipilimumab initiation. When a cosyntropin stimulation test done then showed no cortisol response the authors concluded the patient also had PAI. A negative CST occurs in PAI but can also occur with SAI of significant duration.</p>
        </sec>
        <sec id="Sec20">
          <title>Pituitary ACTH-dependent Cushing&#x2019;s syndrome [<xref ref-type="bibr" rid="CR127">127</xref>]</title>
          <p id="Par108">Onset of the hypercortisolism symptoms was 12&#x2009;weeks after initiation of ipilimumab plus nivolumab for melanoma. Four weeks later, secondary adrenal insufficiency developed. Both these were preceded by transient hyperthyroidism in week 6 that progressed to secondary hypothyroidism in week 9 after the first dose of ICI.</p>
        </sec>
        <sec id="Sec21">
          <title>Primary hypoparathyroidism [<xref ref-type="bibr" rid="CR122">122</xref>]</title>
          <p id="Par109">This melanoma patient, treated with ipilimumab plus nivolumab, developed symptoms of acute hypocalcemia 6&#x2009;weeks after the first dose of ICIs. On the 3rd day in hospital, he developed transient thyroiditis which progressed to hypothyroidism.</p>
        </sec>
        <sec id="Sec22">
          <title>Diabetes insipidus (DI) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR189">189</xref>]</title>
          <p id="Par110">Two patients were treated with ipilimumab and 1 with avelumab (the first case of DI following anti-PD-L1 therapy). The median onset of symptoms (polydipsia and polyuria with euglycemia) was 12&#x2009;weeks after initiation of ICI. Two [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR189">189</xref>] reported biochemical data in keeping with DI and these 2 were discharged on desmopressin.</p>
        </sec>
      </sec>
      <sec id="Sec23">
        <title>Reported endocrinopathies not supported by data</title>
        <p id="Par111">Two cases of hyponatremia were attributed to syndrome of inappropriate ADH secretion [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR186">186</xref>]. However, both had secondary adrenal insufficiency that could have caused the hyponatremia.</p>
        <p id="Par112">The only case of hypercalcemia was associated with increased PTH-related peptide, not PTH; hence, it was not primary hyperparathyroidism [<xref ref-type="bibr" rid="CR189">189</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec24">
      <title>Discussion</title>
      <sec id="Sec25">
        <title>Clinical presentations</title>
        <p id="Par113">Compared with the 2016 systematic review of case reports of irAEs, which included 84 cases of endocrine irAEs, in ICI treated cancer patients [<xref ref-type="bibr" rid="CR9">9</xref>], our review shows a five-fold increase in case reports of endocrine irAEs (from 84 to 451). This increase most likely reflects wider use of ICI therapy in more cancer patients - (a) more melanoma patients (the original indication) are now treated with 2 classes of ICIs; (b) as new indications are approved for other cancers, more patients are now treated with ICIs (Table <xref rid="Tab1" ref-type="table">1</xref>); and (c) more cases of anti-PD-1-induced endocrinopathies were reported in the past 3&#x2009;years after their approval in 2014 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). During the 3&#x2013;4-years period after approval of each class of ICI (ipilimumab in 2011 and nivolumab and pembrolizumab in 2014) a striking increase in cases of ICI-induced endocrinopathies were published with their use in the first 2&#x2013;3&#x2009;years post-marketing period (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). With the introduction of anti-PD-L1 drugs in 2016 and 2017 for cancer patients, more cases ICI-induced endocrinopathies [<xref ref-type="bibr" rid="CR190">190</xref>] will likely be reported in the coming 3&#x2013;4&#x2009;years.<fig id="Fig2"><label>Fig. 2</label><caption><p>Reported cases of immune checkpoint inhibitor-induced endocrinopathies are increasing</p></caption><graphic xlink:href="40842_2018_73_Fig2_HTML" id="MO2"/></fig></p>
        <p id="Par114">In the 2016 review [<xref ref-type="bibr" rid="CR9">9</xref>] ipilimumab was associated with 68 cases of hypophysitis, 4 cases of thyrotoxicosis, 4 cases of hypothyroidism, 1 case of syndrome of inappropriate secretion of antidiuretic hormone, 1 case of central adrenal insufficiency, 1 case of primary adrenal insufficiency; pembrolizumab was associated with 1 case of hypothyroidism and 1 case of diabetes mellitus; and nivolumab was associated with 2 cases of hypothyroidism. Our scoping study uncovers a wider spectrum of ICI-induced endocrinopathies - 222 hypopituitarism, 152 thyroid disorders, 66 diabetes mellitus, 6 primary adrenal insufficiency, 1 pituitary ACTH-dependent Cushing&#x2019;s syndrome, 1 hypoparathyroidism and 3 diabetes insipidus cases (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Spectrum of immune checkpoint inhibitor-induced endocrinopathies</p></caption><graphic xlink:href="40842_2018_73_Fig3_HTML" id="MO3"/></fig></p>
        <p id="Par115">Clinically, endocrinopathies can present with symptoms of hormone deficiency, hormone excess or both (in the same or different glands). The spectrum of clinical presentation ranges from no symptoms [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR135">135</xref>] (diagnosis made by biochemical tests) to severe, life-threatening symptoms - thyroid storm [<xref ref-type="bibr" rid="CR105">105</xref>], myxedema coma [<xref ref-type="bibr" rid="CR133">133</xref>] and diabetic ketoacidosis [<xref ref-type="bibr" rid="CR144">144</xref>]. When symptomatic, the presentations of these ICI-induced endocrinopathies reflect the perturbations of hormone(s) produced by the affected gland(s).</p>
        <p id="Par116">Single hormone deficiency - ACTH in isolated ACTH deficiency [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR86">86</xref>] or insulin in T1DM [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR142">142</xref>]) are more commonly reported than single hormone excess - thyroxine in Graves&#x2019; disease [<xref ref-type="bibr" rid="CR102">102</xref>] and ACTH in Cushing&#x2019;s syndrome [<xref ref-type="bibr" rid="CR127">127</xref>]. Occasionally, the endocrinopathy may present with symptoms of one hormone excess followed by symptoms that reflect the same hormone&#x2019;s deficiency - hyperthyroidism progressing to hypothyroidism [<xref ref-type="bibr" rid="CR116">116</xref>].</p>
        <p id="Par117">Multiple glands may be affected presenting as polyglandular endocrinopathies. The patient can present with symptoms and biochemical changes of two endocrine glands in sequence - thyroiditis and type 1 diabetes mellitus [<xref ref-type="bibr" rid="CR130">130</xref>], hypoparathyroidism and thyroiditis [<xref ref-type="bibr" rid="CR122">122</xref>], thyroiditis and ACTH-dependent Cushing&#x2019;s syndrome [<xref ref-type="bibr" rid="CR127">127</xref>], and primary hypothyroidism and isolated ACTH deficiency [<xref ref-type="bibr" rid="CR93">93</xref>].</p>
        <p id="Par118">When the pituitary gland, which secretes 7 hormones, is affected, multiple hormonal deficiencies can occur simultaneously; then, the patient presents with symptoms of multiple pituitary hormones deficiencies [<xref ref-type="bibr" rid="CR14">14</xref>]. In our review, various combinations of pituitary hormone deficiencies occurred, with 3 hormone deficiencies being the commonest. Finally, patients with hypophysitis are sick and their thyroid/gonadal axis may be suppressed in the acute phase of the disease.</p>
        <p id="Par119">Onset of symptoms can occur as early as 1&#x2009;week [<xref ref-type="bibr" rid="CR140">140</xref>] or as late as 416&#x2009;weeks [<xref ref-type="bibr" rid="CR102">102</xref>] with most in the first 20&#x2009;weeks.</p>
        <p id="Par120">The pituitary ACTH-dependent Cushing&#x2019;s syndrome [<xref ref-type="bibr" rid="CR127">127</xref>] is the first case reported and needs to be confirmed. The etiology of the increased ACTH secretion may be due to ectopic Corticotropin-Releasing Hormone (CRH) production as expression of CRH has been reported in advanced melanoma cells [<xref ref-type="bibr" rid="CR191">191</xref>] and Cushing&#x2019;s syndrome due to ectopic CRH secretion has been reported [<xref ref-type="bibr" rid="CR192">192</xref>]. As this case report&#x2019;s authors did not investigate this, we cannot comment further but raised this as a possible etiology and point out that this patient&#x2019;s Cushing&#x2019;s syndrome and hypophysitis are unlikely to be related. Whether and how the ICIs stimulate the secretion of CRH remains to be reported.</p>
        <p id="Par121">High-dose systemic glucocorticoids are given as immunosuppressive to treat concomitant non-endocrine irABs (colitis, hepatitis, etc). For endocrine irABs, high-dose systemic glucocorticoids are given to treat adrenal crisis, hypophysitis and in selected cases of thyroiditis. Such treatment did not improve the outcome of ipilimumab-related hypophysitis in melanoma patients [<xref ref-type="bibr" rid="CR8">8</xref>]. Recently, high-dose glucocorticoids treatment for ipilimumab-related hypophysitis in melanoma patients was associated with reduced survival [<xref ref-type="bibr" rid="CR193">193</xref>]. High dose systemic glucocorticoids when given to diabetes patients (see Table <xref rid="Tab4" ref-type="table">4</xref>) can worsen their hyperglycemia.</p>
      </sec>
      <sec id="Sec26">
        <title>Subclass of ICI and ICI-induced endocrinopathies</title>
        <p id="Par122">We found anti-CTLA-4 mAb to be the ICI most frequently associated with hypophysitis and anterior pituitary hormone(s) deficiencies (<italic>n</italic> = 188 as monotherapy) compared with Anti-PD-1 mAbs (<italic>n</italic> = 13). The differences observed above may reflect longer period of use as ipilimumab was approved in 2011, 3&#x2009;years before nivolumab and pembrolizumab. Other reasons, including biology of endocrine glands, may explain this difference (see below).</p>
        <p id="Par123">We found anti-PD-1 mAbs are the ICIs more often associated (when compared with CTLA-4 Ab) with autoimmune thyroiditis (37 vs 6 as monotherapy), primary hypothyroidism (15 vs 2 as monotherapy), hyperthyroidism progressing to hypothyroidism (30 vs 2 as monotherapy) and type 1 diabetes mellitus (45 vs 1 as monotherapy). Of note, in our review, all 6 patients with Graves&#x2019; disease were treated with anti-CTLA-4 mAb (5 as monotherapy). A meta-analysis reported polymorphism of CTLA-4 can increase the risk for Graves&#x2019; disease [<xref ref-type="bibr" rid="CR194">194</xref>] but how this interacts with ICI is unclear.</p>
        <p id="Par124">It is improper to calculate the frequency of each ICI-induced endocrinopathies in this review as we do not have the total number of cases that have been reported other than those that have been published. Cukier et al. reported frequencies of endocrine irAEs observed with immunotherapies [<xref ref-type="bibr" rid="CR195">195</xref>]. Relevant to this review, the frequencies for endocrine irAEs for ipilimumab, nivolumab and pembrolizumab respectively are: hypophysitis 1.5&#x2013;17, 0.6&#x2013;1.5 and 0.6&#x2013;1%; hypothyroidism 1.5&#x2013;6.8, 9&#x2013;10.8 and 7&#x2013;9.1%; hyperthyroidism 4, 2.7 and 3.4&#x2013;7.8%; primary adrenal insufficiency 0.8&#x2013;1.6, 1% and not reported; Type 1 diabetes not reported, 0.9, and 0.2%. There are similarities in the frequencies of endocrinopathies associated with different ICIs reported by Cukier et al. [<xref ref-type="bibr" rid="CR195">195</xref>] and those reported in this review.</p>
      </sec>
      <sec id="Sec27">
        <title>Pathogenesis</title>
        <p id="Par125">How ICIs damage endocrine glands are unclear; however, several hypotheses to explain this have emerged [<xref ref-type="bibr" rid="CR196">196</xref>]. All endocrinopathies associated with ICI therapy are hypothesized to be autoimmune in etiology. Checkpoint regulator proteins diminish the immune response to antigen and hence act as a brake on the immune system [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>]. Blockade of these checkpoint regulator proteins releases this brake and allows the patient&#x2019;s immune system to attack cancer cells as well as damage certain healthy tissues by autoimmune mechanisms (Fig. <xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>Mechanisms of Action of Anti-PD(L)1 and CTLA-4 Drugs. <bold>1a</bold> Normal activation state of T cells after interaction with Antigen presenting cell (APC). TCR = T-Cell receptor. <bold>1b</bold> Inhibition of T cell activation due to CTLA-4 out-competing CD28 for interaction with CD 80/86. <bold>1c</bold> Anti-CTLA-4 drug inhibits CTLA-4 thus CD28 is able to interact with CD80/86 and activate T cell. <bold>2a</bold> PD-L1 on tumor cell prevents T cell activation. <bold>2b</bold> PD-L1 is blocked by anti-PD(L)1 drugs, T cell activation against tumor is possible</p></caption><graphic xlink:href="40842_2018_73_Fig4_HTML" id="MO4"/></fig></p>
        <p id="Par126">For hypophysitis, a mouse model of anti-CLTA-4-induced hypophysitis demonstrated that CTLA-4 is expressed in pituitary endocrine cells and, when blocked by administration of anti-CTLA-4 mAb, leads to site-specific deposition of complement components, pituitary infiltration and pituitary Ab formation. This study also evaluated patients with prostate cancer and melanoma treated with ipilimumab and showed that those who developed hypophysitis developed pituitary Abs that were not seen in the patients who did not develop hypophysitis [<xref ref-type="bibr" rid="CR47">47</xref>]. CTLA-4 antigen expressed by pituitary endocrine glands in cancer patients treated with CTLA-4 blockade was also reported by Caturegli et al. [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
        <p id="Par127">Hypophysitis is less common among patients treated with anti-PD-1/PD-L1 drugs. Some have hypothesized this is because mAbs to nivolumab and pembrolizumab are in the immunoglobulin (IgG) 4 class [<xref ref-type="bibr" rid="CR197">197</xref>], as opposed to ipilimumab, a CTLA-4 antibody of the IgG1 class, which can activate the classical complement pathway [<xref ref-type="bibr" rid="CR47">47</xref>].</p>
        <p id="Par128">The mechanism behind anti-PD-1 induced thyroid dysfunction is unclear. However, the development of anti-thyroid antibodies after the initiation of anti-PD-1 therapy suggests these drugs may be modulating the autoimmune equilibrium and unmasking latent autoimmunity [<xref ref-type="bibr" rid="CR119">119</xref>]. As many cases of ICI-induced hypothyroidism are preceded by a period of transient hyperthyroidism, the mechanism may be destructive thyroiditis with release of thyroid antigen and consequent secondary antibody production [<xref ref-type="bibr" rid="CR111">111</xref>]. In our study&#x2019;s thyroiditis cohort, of the 49 patients tested for TPO/TG Ab, only 18 had positive titers. In addition, in one patient the hypothyroidism was preceded by Graves&#x2019;s disease [<xref ref-type="bibr" rid="CR76">76</xref>].</p>
        <p id="Par129">In our study, in those autoimmune diabetes patients who were tested for islet-related Abs (GAD65, IA2, ZnT8, IAA) 51.5% had positive titers, 41% had negative titers and 7.5% not reported. Insulin deficiency with low C-peptide was noted in over 70% patients. Several case reports [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR176">176</xref>, <xref ref-type="bibr" rid="CR177">177</xref>] of autoimmune diabetes following ICI therapy reported the HLA type of their patients increased their risk for developing type 1 diabetes.</p>
        <p id="Par130">Many cases of diabetes following ICI therapy were reported in 2016 and 2017, after the anti-PD-1 drugs were approved in 2014. Prior to this, T1DM following ICI therapy was reported to be rare &#x2013; (a) diabetes was not reported in a 2016 meta-analysis [<xref ref-type="bibr" rid="CR198">198</xref>] (b) reported as 0.2&#x2013;0.9% after anti-PD-1 and 0.1&#x2013;0.3% after anti-PD-L1 therapy in 2017 [<xref ref-type="bibr" rid="CR195">195</xref>], and (c) only 13 cases (0.2%) in the 2018 systematic review and meta-analysis [<xref ref-type="bibr" rid="CR199">199</xref>]. Our study identified 65 case reports of T1DM, many more than identified in meta-analysis of clinical trials [<xref ref-type="bibr" rid="CR199">199</xref>]. In our study, 12 T1DM cases were fulminant T1DM - acute, recent onset of severe hyperglycemia with ketoacidosis with negative islet-related Abs in general [<xref ref-type="bibr" rid="CR200">200</xref>]. Recently Stamatouli et al. reported that insulin-dependent diabetes induced with checkpoint inhibitors have similarities and differences when compared with classic T1DM [<xref ref-type="bibr" rid="CR201">201</xref>].</p>
      </sec>
      <sec id="Sec28">
        <title>Case documentation</title>
        <p id="Par131">Very few case reports in our review specified the severity of the endocrine irABs considered &#x201C;required&#x201D; when reporting adverse events [<xref ref-type="bibr" rid="CR12">12</xref>]. However, based on the information in the case reports, most were Grade 2 or 3 with a few Grade 4 cases. Grading the severity of endocrinopathies can be helpful as some endocrine irABs are emergencies &#x2013; DKA, adrenal crisis, thyroid storm and myxedema coma &#x2013; and can be life threatening requiring urgent care. Similarly, the information on the personal and family history of the specific endocrine disorder or autoimmune disorder is sparse except for the DM cases. Finally, only 91/445 cases reported stopping the ICI drugs when the irAE occurred with insufficient information on whether they were transient or permanent. Of great interest is 1 patient with T1DM did not need insulin 81&#x2009;days after pembrolizumab was discontinued [<xref ref-type="bibr" rid="CR144">144</xref>].</p>
      </sec>
      <sec id="Sec29">
        <title>Limitations and strengths</title>
        <p id="Par132">This scoping review has limitations. The first is the variability of information in published case reports. Some did not have all the data identified as &#x201C;required&#x201D; or &#x201C;highly desirable&#x201D; [<xref ref-type="bibr" rid="CR12">12</xref>] but had enough to meet the study criteria. There was variability in the diagnostic tests done, including their timing. In the hypophysitis cases the pituitary imaging may be delayed and not all had pre-treatment imaging for comparison. Secondly, although almost all had close temporal relationship, there were a few irAEs which occurred much later [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR147">147</xref>]. Thirdly, although many cases reported were in full papers, 43 were abstracts as their full reports could not be located at the time of writing. Fourthly, our scoping study covered only published case reports mainly in post-marketing. Fifthly, our scoping review included case reports up to January 31, 2018. Since then other case reports have been published [<xref ref-type="bibr" rid="CR193">193</xref>]. Finally, as pointed out in a systematic review [<xref ref-type="bibr" rid="CR202">202</xref>], some reports on irAEs in clinical trials, as in our review, do not have all required information.</p>
        <p id="Par133">Our review has strengths: (a) It is comprehensive with data collected in a standardized way from before and after marketing published case reports and can uncover important irAEs not previously addressed. A 2018 meta-analysis [<xref ref-type="bibr" rid="CR199">199</xref>] addressed only hypothyroidism, hyperthyroidism, hypophysitis, primary adrenal insufficiency and diabetes mellitus. (b) Using clinical reasoning, diagnoses were based on integrated clinical, biochemical and management documentation complemented by a temporal relationship between initiation of ICI and development of endocrinopathies [<xref ref-type="bibr" rid="CR203">203</xref>]; (c) our study uncovered many more cases of ICI-induced T1DM than in a 2016 systematic review of irAEs case reports [<xref ref-type="bibr" rid="CR9">9</xref>] and a 2018 meta-analysis of clinical trials data [<xref ref-type="bibr" rid="CR199">199</xref>]; and (d) we report unique or first of a kind endocrinopathy [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR127">127</xref>] not mentioned in prior systematic reviews and meta-analysis [<xref ref-type="bibr" rid="CR199">199</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec30">
      <title>Conclusion</title>
      <p id="Par134">In closing, this scoping review mapped the changing landscapes of ICI-induced endocrinopathies before and after marketing of 1 anti-CTL4&#x2013;1 mAb (approved 2011), 2 anti-PD-1 mAbs (approved 2014) and 3 anti-PDL-1 mAbs (approved 2016/2017). In mostly real-world patients, we uncovered a spectrum of endocrinopathies &#x2013; in 5 glands with 12 endocrinopathies that manifest with symptoms of hormone excess or deficiency.</p>
      <p id="Par135">Case reports can alert physicians of a drug&#x2019;s AEs [<xref ref-type="bibr" rid="CR12">12</xref>]. With increasing use of ICIs, physicians in many medical specialties (oncology, endocrinology, emergency medicine and primary care) should be vigilant for these ICI-induced endocrinopathies&#x2019; occurrence and be able to diagnose and treat them. &#x201C;Cross talk&#x201D; for collaborative care between oncologists and endocrinologists has been proposed [<xref ref-type="bibr" rid="CR204">204</xref>]. It is beyond the scope of this paper to cover algorithms and guidelines for the diagnosis and management of ICI-induced endocrinopathies in cancer patients. Some oncology centers [<xref ref-type="bibr" rid="CR205">205</xref>, <xref ref-type="bibr" rid="CR206">206</xref>], National Oncology Societies [<xref ref-type="bibr" rid="CR207">207</xref>, <xref ref-type="bibr" rid="CR208">208</xref>] and Society of Endocrinology Emergency Guidance document [<xref ref-type="bibr" rid="CR209">209</xref>] have published algorithms and clinical practice guidelines. The reporting of endocrine irAEs can be improved [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR202">202</xref>]. Our findings can help physicians manage their patients and professional societies develop their clinical practice guidelines.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Additional files</title>
      <sec id="Sec31">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40842_2018_73_MOESM1_ESM.docx"><label>Additional file 1:</label><caption><p><bold>Appendix 1.</bold> Literature Search. (DOCX 16&#x2009;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="40842_2018_73_MOESM2_ESM.docx"><label>Additional file 2:</label><caption><p><bold>Appendix 2.</bold> Standardized Case Form for Data Collection. (DOCX 13&#x2009;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="40842_2018_73_MOESM3_ESM.docx"><label>Additional file 3:</label><caption><p><bold>Appendix 3.</bold> Cases of Immune Checkpoint Inhibitor-Induced Endocrinopathies &#x2013;Hypophysitis and Anterior Hypopituitarism. (DOCX 51&#x2009;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="40842_2018_73_MOESM4_ESM.docx"><label>Additional file 4:</label><caption><p><bold>Appendix 4.</bold> Cases of Immune Checkpoint Inhibitors-Induced Endocrinopathies &#x2013; Thyroid Disorders: (a) Thyrotoxicosis (b) Hypothyroidism. (DOCX 48&#x2009;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="40842_2018_73_MOESM5_ESM.docx"><label>Additional file 5:</label><caption><p><bold>Appendix 5.</bold> Cases of Immune Checkpoint Inhibitors-Induced Endocrinopathies &#x2013;Diabetes Mellitus. (DOCX 41&#x2009;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="40842_2018_73_MOESM6_ESM.docx"><label>Additional file 6:</label><caption><p><bold>Appendix 6.</bold> Cases of Immune Checkpoint Inhibitor-Induced Endocrinopathies &#x2013; Primary Adrenal Insufficiency, Cushing&#x2019;s Syndrome, Hypoparathyroidism, Diabetes Insipidus. (DOCX 22&#x2009;kb)</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>A1c</term>
          <def>
            <p id="Par5">Glycated hemoglobin</p>
          </def>
        </def-item>
        <def-item>
          <term>ACTH</term>
          <def>
            <p id="Par6">Adrenocorticotropic hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>ADH</term>
          <def>
            <p id="Par7">Anti-diuretic hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>Anti-CTLA-4</term>
          <def>
            <p id="Par8">Anti-Cytotoxic T-lymphocyte-associated antigen-4</p>
          </def>
        </def-item>
        <def-item>
          <term>Anti-PD-1</term>
          <def>
            <p id="Par9">Anti-programmed cell death protein-1</p>
          </def>
        </def-item>
        <def-item>
          <term>Anti-PDL-1</term>
          <def>
            <p id="Par10">Anti-Programmed Death Ligand-1</p>
          </def>
        </def-item>
        <def-item>
          <term>Atezo</term>
          <def>
            <p id="Par11">Atezolumab</p>
          </def>
        </def-item>
        <def-item>
          <term>AutoD</term>
          <def>
            <p id="Par12">Autoimmune disease</p>
          </def>
        </def-item>
        <def-item>
          <term>Avelu</term>
          <def>
            <p id="Par13">Avelumab</p>
          </def>
        </def-item>
        <def-item>
          <term>Ca</term>
          <def>
            <p id="Par14">Carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>C-pep</term>
          <def>
            <p id="Par15">C-peptide</p>
          </def>
        </def-item>
        <def-item>
          <term>CRH</term>
          <def>
            <p id="Par151">Corticotropin releasing hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>CST</term>
          <def>
            <p id="Par16">Cosyntropin stimulation test</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p id="Par17">Computerized tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>CTCAE</term>
          <def>
            <p id="Par18">Common terminology criteria for adverse events</p>
          </def>
        </def-item>
        <def-item>
          <term>D/C</term>
          <def>
            <p id="Par19">Discontinued</p>
          </def>
        </def-item>
        <def-item>
          <term>DI</term>
          <def>
            <p id="Par20">Diabetes insipidus</p>
          </def>
        </def-item>
        <def-item>
          <term>DKA</term>
          <def>
            <p id="Par21">Diabetic ketoacidosis</p>
          </def>
        </def-item>
        <def-item>
          <term>EKG</term>
          <def>
            <p id="Par22">Electrocardiogram</p>
          </def>
        </def-item>
        <def-item>
          <term>EndoD</term>
          <def>
            <p id="Par23">Endocrine disease</p>
          </def>
        </def-item>
        <def-item>
          <term>FHx</term>
          <def>
            <p id="Par24">Family history</p>
          </def>
        </def-item>
        <def-item>
          <term>FSH</term>
          <def>
            <p id="Par25">Follicle stimulating hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>FT3</term>
          <def>
            <p id="Par26">Free triiodothyronine</p>
          </def>
        </def-item>
        <def-item>
          <term>FT4</term>
          <def>
            <p id="Par27">Free thyroxine</p>
          </def>
        </def-item>
        <def-item>
          <term>GAD 65</term>
          <def>
            <p id="Par28">Glutamic acid decarboxylase 65</p>
          </def>
        </def-item>
        <def-item>
          <term>GH</term>
          <def>
            <p id="Par29">Growth hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>HCT</term>
          <def>
            <p id="Par30">Hydrocortisone</p>
          </def>
        </def-item>
        <def-item>
          <term>HD steroids</term>
          <def>
            <p id="Par31">High dose steroids</p>
          </def>
        </def-item>
        <def-item>
          <term>IA-2</term>
          <def>
            <p id="Par32">Islet antigen 2</p>
          </def>
        </def-item>
        <def-item>
          <term>IAA</term>
          <def>
            <p id="Par33">Insulin auto-antibody</p>
          </def>
        </def-item>
        <def-item>
          <term>IGF1</term>
          <def>
            <p id="Par34">Insulin growth factor-1</p>
          </def>
        </def-item>
        <def-item>
          <term>IgG</term>
          <def>
            <p id="Par35">Immunoglobulin</p>
          </def>
        </def-item>
        <def-item>
          <term>Ipi</term>
          <def>
            <p id="Par36">Ipilimumab</p>
          </def>
        </def-item>
        <def-item>
          <term>LH</term>
          <def>
            <p id="Par37">Luteinizing hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>LT4</term>
          <def>
            <p id="Par38">Levothyroxine</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p id="Par39">Magnetic resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>Nivo</term>
          <def>
            <p id="Par40">Nivolumab</p>
          </def>
        </def-item>
        <def-item>
          <term>NL</term>
          <def>
            <p id="Par41">Normal</p>
          </def>
        </def-item>
        <def-item>
          <term>NR</term>
          <def>
            <p id="Par42">Not reported</p>
          </def>
        </def-item>
        <def-item>
          <term>NSCLC</term>
          <def>
            <p id="Par43">Non-small cell lung cancer</p>
          </def>
        </def-item>
        <def-item>
          <term>PAI</term>
          <def>
            <p id="Par44">Primary adrenal insufficiency</p>
          </def>
        </def-item>
        <def-item>
          <term>Pembro</term>
          <def>
            <p id="Par45">Pembrolizumab</p>
          </def>
        </def-item>
        <def-item>
          <term>PET</term>
          <def>
            <p id="Par46">Positron emission tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>PHx</term>
          <def>
            <p id="Par47">Personal history</p>
          </def>
        </def-item>
        <def-item>
          <term>PRL</term>
          <def>
            <p id="Par48">Prolactin</p>
          </def>
        </def-item>
        <def-item>
          <term>PTH</term>
          <def>
            <p id="Par49">Parahormone</p>
          </def>
        </def-item>
        <def-item>
          <term>RAI</term>
          <def>
            <p id="Par50">Radioactive iodine</p>
          </def>
        </def-item>
        <def-item>
          <term>RCC</term>
          <def>
            <p id="Par51">Renal cell carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>Rx</term>
          <def>
            <p id="Par52">Treatment</p>
          </def>
        </def-item>
        <def-item>
          <term>SAI</term>
          <def>
            <p id="Par53">Secondary adrenal insufficiency</p>
          </def>
        </def-item>
        <def-item>
          <term>SD</term>
          <def>
            <p id="Par54">Standard deviation</p>
          </def>
        </def-item>
        <def-item>
          <term>T</term>
          <def>
            <p id="Par55">Testosterone</p>
          </def>
        </def-item>
        <def-item>
          <term>T1DM</term>
          <def>
            <p id="Par56">Type 1 diabetes mellitus</p>
          </def>
        </def-item>
        <def-item>
          <term>T2DM</term>
          <def>
            <p id="Par57">Type 2 diabetes mellitus</p>
          </def>
        </def-item>
        <def-item>
          <term>TCR</term>
          <def>
            <p id="Par58">T-cell receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>TG</term>
          <def>
            <p id="Par59">Thyroglobulin Ab</p>
          </def>
        </def-item>
        <def-item>
          <term>ThyD</term>
          <def>
            <p id="Par60">Thyroid disease</p>
          </def>
        </def-item>
        <def-item>
          <term>TPO</term>
          <def>
            <p id="Par61">Thyroperoxidase antibodies (Ab)</p>
          </def>
        </def-item>
        <def-item>
          <term>TRAb</term>
          <def>
            <p id="Par62">Thyroreceptor Ab</p>
          </def>
        </def-item>
        <def-item>
          <term>Treme</term>
          <def>
            <p id="Par63">Tremelimumab</p>
          </def>
        </def-item>
        <def-item>
          <term>TSH</term>
          <def>
            <p id="Par64">Thyroid stimulating hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>TSI</term>
          <def>
            <p id="Par65">Thyroid stimulating immunoglobulin</p>
          </def>
        </def-item>
        <def-item>
          <term>US</term>
          <def>
            <p id="Par66">Ultrasound</p>
          </def>
        </def-item>
        <def-item>
          <term>Utomi</term>
          <def>
            <p id="Par67">Utomilumab</p>
          </def>
        </def-item>
        <def-item>
          <term>ZnT8</term>
          <def>
            <p id="Par68">Zinc Transporter 8</p>
          </def>
        </def-item>
        <def-item>
          <term>&#x3B2;OB</term>
          <def>
            <p id="Par69">&#x3B2;-OH butyrate</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ack>
      <title>Acknowledgements</title>
      <p>None</p>
      <sec id="FPar1">
        <title>Funding</title>
        <p id="Par136">None.</p>
      </sec>
      <sec id="FPar2" sec-type="data-availability">
        <title>Availability of data and materials</title>
        <p id="Par137">Data supporting the findings and conclusion of this review are found in the Supplementary Materials section.</p>
      </sec>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions</title>
      <p>MHT, RG and BR conceived this scoping review and designed it with MPM who conducted the original and supplemental literature searches. LYS, RI, KMS, RG, and MHT collected, analyzed and interpreted the case reports. They were also involved in the hand search of references of articles and relevant journals from July 2017 to January 2018. SY, MPM and MHT prepared the first draft of the manuscript. Every author critically reviewed and revised the various drafts of the manuscripts before approving the final version for submission. MHT coordinated the preparation of this scoping review.</p>
    </notes>
    <notes notes-type="COI-statement">
      <sec id="FPar3">
        <title>Ethics approval and consent to participate</title>
        <p>Not applicable.</p>
      </sec>
      <sec id="FPar4">
        <title>Consent for publication</title>
        <p>No patient consent needed.</p>
      </sec>
      <sec id="FPar5">
        <title>Competing interests</title>
        <p>None.</p>
      </sec>
      <sec id="FPar6">
        <title>Publisher&#x2019;s Note</title>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="other">FDA. Pembrolizumab (KEYTRUDA) Prescribing Information 2017 [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s031lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s031lbl.pdf</ext-link> Accessed 17 May 2018.</mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="other">FDA. Nivolumab (OPDIVO) Prescribing Information 2017 [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s035s036s037s038s039lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s035s036s037s038s039lbl.pdf</ext-link> Accessed 17 May 2018.</mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="other">FDA. Ipilimumab (YERVOY) Prescribing Information 2017 [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125377s091lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125377s091lbl.pdf</ext-link> Accessed 17 May 2018.</mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="other">FDA. <italic>Atezolizumab (TECENTRIQ) Prescribing Information</italic>. 2018 [cited 2018; Available from: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761034s005lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761034s005lbl.pdf</ext-link> Accessed 17 May 2018.</mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="other">FDA. <italic>Durvalumab (IMFINZI) Prescribing Information</italic>. 2018 [cited 2018; Available fro Accessed 17 May 2018.</mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="other">FDA. <italic>Avelumab (BAVENCIO) Prescribing Information</italic>. 2017 [cited 2018; Available from:<ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf</ext-link> Accessed 17 May 2018.</mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Min</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Immune-related endocrine disorders in novel immune checkpoint inhibition therapy</article-title>
          <source>Genes Dis</source>
          <year>2016</year>
          <volume>3</volume>
          <fpage>252</fpage>
          <lpage>256</lpage>
          <pub-id pub-id-type="doi">10.1016/j.gendis.2016.10.002</pub-id>
          <pub-id pub-id-type="pmid">29623291</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Min</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hodi</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Giobbie-Hurder</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ott</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Luke</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Donahue</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study</article-title>
          <source>Clin Cancer Res</source>
          <year>2015</year>
          <volume>21</volume>
          <fpage>749</fpage>
          <lpage>755</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2353</pub-id>
          <pub-id pub-id-type="pmid">25538262</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdel-Wahab</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suarez-Almazor</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports</article-title>
          <source>PLoS One</source>
          <year>2016</year>
          <volume>11</volume>
          <fpage>e0160221</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0160221</pub-id>
          <pub-id pub-id-type="pmid">27472273</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arksey</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>O&#x2019;Malley</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Scoping studies: towards a methodological framework</article-title>
          <source>Int J Soc Res Methodol</source>
          <year>2005</year>
          <volume>8</volume>
          <fpage>19</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1080/1364557032000119616</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levac</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Colquhoun</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>O&#x2019;Brien</surname>
              <given-names>KK</given-names>
            </name>
          </person-group>
          <article-title>Scoping studies: advancing the methodology</article-title>
          <source>Implement Sci</source>
          <year>2010</year>
          <volume>5</volume>
          <fpage>69</fpage>
          <pub-id pub-id-type="doi">10.1186/1748-5908-5-69</pub-id>
          <pub-id pub-id-type="pmid">20854677</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelly</surname>
              <given-names>WN</given-names>
            </name>
            <name>
              <surname>Arellano</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bergman</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Guidelines for submitting adverse event reports for publication</article-title>
          <source>Drug Saf</source>
          <year>2007</year>
          <volume>30</volume>
          <fpage>367</fpage>
          <lpage>373</lpage>
          <pub-id pub-id-type="doi">10.2165/00002018-200730050-00001</pub-id>
          <pub-id pub-id-type="pmid">17472416</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phan</surname>
              <given-names>GQ</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Sherry</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Hwu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Topalian</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Schwartzentruber</surname>
              <given-names>DJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2003</year>
          <volume>100</volume>
          <fpage>8372</fpage>
          <lpage>8377</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.1533209100</pub-id>
          <pub-id pub-id-type="pmid">12826605</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="other">Blansfield J, Beck K, Tran K, Yang JC, Hughes M, Kammula U, et al. Cytotoxic T-Lymphocyte&#x2013;associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28:593&#x2013;8.</mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Camacho</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>McCutcheon</surname>
              <given-names>IE</given-names>
            </name>
            <name>
              <surname>Waguespack</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
          <article-title>Transient hypophysitis after cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2007</year>
          <volume>92</volume>
          <fpage>1201</fpage>
          <lpage>1202</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2006-2484</pub-id>
          <pub-id pub-id-type="pmid">17409339</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="other">Yang JC, Hughes M, Kammula U, Royal R, Sherry R, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and Hypophysitis. J Immunother. 2007;30:825&#x2013;30.</mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaehler</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Egberts</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lorigan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hauschild</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient</article-title>
          <source>Melanoma Res</source>
          <year>2009</year>
          <volume>19</volume>
          <issue>5</issue>
          <fpage>333</fpage>
          <lpage>334</lpage>
          <pub-id pub-id-type="doi">10.1097/CMR.0b013e32832e0bff</pub-id>
          <pub-id pub-id-type="pmid">19512947</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carpenter</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Murtagh</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Lilienfeld</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Murtagh</surname>
              <given-names>FR</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-induced hypophysitis: MR imaging findings</article-title>
          <source>AJNR Am J Neuroradiol</source>
          <year>2009</year>
          <volume>30</volume>
          <fpage>1751</fpage>
          <lpage>1753</lpage>
          <pub-id pub-id-type="doi">10.3174/ajnr.A1623</pub-id>
          <pub-id pub-id-type="pmid">19474123</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dillard</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yedinak</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Alumkal</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fleseriu</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes</article-title>
          <source>Pituitary</source>
          <year>2010</year>
          <volume>13</volume>
          <fpage>29</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-009-0193-z</pub-id>
          <pub-id pub-id-type="pmid">19639414</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Min</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vaidya</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series</article-title>
          <source>Endocr Pract</source>
          <year>2012</year>
          <volume>18</volume>
          <fpage>5</fpage>
          <pub-id pub-id-type="doi">10.4158/EP11273.OR</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andrews</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Holden</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma</article-title>
          <source>Cancer Manag Res</source>
          <year>2012</year>
          <volume>4</volume>
          <fpage>299</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="doi">10.2147/CMAR.S31873</pub-id>
          <pub-id pub-id-type="pmid">23049279</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barnard</surname>
              <given-names>ZR</given-names>
            </name>
            <name>
              <surname>Walcott</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Kahle</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Nahed</surname>
              <given-names>BV</given-names>
            </name>
            <name>
              <surname>Coumans</surname>
              <given-names>JV</given-names>
            </name>
          </person-group>
          <article-title>Hyponatremia associated with Ipilimumab-induced hypophysitis</article-title>
          <source>Med Oncol</source>
          <year>2012</year>
          <volume>29</volume>
          <fpage>374</fpage>
          <lpage>377</lpage>
          <pub-id pub-id-type="doi">10.1007/s12032-010-9794-7</pub-id>
          <pub-id pub-id-type="pmid">21264545</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Juszczak</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Karavitaki</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Middleton</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review</article-title>
          <source>Eur J Endocrinol</source>
          <year>2012</year>
          <volume>167</volume>
          <fpage>1</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-12-0167</pub-id>
          <pub-id pub-id-type="pmid">22495490</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carra</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gaudy-Marqueste</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Albarel</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Monestier</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mallet</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brue</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ipilimumab-induced hypophysitis in melanoma patients</article-title>
          <source>J Clin Oncol</source>
          <year>2012</year>
          <volume>30</volume>
          <issue>15</issue>
          <fpage>1</fpage>
          <pub-id pub-id-type="pmid">22105825</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eranki</surname>
              <given-names>VG</given-names>
            </name>
            <name>
              <surname>Elhomsy</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Silverberg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Albert</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-associated hypophysitis-time course of MRI and hormonal changes</article-title>
          <source>Endocr Rev</source>
          <year>2012</year>
          <volume>33</volume>
          <fpage>2012</fpage>
          <lpage>2006</lpage>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwun</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lukacova-Zib</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gopalakrishnan</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Central adrenal insufficiency and hypothyroidism after ipilimumab treatment</article-title>
          <source>Endocr Rev</source>
          <year>2012</year>
          <volume>33</volume>
          <fpage>2012</fpage>
          <lpage>2006</lpage>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lammert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Bergmann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Benck</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Gartner</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy</article-title>
          <source>Exp Clin Endocrinol Diabetes</source>
          <year>2013</year>
          <volume>121</volume>
          <fpage>581</fpage>
          <lpage>587</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0033-1355337</pub-id>
          <pub-id pub-id-type="pmid">24122241</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bhatia</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab immune. related adverse reactions: a case report</article-title>
          <source>S D J Med</source>
          <year>2013</year>
          <volume>66</volume>
          <fpage>4</fpage>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leonard</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hyponatremia and hypopituitarism secondary to Ipilimumab</article-title>
          <source>Am J Kidney Dis</source>
          <year>2013</year>
          <volume>61</volume>
          <fpage>A59</fpage>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarvaideo</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Block</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Brockstein</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Adrenal crisis secondary to hypophysitis after ipilimumab therapy and steroid treatment</article-title>
          <source>Endocr Rev</source>
          <year>2013</year>
          <volume>34</volume>
          <fpage>2013</fpage>
          <lpage>2006</lpage>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Joshi</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-induced hypophysitis and thyroiditis</article-title>
          <source>Endocr Rev</source>
          <year>2013</year>
          <volume>34</volume>
          <fpage>2013</fpage>
          <lpage>2006</lpage>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmed</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Rein</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Shenker</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Albertini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
          <article-title>Central adrenal insufficiency due to ipilimumab (Yervoy)</article-title>
          <source>Endocr Rev</source>
          <year>2013</year>
          <volume>34</volume>
          <fpage>2013</fpage>
          <lpage>2006</lpage>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gil</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Aparicio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bertini</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sankowicz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ballarino</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Autoimmune hypophysitis due to ipilimumab</article-title>
          <source>Endocr Rev</source>
          <year>2013</year>
          <volume>34</volume>
          <fpage>2013</fpage>
          <lpage>2006</lpage>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <mixed-citation publication-type="other">Min L, Ibrahim N. Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol. 2013;1(3):e15.</mixed-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Assi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>KS</given-names>
            </name>
          </person-group>
          <article-title>Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases</article-title>
          <source>Curr Oncol</source>
          <year>2013</year>
          <volume>20</volume>
          <fpage>e165</fpage>
          <lpage>e169</lpage>
          <pub-id pub-id-type="doi">10.3747/co.20.1265</pub-id>
          <pub-id pub-id-type="pmid">23559884</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Hollanda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aranda</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Mora</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gaba</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Halperin</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab, a cause of autoimmune hypophysitis</article-title>
          <source>Endocrinolog&#xED;a y Nutrici&#xF3;n (English Edition)</source>
          <year>2013</year>
          <volume>60</volume>
          <fpage>604</fpage>
          <lpage>606</lpage>
          <pub-id pub-id-type="doi">10.1016/j.endoen.2013.12.003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hermes</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tsiogka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rompoti</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Suttorp</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zimmer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schadendorf</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Autoimmune hypophysitis, autoimmunolitis and autoimmune hepatitis in a patient with metastatic melanoma under CTLA-4 therapy antibody ipilimumab</article-title>
          <source>J Dtsch Dermatol Ges</source>
          <year>2013</year>
          <volume>11</volume>
          <fpage>932</fpage>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burgess</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Loh</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Sixth cranial palsy as an unusual presenting symptom of ipilimumab induced hypophysitis</article-title>
          <source>J Gen Intern Med</source>
          <year>2013</year>
          <volume>28</volume>
          <issue>S1</issue>
          <fpage>S390</fpage>
          <lpage>S391</lpage>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chodakiewitz</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Boxerman</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Brody</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Rogg</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis</article-title>
          <source>Clin Neurol Neurosurg</source>
          <year>2014</year>
          <volume>125</volume>
          <fpage>125</fpage>
          <lpage>130</lpage>
          <pub-id pub-id-type="doi">10.1016/j.clineuro.2014.06.011</pub-id>
          <pub-id pub-id-type="pmid">25127260</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodrigues</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Otty</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Sangla</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shenoy</surname>
              <given-names>VV</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesions</article-title>
          <source>Endocrinol Diabetes Metab Case Rep</source>
          <year>2014</year>
          <volume>2014</volume>
          <fpage>140098</fpage>
          <pub-id pub-id-type="pmid">25614822</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nallapaneni</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mourya</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bhatt</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Malhotra</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ganti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tendulkar</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash</article-title>
          <source>J Natl Compr Canc Netw</source>
          <year>2014</year>
          <volume>12</volume>
          <fpage>5</fpage>
          <pub-id pub-id-type="doi">10.6004/jnccn.2014.0105</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faje</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tritos</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Fadden</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Klibanski</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2014</year>
          <volume>99</volume>
          <fpage>4078</fpage>
          <lpage>4085</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2014-2306</pub-id>
          <pub-id pub-id-type="pmid">25078147</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <mixed-citation publication-type="other">Buddhdev K, Buddhdev B. A rare case of Ipilimumab induced pituitary Hypophysitis: an evolving clinical entity. Endocr Soc. 2014;35(4 Suppl):677</mixed-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marlier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cocquyt</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Brochez</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Van Belle</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kruse</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports</article-title>
          <source>Endocrine</source>
          <year>2014</year>
          <volume>47</volume>
          <issue>3</issue>
          <fpage>878</fpage>
          <lpage>883</lpage>
          <pub-id pub-id-type="doi">10.1007/s12020-014-0199-9</pub-id>
          <pub-id pub-id-type="pmid">24554495</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ryder</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Callahan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Postow</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Wolchok</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fagin</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution</article-title>
          <source>Endocr Relat Cancer</source>
          <year>2014</year>
          <volume>21</volume>
          <fpage>371</fpage>
          <lpage>381</lpage>
          <pub-id pub-id-type="doi">10.1530/ERC-13-0499</pub-id>
          <pub-id pub-id-type="pmid">24610577</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <mixed-citation publication-type="other">Alkhaddo J, Khowaja A, Saeed A, Burmeister L. Serial TSH levels during treatment and onset of ipilimumab-induced hypophysitis. failure of tsh alone to make the diagnosis. Endocr Soc. 2014;35(4 Suppl):676</mixed-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iwama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>de Remigis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Callahan</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Slovin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wolchok</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Caturegli</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody</article-title>
          <source>Sci Transl Med</source>
          <year>2014</year>
          <volume>6</volume>
          <fpage>230ra45</fpage>
          <pub-id pub-id-type="doi">10.1126/scitranslmed.3008002</pub-id>
          <pub-id pub-id-type="pmid">24695685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tiu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pezaro</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>Grossmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Parente</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: case studies and recommendations for management</article-title>
          <source>Asia Pac J Clin Oncol</source>
          <year>2015</year>
          <volume>11</volume>
          <fpage>190</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="doi">10.1111/ajco.12348</pub-id>
          <pub-id pub-id-type="pmid">25855890</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kotwal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab induced hypophysitis may not affect all pituitary cell lines: a case study</article-title>
          <source>Endocr Rev</source>
          <year>2015</year>
          <volume>36</volume>
          <issue>2</issue>
          <fpage>2015</fpage>
          <lpage>2003</lpage>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <mixed-citation publication-type="other">Denman D, Mongelluzzo G, Lock J, Panikkar R, Zeng Y, Gingrich P, et al. The growing concern for autoimmune hypophysitis due to ipilimumab. Endocr Rev. 2015;36(2 Suppl):469.</mixed-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heaney</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Sumerel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rajalingam</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bergsneider</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yong</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Liau</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>HLA markers DQ8 and DR53 are associated with lymphocytic Hypophysitis and may aid in differential diagnosis</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2015</year>
          <volume>100</volume>
          <fpage>4092</fpage>
          <lpage>4097</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2015-2702</pub-id>
          <pub-id pub-id-type="pmid">26317559</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Majchel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Korytkowski</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Anticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review</article-title>
          <source>Case Rep Endocrinol</source>
          <year>2015</year>
          <volume>2015</volume>
          <fpage>570293</fpage>
          <pub-id pub-id-type="pmid">25694832</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lam</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Sweeting</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>De Sousa</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carlino</surname>
              <given-names>MS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series</article-title>
          <source>Intern Med J</source>
          <year>2015</year>
          <volume>45</volume>
          <fpage>1066</fpage>
          <lpage>1073</lpage>
          <pub-id pub-id-type="doi">10.1111/imj.12819</pub-id>
          <pub-id pub-id-type="pmid">26010858</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DeSousa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Tonks</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-induced hypophysitis: early Australian experience</article-title>
          <source>MJA</source>
          <year>2014</year>
          <volume>201</volume>
          <fpage>2</fpage>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <mixed-citation publication-type="other">Hanseree P, Poehls J. Ipilimumab induced Hypophysitis &#x2013; recurrence of symptoms during the course of steroid treatment. Endocr Soc. 2015;36(2 Suppl):470.</mixed-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Albarel</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gaudy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Castinetti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Carre</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Morange</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Conte-Devolx</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma</article-title>
          <source>Eur J Endocrinol</source>
          <year>2015</year>
          <volume>172</volume>
          <fpage>195</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-14-0845</pub-id>
          <pub-id pub-id-type="pmid">25416723</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Araujo</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Coelho</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Arruda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gadelha</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Neto</surname>
              <given-names>LV</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-induced hypophysitis: review of the literature</article-title>
          <source>J Endocrinol Investig</source>
          <year>2015</year>
          <volume>38</volume>
          <fpage>1159</fpage>
          <lpage>1166</lpage>
          <pub-id pub-id-type="doi">10.1007/s40618-015-0301-z</pub-id>
          <pub-id pub-id-type="pmid">25957829</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carl</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Grullich</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hering</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schabet</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report</article-title>
          <source>BMC Res Notes</source>
          <year>2015</year>
          <volume>8</volume>
          <fpage>316</fpage>
          <pub-id pub-id-type="doi">10.1186/s13104-015-1283-9</pub-id>
          <pub-id pub-id-type="pmid">26209970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mahzari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Arnaout</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lochnan</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Immune checkpoint inhibitor therapy associated hypophysitis</article-title>
          <source>Clin Med Insights Endocrinol Diabetes</source>
          <year>2015</year>
          <volume>8</volume>
          <fpage>21</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="doi">10.4137/CMED.S22469</pub-id>
          <pub-id pub-id-type="pmid">25861234</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <mixed-citation publication-type="other">Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life- threatening complication. Case Rep Oncol Med. 2015;2015:794842. pp. 1-5.</mixed-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Guld</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Galetta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Kharlip</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tamhankar</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute visual loss after ipilimumab treatment for metastatic melanoma</article-title>
          <source>J Immunother Cancer</source>
          <year>2016</year>
          <volume>4</volume>
          <fpage>66</fpage>
          <pub-id pub-id-type="doi">10.1186/s40425-016-0170-9</pub-id>
          <pub-id pub-id-type="pmid">27777775</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohnuma</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Matsuzawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kinoshita</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sano</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kawamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shimada</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Case of metastatic uveal melanoma in which an antitumor effect appeared after ipilimumab discontinuation due to autoimmune hypophysitis</article-title>
          <source>J Dermatol</source>
          <year>2017</year>
          <volume>44</volume>
          <fpage>1325</fpage>
          <lpage>1326</lpage>
          <pub-id pub-id-type="doi">10.1111/1346-8138.13692</pub-id>
          <pub-id pub-id-type="pmid">27864834</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <mixed-citation publication-type="other">Grenier M, Maditz R, Pabbathi S. Can&#x2019;t cope with the stress of nivolumab therapy: immune mediated adrenal insufficiency [abstract]. J Hosp Med. 2016;11(suppl 1). <ext-link ext-link-type="uri" xlink:href="https://www.shmabstracts.com/abstract/cant-cope-with-the-stress-of-nivolumab-therapyimmune-mediated-adrenal-insufficiency/">https://www.shmabstracts.com/abstract/cant-cope-with-the-stress-of-nivolumab-therapyimmune-mediated-adrenal-insufficiency/</ext-link>.</mixed-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caturegli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Di Dalmazi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grosso</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Larman</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Larman</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series</article-title>
          <source>Am J Pathol</source>
          <year>2016</year>
          <volume>186</volume>
          <fpage>3225</fpage>
          <lpage>3235</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajpath.2016.08.020</pub-id>
          <pub-id pub-id-type="pmid">27750046</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marques</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-induced autoimmune Hypophysitis: diagnostic and management challenges illustrated by a clinical case</article-title>
          <source>Acta Medica Port</source>
          <year>2015</year>
          <volume>28</volume>
          <fpage>6</fpage>
        </element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koessler</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Olivier</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fertani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marinari</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dutoit</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Dietrich</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-related hypophysitis may precede severe CNS immune attack</article-title>
          <source>Ann Oncol</source>
          <year>2016</year>
          <volume>27</volume>
          <fpage>2</fpage>
          <pub-id pub-id-type="doi">10.1093/annonc/mdw255</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okano</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Satoh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Horiguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Toyoda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Osaki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma</article-title>
          <source>Endocr J</source>
          <year>2016</year>
          <volume>63</volume>
          <fpage>8</fpage>
          <pub-id pub-id-type="doi">10.1507/endocrj.EJ16-0161</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miller</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Brock</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jim Yeung</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>Pituitary dysfunction: a case series of immune checkpoint inhibitor-related Hypophysitis in an emergency department</article-title>
          <source>Ann Emerg Med</source>
          <year>2016</year>
          <volume>68</volume>
          <fpage>249</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="doi">10.1016/j.annemergmed.2016.03.048</pub-id>
          <pub-id pub-id-type="pmid">27451306</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Todd</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Adrenal insufficiency secondary to ipilimumab induced hypophysitis: the northern Irish experience</article-title>
          <source>Ir J Med Sci</source>
          <year>2016</year>
          <volume>185</volume>
          <issue>Suppl 7</issue>
          <fpage>363</fpage>
          <lpage>419</lpage>
          <pub-id pub-id-type="pmid">27571959</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freeman-Keller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cronin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gibney</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab in resected and Unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes</article-title>
          <source>Clin Cancer Res</source>
          <year>2016</year>
          <volume>22</volume>
          <fpage>886</fpage>
          <lpage>894</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-1136</pub-id>
          <pub-id pub-id-type="pmid">26446948</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vancieri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Beilla</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lauro</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Lat-onset panhypopituitarism in a 72-year-old male patient with ipilimumab for metastatic melanoma: a case report</article-title>
          <source>J Endocrinol Investig</source>
          <year>2016</year>
          <volume>39</volume>
          <fpage>805</fpage>
          <lpage>806</lpage>
          <pub-id pub-id-type="doi">10.1007/s40618-016-0439-3</pub-id>
          <pub-id pub-id-type="pmid">26883763</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Bhat</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Novel immunomodulating therapy ipilimumab induced acute adrenal insufficiency secondary to autoimmune hypophysitis in a patient with squamous cell lung carcinoma</article-title>
          <source>Endocr Rev</source>
          <year>2016</year>
          <volume>37</volume>
          <fpage>2016</fpage>
          <lpage>2004</lpage>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gill</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Story</surname>
              <given-names>ES</given-names>
            </name>
          </person-group>
          <article-title>A case of pituitary failure following treatment with ipilimumab</article-title>
          <source>J Gen Intern Med</source>
          <year>2016</year>
          <volume>31</volume>
          <issue>2 SUPPL 1</issue>
          <fpage>S493</fpage>
          <lpage>S4S4</lpage>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Telford</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Roberson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bag</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-induced hypophysitis</article-title>
          <source>Endocr Rev</source>
          <year>2016</year>
          <volume>37</volume>
          <fpage>2016</fpage>
          <lpage>2004</lpage>
        </element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Humanyun</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Poole</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment</article-title>
          <source>Hormones</source>
          <year>2016</year>
          <volume>15</volume>
          <fpage>303</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="pmid">27376434</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lowe</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Salama</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Mathews</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Hanks</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
          <article-title>Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy</article-title>
          <source>J Immunother Cancer</source>
          <year>2016</year>
          <volume>4</volume>
          <fpage>89</fpage>
          <pub-id pub-id-type="doi">10.1186/s40425-016-0196-z</pub-id>
          <pub-id pub-id-type="pmid">28031819</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bot</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Blank</surname>
              <given-names>CU</given-names>
            </name>
            <name>
              <surname>Boogerd</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Brandsma</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Neurological immune-related adverse events of ipilimumab</article-title>
          <source>Pract Neurol</source>
          <year>2013</year>
          <volume>13</volume>
          <fpage>278</fpage>
          <lpage>280</lpage>
          <pub-id pub-id-type="doi">10.1136/practneurol-2012-000447</pub-id>
          <pub-id pub-id-type="pmid">23487828</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ishikawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oashi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Case of hypophysitis caused by nivolumab</article-title>
          <source>J Dermatol</source>
          <year>2017</year>
          <volume>44</volume>
          <fpage>109</fpage>
          <lpage>110</lpage>
          <pub-id pub-id-type="doi">10.1111/1346-8138.13437</pub-id>
          <pub-id pub-id-type="pmid">27178147</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mansoor</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mihalek</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Use of immune checkpoint inhibitors induces an immune mediated Hypophysitis</article-title>
          <source>Am J Respir Critical Care Med</source>
          <year>2017</year>
          <volume>195</volume>
          <fpage>1</fpage>
        </element-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Konda</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Nabhan</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Endocrine dysfunction following immune checkpoint inhibitor therapy</article-title>
          <source>Curr Opin Endocrinol Diabetes Obes</source>
          <year>2017</year>
          <volume>24</volume>
          <fpage>337</fpage>
          <lpage>347</lpage>
          <pub-id pub-id-type="doi">10.1097/MED.0000000000000357</pub-id>
          <pub-id pub-id-type="pmid">28661915</pub-id>
        </element-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujimura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kambayashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Furudate</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kakizaki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hidaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Haga</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient</article-title>
          <source>J Dermatol</source>
          <year>2017</year>
          <volume>44</volume>
          <fpage>e13</fpage>
          <lpage>ee4</lpage>
          <pub-id pub-id-type="doi">10.1111/1346-8138.13532</pub-id>
          <pub-id pub-id-type="pmid">27440178</pub-id>
        </element-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sawada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Okada</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ohmori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Haruyama</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hypopituitarism and hypothyroidism following atrioventricular block during nivolumab treatment</article-title>
          <source>J Dermatol</source>
          <year>2017</year>
          <volume>44</volume>
          <fpage>e144</fpage>
          <lpage>e1e5</lpage>
          <pub-id pub-id-type="doi">10.1111/1346-8138.13797</pub-id>
          <pub-id pub-id-type="pmid">28295551</pub-id>
        </element-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neril</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lorton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zonszein</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab-induced isolated adrenal insufficiency: a case report</article-title>
          <source>AACE Clin Case Rep</source>
          <year>2017</year>
          <volume>3</volume>
          <issue>3</issue>
          <fpage>e210</fpage>
          <lpage>e2e2</lpage>
          <pub-id pub-id-type="doi">10.4158/EP161491.CR</pub-id>
        </element-citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Narahira</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yanagi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>KY</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Miyoshi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hata</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy</article-title>
          <source>J Dermatol</source>
          <year>2017</year>
          <volume>44</volume>
          <issue>4</issue>
          <fpage>e70</fpage>
          <pub-id pub-id-type="doi">10.1111/1346-8138.13571</pub-id>
          <pub-id pub-id-type="pmid">27608187</pub-id>
        </element-citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kitajima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ashida</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Suetsugul</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Takeichi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab</article-title>
          <source>Jap J Clin Oncol</source>
          <year>2017</year>
          <volume>47</volume>
          <fpage>463</fpage>
          <lpage>466</lpage>
          <pub-id pub-id-type="doi">10.1093/jjco/hyx018</pub-id>
          <pub-id pub-id-type="pmid">28334791</pub-id>
        </element-citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brilli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Danielli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ciuoli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Calabro</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Di Giacomo</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Cerase</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab</article-title>
          <source>Endocrine</source>
          <year>2017</year>
          <volume>58</volume>
          <fpage>535</fpage>
          <lpage>541</lpage>
          <pub-id pub-id-type="doi">10.1007/s12020-017-1289-2</pub-id>
          <pub-id pub-id-type="pmid">28401443</pub-id>
        </element-citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Kwan</surname>
              <given-names>GN</given-names>
            </name>
            <name>
              <surname>Bhuta</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-induced hypophysitis and ileocolitis: serial pituitary MRI findings</article-title>
          <source>Neurol India</source>
          <year>2017</year>
          <volume>65</volume>
          <issue>1</issue>
          <fpage>165</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="doi">10.4103/0028-3886.198182</pub-id>
          <pub-id pub-id-type="pmid">28084260</pub-id>
        </element-citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Otsubo</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakatomi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Furukawa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ashida</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yoneshima</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nakanishi</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab</article-title>
          <source>Ann Oncol</source>
          <year>2017</year>
          <volume>28</volume>
          <fpage>3106</fpage>
          <lpage>3107</lpage>
          <pub-id pub-id-type="doi">10.1093/annonc/mdx497</pub-id>
          <pub-id pub-id-type="pmid">28945828</pub-id>
        </element-citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>McKenna</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Westrup</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kelleher</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hypophysitis secondary to the checkpoint inhibitor Pembrolizumab-a rare condition, a new cause-a case report</article-title>
          <source>Irish J Med Sci</source>
          <year>2017</year>
          <volume>186</volume>
          <issue>9 Supplement 1</issue>
          <fpage>S355</fpage>
          <lpage>S3S6</lpage>
        </element-citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bhalla</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hauck</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Hypophysitis and adrenal insufficiency secondary to ipilimumab and nivolumab: A nearly life-threatening side effect of novel immunotherapy agents</article-title>
          <source>J Gen Intern Med</source>
          <year>2017</year>
          <volume>32</volume>
          <issue>2 Supplement 1</issue>
          <fpage>S514</fpage>
        </element-citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mian</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rukmangadachar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Choucair</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab induced auto-immune hypophysitis</article-title>
          <source>Ann Neurol</source>
          <year>2017</year>
          <volume>82</volume>
          <issue>Supplement 21</issue>
          <fpage>S29</fpage>
        </element-citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okiro</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>McHugh</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab induced hypophysitis, pathogenesis and review of current literatures</article-title>
          <source>Irish J Med Sci</source>
          <year>2017</year>
          <volume>186</volume>
          <issue>9 Supplement 1</issue>
          <fpage>S379</fpage>
        </element-citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zeng</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Gong</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>LN</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>YM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy -case report and review</article-title>
          <source>Medicine</source>
          <year>2017</year>
          <volume>96</volume>
          <issue>44</issue>
          <fpage>e8426</fpage>
          <pub-id pub-id-type="doi">10.1097/MD.0000000000008426</pub-id>
          <pub-id pub-id-type="pmid">29095280</pub-id>
        </element-citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takaya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sonoda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hiyoshi</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer</article-title>
          <source>Intern Med</source>
          <year>2017</year>
          <volume>56</volume>
          <fpage>2463</fpage>
          <lpage>2469</lpage>
          <pub-id pub-id-type="doi">10.2169/internalmedicine.8548-16</pub-id>
          <pub-id pub-id-type="pmid">28824067</pub-id>
        </element-citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marchand</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Paulus</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Fabien</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Perol</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Thivolet</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Santignyu</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab-induced acute diabetes mellitus and Hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response</article-title>
          <source>J Thorac Oncol</source>
          <year>2017</year>
          <volume>12</volume>
          <fpage>e182</fpage>
          <lpage>e184</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jtho.2017.07.021</pub-id>
          <pub-id pub-id-type="pmid">29074210</pub-id>
        </element-citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kanie</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Iguchi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bando</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Odake</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Two cases of Atezolizumab-induced Hypophysitis</article-title>
          <source>J Endocr Soc</source>
          <year>2018</year>
          <volume>2</volume>
          <fpage>91</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="doi">10.1210/js.2017-00414</pub-id>
          <pub-id pub-id-type="pmid">29362727</pub-id>
        </element-citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Min</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vaidya</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy</article-title>
          <source>Eur J Endocrinol</source>
          <year>2011</year>
          <volume>164</volume>
          <fpage>303</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-10-0833</pub-id>
          <pub-id pub-id-type="pmid">21088057</pub-id>
        </element-citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borodic</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hinkle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cia</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced graves&#x2019; disease from CTLA-4 receptor suppression</article-title>
          <source>Ophthal Plast Reconstr Surg</source>
          <year>2011</year>
          <volume>27</volume>
          <fpage>1</fpage>
          <pub-id pub-id-type="doi">10.1097/IOP.0b013e3181ef72a1</pub-id>
        </element-citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borordic</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hinkle</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Ipilimumab-induced orbital inflammation resembling graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression</article-title>
          <source>Ophthal Plast Reconstr Surg</source>
          <year>2014</year>
          <volume>30</volume>
          <fpage>83</fpage>
          <pub-id pub-id-type="doi">10.1097/IOP.0000000000000033</pub-id>
        </element-citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <mixed-citation publication-type="other">Krull I, Rogowski-Lehmann N, Sigrist S, Siano M, Brandle M, Bilz S. Thyroid dysfunction in a patient treated with Ipilimumab: autoimmune thyroid disease associated with AntiCTLA4 therapy. Endocr Soc. 2014;35(4 Suppl):494</mixed-citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Azmat</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Liebner</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Joehlin-Price</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Agrawal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nabhan</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Treatment of Ipilimumab induced Graves&#x2019; disease in a patient with metastatic melanoma</article-title>
          <source>Case Rep Endocrinol</source>
          <year>2016</year>
          <volume>2016</volume>
          <fpage>2087525</fpage>
          <pub-id pub-id-type="pmid">26881150</pub-id>
        </element-citation>
      </ref>
      <ref id="CR102">
        <label>102.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gan</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Plummer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Perros</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Tremelimumab-induced graves hyperthyroidism</article-title>
          <source>Eur Thyroid J</source>
          <year>2017</year>
          <volume>6</volume>
          <fpage>167</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="doi">10.1159/000464285</pub-id>
          <pub-id pub-id-type="pmid">28785544</pub-id>
        </element-citation>
      </ref>
      <ref id="CR103">
        <label>103.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orlov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Salari</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kashat</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Walfish</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2015</year>
          <volume>100</volume>
          <fpage>1738</fpage>
          <lpage>1741</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2014-4560</pub-id>
          <pub-id pub-id-type="pmid">25751110</pub-id>
        </element-citation>
      </ref>
      <ref id="CR104">
        <label>104.</label>
        <mixed-citation publication-type="other">Verma I, Modi A, Tripathi H, Agrawal A. Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung. BMJ Case Rep. 2016;1-3. 10.1136/bcr2015-213692</mixed-citation>
      </ref>
      <ref id="CR105">
        <label>105.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chopra</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Ha</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis</article-title>
          <source>Endocrinol Diabetes Metab Case Rep</source>
          <year>2015</year>
          <volume>2015</volume>
          <fpage>140092</fpage>
          <pub-id pub-id-type="pmid">25759760</pub-id>
        </element-citation>
      </ref>
      <ref id="CR106">
        <label>106.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferdousy</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sherman</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fouty</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Vu</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Where is the storm coming from: a case of thyroid storm secondary to Ipilimumab</article-title>
          <source>Chest</source>
          <year>2016</year>
          <volume>150</volume>
          <issue>4</issue>
          <fpage>379A</fpage>
          <pub-id pub-id-type="doi">10.1016/j.chest.2016.08.392</pub-id>
        </element-citation>
      </ref>
      <ref id="CR107">
        <label>107.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Panach</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Oo</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab-induced thyroiditis in a patient with metastatic renal cell carcinoma</article-title>
          <source>Thyroid</source>
          <year>2016</year>
          <volume>26</volume>
          <issue>Supplement 1</issue>
          <fpage>A14</fpage>
        </element-citation>
      </ref>
      <ref id="CR108">
        <label>108.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>JMM</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kung</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Silent (painless) thyroiditis induced by newest PD-1 inhibitor pembrolizumab</article-title>
          <source>Endocr Rev</source>
          <year>2016</year>
          <volume>37</volume>
          <fpage>2016</fpage>
          <lpage>2004</lpage>
        </element-citation>
      </ref>
      <ref id="CR109">
        <label>109.</label>
        <mixed-citation publication-type="other">Somasundaram A, UKrainski M, Ahmed I, Fallon JJ Jr. Ipilimumab and pembrolizumab induced thyroiditis. Endocr Rev. 2015;36:2003&#x2013;15.</mixed-citation>
      </ref>
      <ref id="CR110">
        <label>110.</label>
        <mixed-citation publication-type="other">McMillen B, Dhillon MS, Yong-Yow S. A rare case of thyroid storm. BMJ Case Rep. 2016;1-4. 10.1136/bcr:2016-214603.</mixed-citation>
      </ref>
      <ref id="CR111">
        <label>111.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Narita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Oiso</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Taketomo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Okahashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamauchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab</article-title>
          <source>J Dermatol</source>
          <year>2016</year>
          <volume>43</volume>
          <fpage>210</fpage>
          <lpage>214</lpage>
          <pub-id pub-id-type="doi">10.1111/1346-8138.13028</pub-id>
          <pub-id pub-id-type="pmid">26198822</pub-id>
        </element-citation>
      </ref>
      <ref id="CR112">
        <label>112.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tanaka</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fujisawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yoshino</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohtsuka</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nivolumab-induced thyroid dysfunction</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>2016</year>
          <volume>46</volume>
          <fpage>575</fpage>
          <lpage>579</lpage>
          <pub-id pub-id-type="doi">10.1093/jjco/hyw036</pub-id>
          <pub-id pub-id-type="pmid">27012985</pub-id>
        </element-citation>
      </ref>
      <ref id="CR113">
        <label>113.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Besemer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Mussig</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Rare differential diagnosis of hyperthyroidism</article-title>
          <source>Dtsch Med Wochenschr</source>
          <year>2016</year>
          <volume>141</volume>
          <issue>12</issue>
          <fpage>889</fpage>
          <pub-id pub-id-type="doi">10.1055/s-0041-104686</pub-id>
          <pub-id pub-id-type="pmid">27305306</pub-id>
        </element-citation>
      </ref>
      <ref id="CR114">
        <label>114.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kapoor</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Treatment with nivolumab results in asymptomatic thyroiditis followed by severe hypothyroidism</article-title>
          <source>A Thyroid</source>
          <year>2016</year>
          <volume>26</volume>
          <issue>Supplement 1</issue>
          <fpage>A95</fpage>
        </element-citation>
      </ref>
      <ref id="CR115">
        <label>115.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delivanis</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Gustafson</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Bornschlegl</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Merten</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Kottschade</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Withers</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2017</year>
          <volume>102</volume>
          <issue>8</issue>
          <fpage>2770</fpage>
          <lpage>2780</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2017-00448</pub-id>
          <pub-id pub-id-type="pmid">28609832</pub-id>
        </element-citation>
      </ref>
      <ref id="CR116">
        <label>116.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diamantopoulos</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Gaggadi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kassi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Benopoulou</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Anastasopoulou</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gogas</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events</article-title>
          <source>Melanoma Res</source>
          <year>2017</year>
          <volume>27</volume>
          <fpage>391</fpage>
          <lpage>395</lpage>
          <pub-id pub-id-type="doi">10.1097/CMR.0000000000000355</pub-id>
          <pub-id pub-id-type="pmid">28419059</pub-id>
        </element-citation>
      </ref>
      <ref id="CR117">
        <label>117.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morganstein</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Spain</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Diem</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mace</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma</article-title>
          <source>Clin Endocrinol</source>
          <year>2017</year>
          <volume>86</volume>
          <fpage>614</fpage>
          <lpage>620</lpage>
          <pub-id pub-id-type="doi">10.1111/cen.13297</pub-id>
        </element-citation>
      </ref>
      <ref id="CR118">
        <label>118.</label>
        <mixed-citation publication-type="other">Nandavaram S, Nadkami A. Ipilimumab-Induced Sarcoidosis and Thyroiditis. Am J Therapeutics. 2018;25:e379-e380.</mixed-citation>
      </ref>
      <ref id="CR119">
        <label>119.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Osorio</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Ni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chaft</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Pollina</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kasler</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer</article-title>
          <source>Ann Oncol</source>
          <year>2017</year>
          <volume>28</volume>
          <fpage>583</fpage>
          <lpage>589</lpage>
          <pub-id pub-id-type="pmid">27998967</pub-id>
        </element-citation>
      </ref>
      <ref id="CR120">
        <label>120.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sweeting</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Lomax</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>McGill</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pembrolizumab-induced thyroiditis in patients with metastatic melanoma: a novel form of autoimmune thyroid disease</article-title>
          <source>Clin Endocrinol</source>
          <year>2017</year>
          <volume>86</volume>
          <issue>Supplement 1</issue>
          <fpage>34</fpage>
          <lpage>35</lpage>
        </element-citation>
      </ref>
      <ref id="CR121">
        <label>121.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Kooten</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Van den Berg</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Glaudemans</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hiltermann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Groen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rutgers</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transient thyrotoxicosis during nivolumab tr eatment</article-title>
          <source>Neth J Med</source>
          <year>2017</year>
          <volume>75</volume>
          <issue>5</issue>
          <fpage>4</fpage>
          <pub-id pub-id-type="pmid">28124665</pub-id>
        </element-citation>
      </ref>
      <ref id="CR122">
        <label>122.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Win</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Thein</surname>
              <given-names>KZ</given-names>
            </name>
            <name>
              <surname>Qdaisat</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yeung</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism</article-title>
          <source>Am J Emerg Med</source>
          <year>2017</year>
          <volume>35</volume>
          <fpage>1039 e5</fpage>
          <lpage>1039 e7</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajem.2017.02.048</pub-id>
        </element-citation>
      </ref>
      <ref id="CR123">
        <label>123.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamauchi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sakane</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fukuda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Taura</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hirata</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical features of Nivolumab-induced thyroiditis: a case series study</article-title>
          <source>Thyroid</source>
          <year>2017</year>
          <volume>27</volume>
          <fpage>894</fpage>
          <lpage>901</lpage>
          <pub-id pub-id-type="doi">10.1089/thy.2016.0562</pub-id>
          <pub-id pub-id-type="pmid">28537531</pub-id>
        </element-citation>
      </ref>
      <ref id="CR124">
        <label>124.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okiyama</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Varied immuno-related adverse events induced by immune-check point inhibitors &#x2014; Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6</article-title>
          <source>Japan J Clin Immunol</source>
          <year>2017</year>
          <volume>40</volume>
          <fpage>7</fpage>
          <pub-id pub-id-type="doi">10.2177/jsci.40.95</pub-id>
        </element-citation>
      </ref>
      <ref id="CR125">
        <label>125.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Malley</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Parekh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Galsky</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Friedlander</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rapid evolution of thyroid dysfunction in patients treated with Nivolumab</article-title>
          <source>Endocr Pract</source>
          <year>2017</year>
          <volume>23</volume>
          <fpage>1223</fpage>
          <lpage>1231</lpage>
          <pub-id pub-id-type="doi">10.4158/EP171832.OR</pub-id>
          <pub-id pub-id-type="pmid">29045188</pub-id>
        </element-citation>
      </ref>
      <ref id="CR126">
        <label>126.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paepegaey</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Lheure</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ratour</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lethielleux</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Clerc</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bertherat</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Polyendocrinopathy resulting from Pembrolizumab in a patient with a malignant melanoma</article-title>
          <source>J Endocr Soc</source>
          <year>2017</year>
          <volume>1</volume>
          <fpage>646</fpage>
          <lpage>649</lpage>
          <pub-id pub-id-type="doi">10.1210/js.2017-00170</pub-id>
          <pub-id pub-id-type="pmid">29264517</pub-id>
        </element-citation>
      </ref>
      <ref id="CR127">
        <label>127.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lupu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pages</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Laly</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Delyon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Laloi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Petit</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination</article-title>
          <source>Melanoma Res</source>
          <year>2017</year>
          <volume>27</volume>
          <issue>6</issue>
          <fpage>649</fpage>
          <lpage>652</lpage>
          <pub-id pub-id-type="doi">10.1097/CMR.0000000000000405</pub-id>
          <pub-id pub-id-type="pmid">29036015</pub-id>
        </element-citation>
      </ref>
      <ref id="CR128">
        <label>128.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alhusseini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Samantray</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Autoimmune diabetes superimposed on type 2 diabetes in a patient initiated on immunotherapy for lung cancer</article-title>
          <source>Diabetes Metab</source>
          <year>2017</year>
          <volume>43</volume>
          <fpage>2</fpage>
          <pub-id pub-id-type="doi">10.1016/j.diabet.2016.05.007</pub-id>
        </element-citation>
      </ref>
      <ref id="CR129">
        <label>129.</label>
        <mixed-citation publication-type="other">Reddy SC, Darapu H, Agarwal M. Nivolumab induced auto-immune diabetes mellitus and thyroiditis: a case report. Endocr Rev. 2017;38(3):2004&#x2013;17.</mixed-citation>
      </ref>
      <ref id="CR130">
        <label>130.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sakurai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nitsuma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Arihara</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Painless thyroiditis and fulminant type 1 diabetes mellitus in a patient treated with an immune checkpoint inhibitor, Nivolumab</article-title>
          <source>Tohoku J Exp Med</source>
          <year>2018</year>
          <volume>244</volume>
          <fpage>33</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1620/tjem.244.33</pub-id>
          <pub-id pub-id-type="pmid">29343652</pub-id>
        </element-citation>
      </ref>
      <ref id="CR131">
        <label>131.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Min</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hodi</surname>
              <given-names>FS</given-names>
            </name>
          </person-group>
          <article-title>Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis</article-title>
          <source>Cancer Immunol Res</source>
          <year>2014</year>
          <volume>2</volume>
          <fpage>15</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0146</pub-id>
          <pub-id pub-id-type="pmid">24778161</pub-id>
        </element-citation>
      </ref>
      <ref id="CR132">
        <label>132.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mellati</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eaton</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Brooks-Worrell</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Hagopian</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Martino</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes mellitus</article-title>
          <source>Diabetes Care</source>
          <year>2015</year>
          <volume>38</volume>
          <fpage>e137</fpage>
          <lpage>e138</lpage>
          <pub-id pub-id-type="doi">10.2337/dc15-0889</pub-id>
          <pub-id pub-id-type="pmid">26116720</pub-id>
        </element-citation>
      </ref>
      <ref id="CR133">
        <label>133.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khan</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Rizvi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sano</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chiu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hadid</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab induced myxedema crisis</article-title>
          <source>J Immunother Cancer</source>
          <year>2017</year>
          <volume>5</volume>
          <fpage>13</fpage>
          <pub-id pub-id-type="doi">10.1186/s40425-017-0213-x</pub-id>
          <pub-id pub-id-type="pmid">28239466</pub-id>
        </element-citation>
      </ref>
      <ref id="CR134">
        <label>134.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Masood</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yavuz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grosbach</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Autoimmune diabetes and thyroiditis complicating treatment with Nivolumab</article-title>
          <source>Case Rep Oncol</source>
          <year>2017</year>
          <volume>10</volume>
          <fpage>230</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="doi">10.1159/000456540</pub-id>
          <pub-id pub-id-type="pmid">28611636</pub-id>
        </element-citation>
      </ref>
      <ref id="CR135">
        <label>135</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Imafuku</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yoshino</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsuboi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ohara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hata</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Hypothyroidism associated with Nivolumab treatment of Unresectable malignant melanoma</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2017</year>
          <volume>42</volume>
          <fpage>217</fpage>
          <lpage>218</lpage>
          <pub-id pub-id-type="doi">10.1111/ced.13028</pub-id>
          <pub-id pub-id-type="pmid">28052364</pub-id>
        </element-citation>
      </ref>
      <ref id="CR136">
        <label>136.</label>
        <mixed-citation publication-type="other">Guaraldi F, La Selva R, Sama MT, D&#x2019;Angelo V, Gori D, Fava P, et al. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Investig. 2018;41:549-56.</mixed-citation>
      </ref>
      <ref id="CR137">
        <label>137.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Lucca</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rossini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Morena</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Banfi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pogliani</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Parati</surname>
              <given-names>MC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association between the development of autoimmune hypothyroidism and objective response to nivolumab: report of two cases</article-title>
          <source>Ann Oncol</source>
          <year>2017</year>
          <volume>28</volume>
          <issue>Supplement 6</issue>
          <fpage>vi99</fpage>
        </element-citation>
      </ref>
      <ref id="CR138">
        <label>138.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torimoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Okada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nakayamada</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Anti-PD-1 antibody therapy induces Hashimoto's disease with an increase in peripheral blood follicular helper T cells</article-title>
          <source>Thyroid</source>
          <year>2017</year>
          <volume>27</volume>
          <fpage>1335</fpage>
          <lpage>1336</lpage>
          <pub-id pub-id-type="doi">10.1089/thy.2017.0062</pub-id>
          <pub-id pub-id-type="pmid">28699391</pub-id>
        </element-citation>
      </ref>
      <ref id="CR139">
        <label>139.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaudy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Clevy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Monestier</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dubois</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Preau</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mallet</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-PD1 Pembrolizumab Can induce exceptional fulminant type 1 diabetes</article-title>
          <source>Diabetes Care</source>
          <year>2015</year>
          <volume>38</volume>
          <fpage>e182</fpage>
          <lpage>e183</lpage>
          <pub-id pub-id-type="doi">10.2337/dc15-1331</pub-id>
          <pub-id pub-id-type="pmid">26310693</pub-id>
        </element-citation>
      </ref>
      <ref id="CR140">
        <label>140.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hughes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vudattu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sznol</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gettinger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kluger</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lupsa</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy</article-title>
          <source>Diabetes Care</source>
          <year>2015</year>
          <volume>38</volume>
          <fpage>e55</fpage>
          <lpage>e57</lpage>
          <pub-id pub-id-type="doi">10.2337/dc15-0401</pub-id>
          <pub-id pub-id-type="pmid">25805871</pub-id>
        </element-citation>
      </ref>
      <ref id="CR141">
        <label>141.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin-Liberal</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Furness</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Joshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Peggs</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Quezada</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Larkin</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report</article-title>
          <source>Cancer Immunol</source>
          <year>2015</year>
          <volume>64</volume>
          <fpage>765</fpage>
          <lpage>767</lpage>
          <pub-id pub-id-type="doi">10.1007/s00262-015-1689-1</pub-id>
        </element-citation>
      </ref>
      <ref id="CR142">
        <label>142.</label>
        <mixed-citation publication-type="other">Aleksova J, Lau PK, Soldatos G, McArthur G. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. BMJ Case Rep. 2016;1-5. 10.1136/bcr:2016-217454.</mixed-citation>
      </ref>
      <ref id="CR143">
        <label>143.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akturk</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Meek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Joseph</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab Related Insulin-dependent</article-title>
          <source>Diabetes</source>
          <year>2016</year>
          <volume>65</volume>
          <fpage>A414</fpage>
        </element-citation>
      </ref>
      <ref id="CR144">
        <label>144.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hansen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sahasrabudhe</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sievert</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome</article-title>
          <source>Cancer Immunol</source>
          <year>2016</year>
          <volume>65</volume>
          <fpage>3</fpage>
        </element-citation>
      </ref>
      <ref id="CR145">
        <label>145.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hofmann</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Forschner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Loquai</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Goldinger</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Zimmer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ugurel</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy</article-title>
          <source>Eur J Cancer</source>
          <year>2016</year>
          <volume>60</volume>
          <fpage>190</fpage>
          <lpage>209</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejca.2016.02.025</pub-id>
          <pub-id pub-id-type="pmid">27085692</pub-id>
        </element-citation>
      </ref>
      <ref id="CR146">
        <label>146.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miyoshi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Oyama</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab, an anti-programmed cell Death-1 antibody, induces fulminant type 1 diabetes</article-title>
          <source>Tohoku J Exp Med</source>
          <year>2016</year>
          <volume>239</volume>
          <fpage>4</fpage>
          <pub-id pub-id-type="doi">10.1620/tjem.239.155</pub-id>
        </element-citation>
      </ref>
      <ref id="CR147">
        <label>147.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Okamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gotoh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Masaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ozeki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy</article-title>
          <source>J Diabetes Invest</source>
          <year>2016</year>
          <volume>7</volume>
          <fpage>915</fpage>
          <lpage>918</lpage>
          <pub-id pub-id-type="doi">10.1111/jdi.12531</pub-id>
        </element-citation>
      </ref>
      <ref id="CR148">
        <label>148.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Usui</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Udagawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishibashi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association of Serum Anti-GAD antibody and HLA haplotypes with type 1 diabetes mellitus triggered by Nivolumab in patients with non-small cell lung cancer</article-title>
          <source>J Thorac Oncol</source>
          <year>2017</year>
          <volume>12</volume>
          <fpage>e41</fpage>
          <lpage>ee3</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jtho.2016.12.015</pub-id>
          <pub-id pub-id-type="pmid">28017788</pub-id>
        </element-citation>
      </ref>
      <ref id="CR149">
        <label>149.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kong</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Kwak</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes</article-title>
          <source>Acta Diabetol</source>
          <year>2016</year>
          <volume>53</volume>
          <fpage>853</fpage>
          <lpage>856</lpage>
          <pub-id pub-id-type="doi">10.1007/s00592-016-0872-y</pub-id>
          <pub-id pub-id-type="pmid">27300348</pub-id>
        </element-citation>
      </ref>
      <ref id="CR150">
        <label>150.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shah</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maxfield</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Feroz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Donohue</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Rapid development of type 1 diabetes mellitus after initiation of anti-PD-1 therapy</article-title>
          <source>Int J Cancer Clin Res</source>
          <year>2016</year>
          <volume>3</volume>
          <fpage>066</fpage>
          <lpage>067</lpage>
          <pub-id pub-id-type="doi">10.23937/2378-3419/3/4/1066</pub-id>
        </element-citation>
      </ref>
      <ref id="CR151">
        <label>151.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zaied</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab-induced autoimmune diabetic ketoacidosis</article-title>
          <source>Chest</source>
          <year>2016</year>
          <volume>150</volume>
          <fpage>255A</fpage>
          <pub-id pub-id-type="doi">10.1016/j.chest.2016.08.268</pub-id>
        </element-citation>
      </ref>
      <ref id="CR152">
        <label>152.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsiogka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jansky</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Bauer</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Koelblinger</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma</article-title>
          <source>Melanoma Res</source>
          <year>2017</year>
          <volume>27</volume>
          <fpage>524</fpage>
          <lpage>525</lpage>
          <pub-id pub-id-type="doi">10.1097/CMR.0000000000000384</pub-id>
          <pub-id pub-id-type="pmid">28858175</pub-id>
        </element-citation>
      </ref>
      <ref id="CR153">
        <label>153.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdul Aziz</surname>
              <given-names>MHF</given-names>
            </name>
            <name>
              <surname>Fernando</surname>
              <given-names>IP</given-names>
            </name>
            <name>
              <surname>Lenkanpally</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fernando</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Diabetic ketoacidosis after treatment with Pembrolizumab</article-title>
          <source>J Clin Transl Endocrinol Case Rep</source>
          <year>2017</year>
          <volume>5</volume>
          <fpage>4</fpage>
          <lpage>5</lpage>
        </element-citation>
      </ref>
      <ref id="CR154">
        <label>154.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chae</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Chiec</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mohindra</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gentzler</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Giles</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes</article-title>
          <source>Cancer Immunol Immunother CII</source>
          <year>2017</year>
          <volume>66</volume>
          <fpage>25</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1007/s00262-016-1913-7</pub-id>
          <pub-id pub-id-type="pmid">27761609</pub-id>
        </element-citation>
      </ref>
      <ref id="CR155">
        <label>155.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Teramoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Asami</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nemoto</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient</article-title>
          <source>J Dermatol</source>
          <year>2016</year>
          <volume>44</volume>
          <fpage>2</fpage>
        </element-citation>
      </ref>
      <ref id="CR156">
        <label>156.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thoreau</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gouaillier-Vulcain</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Machet</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mateus</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Robert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ferreira-Maldent</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute lower limb Ischaemia and diabetes in a patient treated with anti-PD1 monoclonal antibody for metastatic melanoma</article-title>
          <source>Acta Derm Venereol</source>
          <year>2017</year>
          <volume>97</volume>
          <fpage>408</fpage>
          <lpage>409</lpage>
          <pub-id pub-id-type="doi">10.2340/00015555-2504</pub-id>
          <pub-id pub-id-type="pmid">27377178</pub-id>
        </element-citation>
      </ref>
      <ref id="CR157">
        <label>157.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Araujo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ligeiro</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Marque</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Trindade</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Correia</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case of fulminant type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient</article-title>
          <source>Immunotherapy</source>
          <year>2017</year>
          <volume>9</volume>
          <fpage>6</fpage>
          <pub-id pub-id-type="doi">10.2217/imt-2017-0020</pub-id>
        </element-citation>
      </ref>
      <ref id="CR158">
        <label>158.</label>
        <mixed-citation publication-type="other">Atkins PW, Thompson DM. Combination avelumab and utomilumab immunotherapy can induce diabetic ketoacidosis. Diabetes Metab. 2018;44:514-5</mixed-citation>
      </ref>
      <ref id="CR159">
        <label>159.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>JTK</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab-induced autoimmune diabetes</article-title>
          <source>J Pharm Pract Res</source>
          <year>2017</year>
          <volume>47</volume>
          <issue>2</issue>
          <fpage>136</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="doi">10.1002/jppr.1247</pub-id>
        </element-citation>
      </ref>
      <ref id="CR160">
        <label>160.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hay</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>VML</given-names>
            </name>
            <name>
              <surname>Szlosarek</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
          <article-title>A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity</article-title>
          <source>Pigment Cell Melanoma Res</source>
          <year>2017</year>
          <volume>30</volume>
          <fpage>558</fpage>
          <lpage>562</lpage>
          <pub-id pub-id-type="doi">10.1111/pcmr.12607</pub-id>
          <pub-id pub-id-type="pmid">28640512</pub-id>
        </element-citation>
      </ref>
      <ref id="CR161">
        <label>161.</label>
        <mixed-citation publication-type="other">Daltry S, Bujanova J, Cranston I. Autoimmune diabetes and anti-programmed cell death-1 (anti-PD-1) cancer immunotherapy. Diabet Med. 2017;34(Suppl 1):102.</mixed-citation>
      </ref>
      <ref id="CR162">
        <label>162.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farrell</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Casasola</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schofield</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Acute onset Type 1 diabetes precipitated by Pembrolizumab, an anti-PD-1 monoclonal antibody used as a treatment for melanoma</article-title>
          <source>Diabetic Med</source>
          <year>2017</year>
          <volume>34</volume>
          <issue>Suppl s1</issue>
          <fpage>1</fpage>
        </element-citation>
      </ref>
      <ref id="CR163">
        <label>163.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gauci</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Laly</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vidal-Trecan</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Baroudjian</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gottlieb</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Madjlessi-Ezra</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review</article-title>
          <source>Cancer Immunol</source>
          <year>2017</year>
          <volume>66</volume>
          <issue>11</issue>
          <fpage>1399</fpage>
          <lpage>1410</lpage>
          <pub-id pub-id-type="doi">10.1007/s00262-017-2033-8</pub-id>
        </element-citation>
      </ref>
      <ref id="CR164">
        <label>164.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hickmott</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>De La Pena</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Protheroe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literature</article-title>
          <source>Target Oncol</source>
          <year>2017</year>
          <volume>12</volume>
          <fpage>235</fpage>
          <lpage>241</lpage>
          <pub-id pub-id-type="doi">10.1007/s11523-017-0480-y</pub-id>
          <pub-id pub-id-type="pmid">28255845</pub-id>
        </element-citation>
      </ref>
      <ref id="CR165">
        <label>165.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ishikawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shono-saito</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamate</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sakai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms</article-title>
          <source>EJD</source>
          <year>2017</year>
          <volume>27</volume>
          <fpage>2</fpage>
        </element-citation>
      </ref>
      <ref id="CR166">
        <label>166.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leonardi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Oxnard</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Awad</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Diabetic ketoacidosis as an immune-related adverse event from Pembrolizumab in non small cell lung cancer</article-title>
          <source>J Immunother</source>
          <year>2017</year>
          <volume>40</volume>
          <fpage>3</fpage>
          <pub-id pub-id-type="doi">10.1097/CJI.0000000000000173</pub-id>
        </element-citation>
      </ref>
      <ref id="CR167">
        <label>167.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsumura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nagasawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Oshima</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kikuno</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab</article-title>
          <source>J Diabetes Invest</source>
          <year>2018</year>
          <volume>9</volume>
          <fpage>438</fpage>
          <lpage>441</lpage>
          <pub-id pub-id-type="doi">10.1111/jdi.12679</pub-id>
        </element-citation>
      </ref>
      <ref id="CR168">
        <label>168.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mizab Mellha</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rey</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Fulminant type 1 diabetes mellitus associated with pembrolizumab</article-title>
          <source>Endocrinolog&#xED;a, Diabetes y Nutrici&#xF3;n</source>
          <year>2017</year>
          <volume>64</volume>
          <issue>5</issue>
          <fpage>2</fpage>
        </element-citation>
      </ref>
      <ref id="CR169">
        <label>169.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Munakata</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ohashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamauchi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tobinai</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma</article-title>
          <source>Int J Hematol</source>
          <year>2017</year>
          <volume>105</volume>
          <fpage>383</fpage>
          <lpage>386</lpage>
          <pub-id pub-id-type="doi">10.1007/s12185-016-2101-4</pub-id>
          <pub-id pub-id-type="pmid">27696192</pub-id>
        </element-citation>
      </ref>
      <ref id="CR170">
        <label>170.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Telo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Carvalhal</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cauduro</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Webber</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Barrios</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fay</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma</article-title>
          <source>Ann Oncol</source>
          <year>2017</year>
          <volume>28</volume>
          <fpage>2</fpage>
        </element-citation>
      </ref>
      <ref id="CR171">
        <label>171.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wright</surname>
              <given-names>LA-C</given-names>
            </name>
            <name>
              <surname>Ramon</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Batacchi</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Hirsch</surname>
              <given-names>IB</given-names>
            </name>
          </person-group>
          <article-title>Progression to insulin dependence post-treatment with immune checkpoint inhibitors in pre-existing type 2 diabetes</article-title>
          <source>AACE Clin Case Rep</source>
          <year>2017</year>
          <volume>3</volume>
          <fpage>e153</fpage>
          <lpage>e1e7</lpage>
          <pub-id pub-id-type="doi">10.4158/EP161303.CR</pub-id>
        </element-citation>
      </ref>
      <ref id="CR172">
        <label>172.</label>
        <mixed-citation publication-type="other">Alzenaidi A, Dendy J, Rejjal L. Autoimmune diabetes presented with diabetic ketoacidosis induced by immunotherapy in an adult with melanoma. J La State Med Soc. 2017;169:49.</mixed-citation>
      </ref>
      <ref id="CR173">
        <label>173.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Godwin</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Jaggi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sirisena</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sharda</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Mehra</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer</article-title>
          <source>J Immunother Cancer</source>
          <year>2017</year>
          <volume>5</volume>
          <fpage>40</fpage>
          <pub-id pub-id-type="doi">10.1186/s40425-017-0245-2</pub-id>
          <pub-id pub-id-type="pmid">28515940</pub-id>
        </element-citation>
      </ref>
      <ref id="CR174">
        <label>174.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Changizzadeh</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Mukkamalla</surname>
              <given-names>SKR</given-names>
            </name>
            <name>
              <surname>Armenio</surname>
              <given-names>VA</given-names>
            </name>
          </person-group>
          <article-title>Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma</article-title>
          <source>J Immunother Cancer</source>
          <year>2017</year>
          <volume>5</volume>
          <fpage>97</fpage>
          <pub-id pub-id-type="doi">10.1186/s40425-017-0303-9</pub-id>
          <pub-id pub-id-type="pmid">29254501</pub-id>
        </element-citation>
      </ref>
      <ref id="CR175">
        <label>175.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith-Cohn</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gill</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Voorhies</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Agarwal</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Garrido-Laguna</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Case report: pembrolizumab-induced type 1 diabetes in a patient with metastatic cholangiocarcinoma</article-title>
          <source>Immunotherapy</source>
          <year>2017</year>
          <volume>9</volume>
          <fpage>8</fpage>
          <pub-id pub-id-type="doi">10.2217/imt-2017-0042</pub-id>
        </element-citation>
      </ref>
      <ref id="CR176">
        <label>176.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kapke</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shaheen</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Kilari</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Knudson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management</article-title>
          <source>Case Rep Oncol</source>
          <year>2017</year>
          <volume>10</volume>
          <fpage>897</fpage>
          <lpage>909</lpage>
          <pub-id pub-id-type="doi">10.1159/000480634</pub-id>
          <pub-id pub-id-type="pmid">29279690</pub-id>
        </element-citation>
      </ref>
      <ref id="CR177">
        <label>177.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumagai</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Muramatsu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>FUjii</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Katakura</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute-onset type 1 diabetes mellitus caused by nivolumab in a patient with advanced pulmonary adenocarcinoma</article-title>
          <source>J Diabetes Invest</source>
          <year>2017</year>
          <volume>8</volume>
          <fpage>798</fpage>
          <lpage>799</lpage>
          <pub-id pub-id-type="doi">10.1111/jdi.12627</pub-id>
        </element-citation>
      </ref>
      <ref id="CR178">
        <label>178.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gambale</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tinari</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Quinzil</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cortellini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carella</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>De Turst</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab and diabetes mellitus: Safe administration in a patient with pancreatic metastases from melanoma</article-title>
          <source>J Transl Med</source>
          <year>2017</year>
          <volume>15</volume>
          <issue>Supplement 1</issue>
          <fpage>11</fpage>
          <pub-id pub-id-type="pmid">28086962</pub-id>
        </element-citation>
      </ref>
      <ref id="CR179">
        <label>179.</label>
        <mixed-citation publication-type="other">Lee JYM, Warshauer JT, Gilliam LK, Park-Segal J, Murphy EJ, Anderson MS. A case of acute severe insulin resistance and fulminant type 1 diabetes after immune checkpoint blockade cancer therapy. Endocr Rev. 2017;38(3):2004&#x2013;17.</mixed-citation>
      </ref>
      <ref id="CR180">
        <label>180.</label>
        <mixed-citation publication-type="other">Nieves CA, Harlan DM, Thompson M, Suzuki S, Ali A. Autoimmune diabetes linked to nivolumab. Diabetes. 2017;66(Supplement 1):A353.</mixed-citation>
      </ref>
      <ref id="CR181">
        <label>181.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reslan</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Paull</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Pembrolizumab induced auto-immune diabetes and hepatitis</article-title>
          <source>J Oncol Pharm Pract</source>
          <year>2017</year>
          <volume>23</volume>
          <issue>Supplement 1</issue>
          <fpage>11</fpage>
        </element-citation>
      </ref>
      <ref id="CR182">
        <label>182.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vodopivec</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Piech</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Treitter</surname>
              <given-names>CG</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab induced autoimmune diabetes in a patient with metastatic renal cell carcinoma: a case report</article-title>
          <source>Endocr Rev</source>
          <year>2017</year>
          <volume>38</volume>
          <fpage>2017</fpage>
          <lpage>2004</lpage>
        </element-citation>
      </ref>
      <ref id="CR183">
        <label>183.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hao</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Renno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Imam</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Alfonso-Jaume</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Elnagar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Jaume</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Development of type 1 diabetes after cancer immunotherapy</article-title>
          <source>AACE Clin Case Rep</source>
          <year>2017</year>
          <volume>3</volume>
          <fpage>e242</fpage>
          <lpage>e245</lpage>
          <pub-id pub-id-type="doi">10.4158/EP161410.CR</pub-id>
        </element-citation>
      </ref>
      <ref id="CR184">
        <label>184.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Villarreal</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Townes</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vrablik</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ro</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>A case of drug-induced severe Endocrinopathies. What providers in the emergency department need to know</article-title>
          <source>Adv Emerg Nurs J</source>
          <year>2018</year>
          <volume>40</volume>
          <fpage>16</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="doi">10.1097/TME.0000000000000173</pub-id>
          <pub-id pub-id-type="pmid">29384770</pub-id>
        </element-citation>
      </ref>
      <ref id="CR185">
        <label>185.</label>
        <mixed-citation publication-type="other">Capitao R, Bello C, Fonseca R, Saraiva C. New onset diabetes after Nivolumab treatment. BMJ Case Rep. 2018;2018:bcr-2017-22099 p1-3.</mixed-citation>
      </ref>
      <ref id="CR186">
        <label>186.</label>
        <mixed-citation publication-type="other">Trainer H, Hulse P, Higham CE, Trainer P, Lorigan P. Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep. 2016:1-4. <pub-id pub-id-type="doi">10.1530/EDM16-0106</pub-id>.</mixed-citation>
      </ref>
      <ref id="CR187">
        <label>187.</label>
        <mixed-citation publication-type="other">Coskun NSS, Simsir IY, G&#xF6;ksel T. A case with a primary adrenal insufficiency secondary to nivolumab. Eur Respir J. 2016;48:PA4853.</mixed-citation>
      </ref>
      <ref id="CR188">
        <label>188.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akarca</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Can</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Yalcinli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Altunci</surname>
              <given-names>YA</given-names>
            </name>
          </person-group>
          <article-title>Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis</article-title>
          <source>Turk J Emerg Med</source>
          <year>2017</year>
          <volume>17</volume>
          <fpage>157</fpage>
          <lpage>159</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tjem.2017.05.007</pub-id>
          <pub-id pub-id-type="pmid">29464222</pub-id>
        </element-citation>
      </ref>
      <ref id="CR189">
        <label>189.</label>
        <mixed-citation publication-type="other">Zhao C, Tella SH, Del Rivero J, Kommalapati A, Ebenuwa I, Gulley J, et al. Anti-PD-L1 treatment induced central diabetes insipidus. J Clin Endocrinol Metab. 2018;103:365&#x2013;9.</mixed-citation>
      </ref>
      <ref id="CR190">
        <label>190.</label>
        <mixed-citation publication-type="other">Mills TA, Orloff M, Domingo-Vidal M, Cotzia P, Bribe RC, Dragonova-Tacheva R, et al. Parathyroid hormone-related peptide-linked hypercalcemia in a melanoma patient treated with Ipilimumab: hormone source and clinical and metabolic correlates. Semin Oncol. 2015;42:909&#x2013;14.</mixed-citation>
      </ref>
      <ref id="CR191">
        <label>191.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Funasaka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Chakrahorty</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Obashi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chrouso</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Ichihashi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Expression of proopiomelanocortin, Corticotropin-releasing hormone (CRH), and CRH receptor in melanoma cells, nevus cells, and Normal human melanocytes</article-title>
          <source>J Investig Dermatol Symp Proc</source>
          <year>1999</year>
          <volume>4</volume>
          <fpage>105</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.jidsp.5640192</pub-id>
          <pub-id pub-id-type="pmid">10536983</pub-id>
        </element-citation>
      </ref>
      <ref id="CR192">
        <label>192.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schteingart</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Llyod</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Akil</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cushing&#x2019;s syndrome secondary to ectopic Corticotropin-releasing hormone-Adrenocorticotropin secretion</article-title>
          <source>J Clin Endo Metab</source>
          <year>1986</year>
          <volume>63</volume>
          <fpage>770</fpage>
          <lpage>775</lpage>
          <pub-id pub-id-type="doi">10.1210/jcem-63-3-770</pub-id>
        </element-citation>
      </ref>
      <ref id="CR193">
        <label>193.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faje</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Flaherty</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Freedman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fadden</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High-dose glucocorticoids for the treatment of Ipilimumab-induced hypophysitiss is associated with reduced survival in patients with melanoma</article-title>
          <source>Cancer</source>
          <year>2018</year>
          <volume>124</volume>
          <fpage>3706</fpage>
          <lpage>3714</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.31629</pub-id>
          <pub-id pub-id-type="pmid">29975414</pub-id>
        </element-citation>
      </ref>
      <ref id="CR194">
        <label>194.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ni</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wen</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>XR</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CTLA-4 CT60 (rs3087243) polymorphism and autoimmune thyroid diseases susceptibility: a comprehensive meta-analysis</article-title>
          <source>J Endocr Res</source>
          <year>2014</year>
          <volume>39</volume>
          <fpage>180</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="doi">10.3109/07435800.2013.879167</pub-id>
        </element-citation>
      </ref>
      <ref id="CR195">
        <label>195.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cukier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Santini</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Scaranti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hoff</surname>
              <given-names>AO</given-names>
            </name>
          </person-group>
          <article-title>Endocrine side effects of cancer immunotherapy</article-title>
          <source>Endocr Relat Cancer</source>
          <year>2017</year>
          <volume>24</volume>
          <fpage>T331</fpage>
          <lpage>T347</lpage>
          <pub-id pub-id-type="doi">10.1530/ERC-17-0358</pub-id>
          <pub-id pub-id-type="pmid">29025857</pub-id>
        </element-citation>
      </ref>
      <ref id="CR196">
        <label>196.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Postow</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sidlow</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hellmann</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>Immune-related adverse events associated with immune checkpoint blockade</article-title>
          <source>N Engl J Med</source>
          <year>2018</year>
          <volume>378</volume>
          <fpage>158</fpage>
          <lpage>168</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra1703481</pub-id>
          <pub-id pub-id-type="pmid">29320654</pub-id>
        </element-citation>
      </ref>
      <ref id="CR197">
        <label>197.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Byun</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cancer immunotherapy&#x2014;immune checkpoint blockade and associated endocrinopathies</article-title>
          <source>Nat Rev Endocrinol</source>
          <year>2017</year>
          <volume>13</volume>
          <fpage>195</fpage>
          <lpage>207</lpage>
          <pub-id pub-id-type="doi">10.1038/nrendo.2016.205</pub-id>
          <pub-id pub-id-type="pmid">28106152</pub-id>
        </element-citation>
      </ref>
      <ref id="CR198">
        <label>198.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdel-Rahman</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>El Halawani</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fouad</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Risk of endocrine complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis</article-title>
          <source>Future Oncol</source>
          <year>2016</year>
          <volume>12</volume>
          <fpage>413</fpage>
          <lpage>425</lpage>
          <pub-id pub-id-type="doi">10.2217/fon.15.222</pub-id>
          <pub-id pub-id-type="pmid">26775673</pub-id>
        </element-citation>
      </ref>
      <ref id="CR199">
        <label>199.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barroso-Sousa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Barry</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Garrido-Castro</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Hodi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Min</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Krop</surname>
              <given-names>IE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis</article-title>
          <source>JAMA Oncology</source>
          <year>2018</year>
          <volume>4</volume>
          <fpage>173</fpage>
          <lpage>182</lpage>
          <pub-id pub-id-type="doi">10.1001/jamaoncol.2017.3064</pub-id>
          <pub-id pub-id-type="pmid">28973656</pub-id>
        </element-citation>
      </ref>
      <ref id="CR200">
        <label>200.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Imagawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hanafusa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Swsts</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ikegami</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Uchigata</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012)</article-title>
          <source>J Diabetes Invest</source>
          <year>2012</year>
          <volume>3</volume>
          <fpage>536</fpage>
          <lpage>539</lpage>
          <pub-id pub-id-type="doi">10.1111/jdi.12024</pub-id>
        </element-citation>
      </ref>
      <ref id="CR201">
        <label>201.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stamatouli</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Quandt</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Perdigoto</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Kluger</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>SA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors</article-title>
          <source>Diabetes</source>
          <year>2018</year>
          <volume>67</volume>
          <fpage>1471</fpage>
          <lpage>1480</lpage>
          <pub-id pub-id-type="doi">10.2337/dbi18-0002</pub-id>
          <pub-id pub-id-type="pmid">29937434</pub-id>
        </element-citation>
      </ref>
      <ref id="CR202">
        <label>202.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Razak</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Bedard</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Siu</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Systematic review of immune-related adverse events reporting in clinical trials of immune checkpoint inhibitors</article-title>
          <source>Ann Oncol</source>
          <year>2015</year>
          <volume>26</volume>
          <fpage>1824</fpage>
          <lpage>1829</lpage>
          <pub-id pub-id-type="doi">10.1093/annonc/mdv182</pub-id>
          <pub-id pub-id-type="pmid">25888611</pub-id>
        </element-citation>
      </ref>
      <ref id="CR203">
        <label>203.</label>
        <mixed-citation publication-type="other"><ext-link ext-link-type="uri" xlink:href="https://medicine.uiowa.edu/internalmedicine/education/master-clinician-program/students/clinical-and-diagnostic-reasoning">https://medicine.uiowa.edu/internalmedicine/education/master-clinician-program/students/clinical-and-diagnostic-reasoning</ext-link>. Accessed 10 Aug 2018.</mixed-citation>
      </ref>
      <ref id="CR204">
        <label>204.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Illouz</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Briet</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cloix</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Le Corre</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Baize</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Urban</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists</article-title>
          <source>Cancer Medicine</source>
          <year>2017</year>
          <volume>6</volume>
          <fpage>1923</fpage>
          <lpage>1929</lpage>
          <pub-id pub-id-type="doi">10.1002/cam4.1145</pub-id>
          <pub-id pub-id-type="pmid">28719055</pub-id>
        </element-citation>
      </ref>
      <ref id="CR205">
        <label>205.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rossi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sgambato</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chiara</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Casaluce</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Losanno</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sacco</surname>
              <given-names>PC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer</article-title>
          <source>Expert Rev Clin Pharmacol</source>
          <year>2016</year>
          <volume>9</volume>
          <fpage>419</fpage>
          <lpage>428</lpage>
          <pub-id pub-id-type="doi">10.1586/17512433.2016.1133289</pub-id>
          <pub-id pub-id-type="pmid">26681547</pub-id>
        </element-citation>
      </ref>
      <ref id="CR206">
        <label>206.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barroso-Sousa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ott</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Hodi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kaiser</surname>
              <given-names>UB</given-names>
            </name>
            <name>
              <surname>Tolaney</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Min</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management</article-title>
          <source>Cancer</source>
          <year>2018</year>
          <volume>124</volume>
          <fpage>1111</fpage>
          <lpage>1121</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.31200</pub-id>
          <pub-id pub-id-type="pmid">29313945</pub-id>
        </element-citation>
      </ref>
      <ref id="CR207">
        <label>207.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haanen</surname>
              <given-names>JBAG</given-names>
            </name>
            <name>
              <surname>Carbonnel</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Robert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kerr</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Larkin</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>
          <source>Ann Oncol</source>
          <year>2017</year>
          <volume>28</volume>
          <issue>Supplement 4</issue>
          <fpage>iv119</fpage>
          <lpage>iv142</lpage>
          <pub-id pub-id-type="doi">10.1093/annonc/mdx225</pub-id>
          <pub-id pub-id-type="pmid">28881921</pub-id>
        </element-citation>
      </ref>
      <ref id="CR208">
        <label>208.</label>
        <mixed-citation publication-type="other">Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in patients treated with checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714-1768.</mixed-citation>
      </ref>
      <ref id="CR209">
        <label>209.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higham</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Olsson-Brown</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carroll</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cooksley</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Larkin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lorigan</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute management of the endocrine complications of checkpoint inhibitor therapy</article-title>
          <source>Endocr Connections</source>
          <year>2018</year>
          <volume>7</volume>
          <fpage>G1</fpage>
          <lpage>G7</lpage>
          <pub-id pub-id-type="doi">10.1530/EC-18-0068</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Endocr Rev</journal-id>
      <journal-id journal-id-type="iso-abbrev">Endocr. Rev</journal-id>
      <journal-id journal-id-type="hwp">edrv</journal-id>
      <journal-id journal-id-type="publisher-id">endre</journal-id>
      <journal-id journal-id-type="pmc">edrv</journal-id>
      <journal-id journal-id-type="publisher-id">edrv</journal-id>
      <journal-title-group>
        <journal-title>Endocrine Reviews</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0163-769X</issn>
      <issn pub-type="epub">1945-7189</issn>
      <publisher>
        <publisher-name>Endocrine Society</publisher-name>
        <publisher-loc>Washington, DC</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27035557</article-id>
      <article-id pub-id-type="pmc">4890265</article-id>
      <article-id pub-id-type="publisher-id">ER-15-1116</article-id>
      <article-id pub-id-type="doi">10.1210/er.2015-1116</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Reviews</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Monogenic Diabetes: What It Teaches Us on the Common Forms of Type 1 and Type 2 Diabetes</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Yang</surname>
            <given-names>Yisheng</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Chan</surname>
            <given-names>Lawrence</given-names>
          </name>
        </contrib>
        <aff>Division of Endocrinology (Y.Y.), Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio 44109; and Diabetes and Endocrinology Research Center (L.C.), Division of Diabetes, Endocrinology and Metabolism, Departments of Medicine, Molecular and Cellular Biology, Biochemistry and Molecular Biology, and Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030</aff>
      </contrib-group>
      <author-notes>
        <corresp>Address all correspondence and requests for reprints to: Yisheng Yang, <addr-line>Division of Endocrinology, Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, 2500 Metrohealth Drive, Cleveland, OH 44109.</addr-line> E-mail: <email>yisheng.yang@case.edu</email>. Or Lawrence Chan, <addr-line>Division of Diabetes, Endocrinology and Metabolism, Departments of Medicine and Molecular &amp; Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030.</addr-line> E-mail: <email>lchan@bcm.edu</email>.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>6</month>
        <year>2017</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
      <volume>37</volume>
      <issue>3</issue>
      <fpage>190</fpage>
      <lpage>222</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>10</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>3</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2016 by the Endocrine Society</copyright-statement>
        <copyright-year>2016</copyright-year>
      </permissions>
      <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zef00316000190.pdf"/>
      <abstract>
        <p>To date, more than 30 genes have been linked to monogenic diabetes. Candidate gene and genome-wide association studies have identified &gt; 50 susceptibility loci for common type 1 diabetes (T1D) and approximately 100 susceptibility loci for type 2 diabetes (T2D). About 1&#x2013;5% of all cases of diabetes result from single-gene mutations and are called monogenic diabetes. Here, we review the pathophysiological basis of the role of monogenic diabetes genes that have also been found to be associated with common T1D and/or T2D. Variants of approximately one-third of monogenic diabetes genes are associated with T2D, but not T1D. Two of the T2D-associated monogenic diabetes genes&#x2014;potassium inward-rectifying channel, subfamily J, member 11 (<italic>KCNJ11</italic>), which controls glucose-stimulated insulin secretion in the &#x3B2;-cell; and peroxisome proliferator-activated receptor &#x3B3; (<italic>PPARG</italic>), which impacts multiple tissue targets in relation to inflammation and insulin sensitivity&#x2014;have been developed as major antidiabetic drug targets. Another monogenic diabetes gene, the preproinsulin gene (<italic>INS</italic>), is unique in that <italic>INS</italic> mutations can cause hyperinsulinemia, hyperproinsulinemia, neonatal diabetes mellitus, one type of maturity-onset diabetes of the young (MODY10), and autoantibody-negative T1D. Dominant heterozygous <italic>INS</italic> mutations are the second most common cause of permanent neonatal diabetes. Moreover, <italic>INS</italic> gene variants are strongly associated with common T1D (type 1a), but inconsistently with T2D. Variants of the monogenic diabetes gene Gli-similar 3 (<italic>GLIS3</italic>) are associated with both T1D and T2D. GLIS3 is a key transcription factor in insulin production and &#x3B2;-cell differentiation during embryonic development, which perturbation forms the basis of monogenic diabetes as well as its association with T1D. GLIS3 is also required for compensatory &#x3B2;-cell proliferation in adults; impairment of this function predisposes to T2D. Thus, monogenic forms of diabetes are invaluable &#x201C;human models&#x201D; that have contributed to our understanding of the pathophysiological basis of common T1D and T2D.</p>
      </abstract>
    </article-meta>
  </front>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Endocrinol (Oxf)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Clin. Endocrinol. (Oxf)</journal-id>
      <journal-id journal-id-type="doi">10.1111/(ISSN)1365-2265</journal-id>
      <journal-id journal-id-type="publisher-id">CEN</journal-id>
      <journal-title-group>
        <journal-title>Clinical Endocrinology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0300-0664</issn>
      <issn pub-type="epub">1365-2265</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">31004513</article-id>
      <article-id pub-id-type="pmc">6850413</article-id>
      <article-id pub-id-type="doi">10.1111/cen.13991</article-id>
      <article-id pub-id-type="publisher-id">CEN13991</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Review Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Review Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis</article-title>
        <alt-title alt-title-type="left-running-head">REFARDT et al.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="cen13991-cr-0001" contrib-type="author">
          <name>
            <surname>Refardt</surname>
            <given-names>Julie</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3040-4685</contrib-id>
          <xref ref-type="aff" rid="cen13991-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="cen13991-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="cen13991-cr-0002" contrib-type="author">
          <name>
            <surname>Winzeler</surname>
            <given-names>Bettina</given-names>
          </name>
          <xref ref-type="aff" rid="cen13991-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="cen13991-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="cen13991-cr-0003" contrib-type="author" corresp="yes">
          <name>
            <surname>Christ&#x2010;Crain</surname>
            <given-names>Mirjam</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6336-0965</contrib-id>
          <xref ref-type="aff" rid="cen13991-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="cen13991-aff-0002">
<sup>2</sup>
</xref>
          <address>
            <email>mirjam.christ-crain@usb.ch</email>
          </address>
        </contrib>
      </contrib-group>
      <aff id="cen13991-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Endocrinology, Diabetology and Metabolism</named-content>
<institution>University Hospital Basel</institution>
<city>Basel</city>
<country country="CH">Switzerland</country>
</aff>
      <aff id="cen13991-aff-0002">
<label><sup>2</sup></label>
<institution>University of Basel</institution>
<city>Basel</city>
<country country="CH">Switzerland</country>
</aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Mirjam Christ&#x2010;Crain, Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.<break/>
Email: <email>mirjam.christ-crain@usb.ch</email><break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>08</day>
        <month>5</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>7</month>
        <year>2019</year>
      </pub-date>
      <volume>91</volume>
      <issue>1</issue>
      <issue-id pub-id-type="doi">10.1111/cen.2019.91.issue-1</issue-id>
      <fpage>22</fpage>
      <lpage>32</lpage>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>3</month>
          <year>2019</year>
        </date>
        <date date-type="rev-recd">
          <day>08</day>
          <month>4</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>4</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 John Wiley & Sons Ltd <copyright-statement>-->
        <copyright-statement content-type="article-copyright">&#xA9; 2019 The Authors. <italic>Clinical Endocrinology</italic> Published by John Wiley &amp; Sons Ltd.</copyright-statement>
        <license license-type="creativeCommonsBy-nc-nd">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x2010;commercial and no modifications or adaptations are made.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="file:CEN-91-22.pdf"/>
      <abstract id="cen13991-abs-0001">
        <title>Abstract</title>
        <p>Copeptin is secreted in an equimolar amount to arginine vasopressin (AVP) but can easily be measured in plasma or serum with a sandwich immunoassay. The main stimuli for copeptin are similar to AVP, that is an increase in osmolality and a decrease in arterial blood volume and pressure. A high correlation between copeptin and AVP has been shown. Accordingly, copeptin mirrors the amount of AVP in the circulation. Copeptin has, therefore, been evaluated as diagnostic biomarker in vasopressin&#x2010;dependent disorders of body fluid homeostasis. Disorders of body fluid homeostasis are common and can be divided into hyper&#x2010; and hypoosmolar circumstances: the classical hyperosmolar disorder is diabetes insipidus, while the most common hypoosmolar disorder is the syndrome of inappropriate antidiuresis (SIAD). Copeptin measurement has led to a &#x201C;revival&#x201D; of the direct test in the differential diagnosis of diabetes insipidus. Baseline copeptin levels, without prior thirsting, unequivocally identify patients with nephrogenic diabetes insipidus. In contrast, for the difficult differentiation between central diabetes insipidus and primary polydipsia, a stimulated copeptin level of 4.9&#xA0;pmol/L upon hypertonic saline infusion differentiates these two entities with a high diagnostic accuracy and is clearly superior to the classical water deprivation test. On the contrary, in the SIAD, copeptin measurement is of only little diagnostic value. Copeptin levels widely overlap in patients with hyponatraemia and emphasize the heterogeneity of the disease. Additionally, a variety of factors lead to unspecific copeptin elevations in the acute setting further complicating its interpretation. The broad use of copeptin as diagnostic marker in hyponatraemia and specifically to detect cancer&#x2010;related disease in SIADH patients can, therefore, not be recommended.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="cen13991-kwd-0001">copeptin</kwd>
        <kwd id="cen13991-kwd-0002">diabetes insipidus</kwd>
        <kwd id="cen13991-kwd-0003">diagnosis</kwd>
        <kwd id="cen13991-kwd-0004">hypernatremia</kwd>
        <kwd id="cen13991-kwd-0005">hyponatraemia</kwd>
        <kwd id="cen13991-kwd-0006">primary polydipsia</kwd>
        <kwd id="cen13991-kwd-0007">SIAD</kwd>
      </kwd-group>
      <funding-group>
        <award-group id="funding-0001">
          <funding-source>
            <institution-wrap>
              <institution>Schweizerischer Nationalfonds zur F&#xF6;rderung der Wissenschaftlichen Forschung </institution>
              <institution-id institution-id-type="open-funder-registry">10.13039/501100001711</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id>162608</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="6"/>
        <table-count count="0"/>
        <page-count count="11"/>
        <word-count count="7841"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>July 2019</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.1 mode:remove_FC converted:12.11.2019</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="cen13991-cit-1001">
<string-name>
<surname>Refardt</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Winzeler</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Christ&#x2010;Crain</surname>
<given-names>M</given-names>
</string-name>. <article-title>Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis</article-title>. <source xml:lang="en">Clin Endocrinol (Oxf)</source>. <year>2019</year>;<volume>91</volume>:<fpage>22</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1111/cen.13991</pub-id>
<pub-id pub-id-type="pmid">31004513</pub-id></mixed-citation>
</p>
      <fn-group id="cen13991-ntgp-0001">
        <fn fn-type="funding" id="cen13991-note-0001">
          <p>
<bold>Funding information</bold>
</p>
          <p>M. Christ&#x2010;Crain was supported by a grant from the Swiss National Science Foundation (SNF&#x2010;162608) and the University Hospital Basel, Switzerland.</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body id="cen13991-body-0001">
    <sec id="cen13991-sec-0001">
      <label>1</label>
      <title>INTRODUCTION</title>
      <p>Arginine vasopressin (AVP) is the main regulating hormone of body fluid homeostasis. It is secreted from the posterior pituitary upon osmotic or nonosmotic stimuli, with the main osmotic stimulus being increased plasma osmolality and the main nonosmotic stimulus being hypovolaemia and promotes water reabsorption via V2 receptors in the kidney, thereby normalizing hypertonicity and vasomotor tone.</p>
      <p>Disorders of body fluid homeostasis are common and can be divided into hyper&#x2010; and hypoosmolar circumstances: the classical hyperosmolar disorder (deficiency of body fluid relative to body solute<xref rid="cen13991-bib-0001" ref-type="ref">1</xref>) is diabetes insipidus, while the most common hypoosmolar disorder (excess of body fluid relative to body solute) is the syndrome of inappropriate antidiuresis (SIAD).</p>
      <p>Diabetes insipidus belongs to the polyuria&#x2010;polydipsia syndrome and is characterized by a high urinary output of more than 50&#xA0;ml per kg body weight per 24&#xA0;hours, accompanied by polydipsia of more than 3&#xA0;L a day.<xref rid="cen13991-bib-0002" ref-type="ref">2</xref> After exclusion of osmotic diuresis (such as hyperglycaemia), the differential diagnosis of polyuria&#x2010;polydipsia syndrome includes impaired AVP synthesis (central diabetes insipidus) or action (nephrogenic diabetes insipidus) as well as primary polydipsia.</p>
      <p>Syndrome of inappropriate antidiuresis is the predominant cause of hyponatraemia<xref rid="cen13991-bib-0003" ref-type="ref">3</xref>, <xref rid="cen13991-bib-0004" ref-type="ref">4</xref> and is characterized by reduced free water excretion and secondary natriuresis,<xref rid="cen13991-bib-0005" ref-type="ref">5</xref> mostly due to an imbalanced secretion of the antidiuretic hormone AVP.<xref rid="cen13991-bib-0006" ref-type="ref">6</xref>, <xref rid="cen13991-bib-0007" ref-type="ref">7</xref>
</p>
      <p>Arginine vasopressin measurement could theoretically help in the guidance of diagnosis and treatment of body fluid disorders. However, AVP is difficult to measure and unreliable, mainly due to complex pre&#x2010;analytical requirements.<xref rid="cen13991-bib-0008" ref-type="ref">8</xref> Copeptin is the C&#x2010;terminal segment of the AVP precursor peptide and mirrors AVP concentrations.<xref rid="cen13991-bib-0009" ref-type="ref">9</xref> It can easily be measured providing a reliable surrogate marker for AVP.</p>
      <p>This review focuses on copeptin and its role in the diagnosis and differential diagnosis of diabetes insipidus and SIAD.</p>
    </sec>
    <sec id="cen13991-sec-0002">
      <label>2</label>
      <title>COPEPTIN</title>
      <p>Copeptin was detected in 1972 in the posterior pituitary of pigs.<xref rid="cen13991-bib-0010" ref-type="ref">10</xref>, <xref rid="cen13991-bib-0011" ref-type="ref">11</xref> Copeptin derives from the precursor protein pre&#x2010;provasopressin together with AVP and neurophysin II. It is a 39&#x2010;amino acid&#x2010;long glycosylated peptide with a leucine&#x2010;rich core region.<xref rid="cen13991-bib-0011" ref-type="ref">11</xref>, <xref rid="cen13991-bib-0012" ref-type="ref">12</xref> Its molecular mass is around 5&#xA0;kDa (Figure <xref rid="cen13991-fig-0001" ref-type="fig">1</xref>).<xref rid="cen13991-bib-0013" ref-type="ref">13</xref>
</p>
      <fig fig-type="Figure" xml:lang="en" id="cen13991-fig-0001" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Structure of Copeptin. Structure of pre&#x2010;provasopressin. The prohormone is packaged into neurosecretory granules of magnocellular neurons. During axonal transport of the granules from the hypothalamus to the posterior pituitary, enzymatic cleavage of the prohormone generates the final products: AVP, neurophysin and the COOH&#x2010;terminal glycoprotein copeptin [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://www.wileyonlinelibrary.com">http://www.wileyonlinelibrary.com</ext-link>]</p>
        </caption>
        <graphic id="nlm-graphic-1" xlink:href="CEN-91-22-g001"/>
      </fig>
      <p>While AVP has been characterized as the main hormone for the regulation of the body fluid homeostasis and vascular tonus as well as an endocrine stress hormone,<xref rid="cen13991-bib-0014" ref-type="ref">14</xref>, <xref rid="cen13991-bib-0015" ref-type="ref">15</xref> the physiological function of copeptin is largely unknown. Its proposed role as a prolactin&#x2010;releasing factor could not be confirmed.<xref rid="cen13991-bib-0016" ref-type="ref">16</xref>, <xref rid="cen13991-bib-0017" ref-type="ref">17</xref> Another function could be the involvement of copeptin in the folding of the AVP precursor, as it seems to interact with the calnexin&#x2010;calreticulin system in the endoplasmic reticulum.<xref rid="cen13991-bib-0018" ref-type="ref">18</xref>, <xref rid="cen13991-bib-0019" ref-type="ref">19</xref> Accordingly, a possible relationship between certain forms of familial cranial diabetes insipidus and the inefficient folding of the AVP precursor in the absence of copeptin was proposed<xref rid="cen13991-bib-0020" ref-type="ref">20</xref>; however, further examinations are needed.</p>
      <p>The elimination pathway of copeptin has not been clarified yet; a renal clearance was suggested as studies from patients with impaired kidney function showed an inverse correlation of plasma copeptin levels with the glomerular filtration rate.<xref rid="cen13991-bib-0021" ref-type="ref">21</xref> Another study evaluating serial measurements of copeptin and AVP during osmotic stimulation, as well as after osmotic suppression in healthy volunteers, showed a two times longer decay kinetic of copeptin compared with AVP (26&#xA0;minutes vs 12&#xA0;minutes).<xref rid="cen13991-bib-0022" ref-type="ref">22</xref>
</p>
      <sec id="cen13991-sec-0003">
        <label>2.1</label>
        <title>Copeptin as reliable surrogate marker of AVP</title>
        <p>Today, the main use of copeptin is its role as stable surrogate marker for AVP concentrations in humans.<xref rid="cen13991-bib-0013" ref-type="ref">13</xref> A prospective trial with 91 healthy volunteers undergoing a standardized test protocol with osmotic stimulation via hypertonic saline infusion and following osmotic suppression with oral and intravenous water load<xref rid="cen13991-bib-0023" ref-type="ref">23</xref> showed a strong correlation between plasma AVP (when measured with a well&#x2010;established radio&#x2010;immunoassay) and copeptin levels with a correlation index of <italic>r</italic>&#xA0;=&#xA0;0.83.<xref rid="cen13991-bib-0022" ref-type="ref">22</xref> Notably, the correlation with plasma osmolality was stronger for copeptin than for AVP.<xref rid="cen13991-bib-0009" ref-type="ref">9</xref> (Figure <xref rid="cen13991-fig-0002" ref-type="fig">2</xref>A,B).</p>
        <fig fig-type="Figure" xml:lang="en" id="cen13991-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Correlation of copeptin with AVP and plasma osmolality. A, The correlation of copeptin with AVP during osmotic stimulation with hypertonic saline infusion (modified from Rref.<xref rid="cen13991-bib-0023" ref-type="ref">23</xref>). Linear regression (solid line) with slope b and coefficient of determination <italic>R</italic>
<sup>2</sup>, the smoothing line (dashed line) and Spearman's rank correlation coefficient rS are shown. B, The correlation of plasma copeptin and AVP concentrations as a scatter plot ranging from hypoosmolality (induced by water load) to hyperosmolality (induced by hypertonic saline infusion) (modified from Ref.<xref rid="cen13991-bib-0009" ref-type="ref">9</xref>). rS denotes Spearman's rank correlation coefficients</p>
          </caption>
          <graphic id="nlm-graphic-3" xlink:href="CEN-91-22-g002"/>
        </fig>
      </sec>
      <sec id="cen13991-sec-0004">
        <label>2.2</label>
        <title>Stimuli of copeptin release</title>
        <p>The main stimuli for copeptin are similar to AVP, that is the main osmotic stimulus being an increase in osmolality and the main nonosmotic stimulus being a decrease in arterial blood volume and pressure.<xref rid="cen13991-bib-0009" ref-type="ref">9</xref>, <xref rid="cen13991-bib-0024" ref-type="ref">24</xref> The osmotic trigger of copeptin secretion was first shown in a study with 24 healthy adults, whereby fluid deprivation and hypertonic saline infusion lead to a significant increase in plasma copeptin levels (4.6&#xA0;&#xB1;&#xA0;1.7 to 9.2&#xA0;&#xB1;&#xA0;5.2&#xA0;pmol/L and 4.9&#xA0;&#xB1;&#xA0;3.0 to 19.9&#xA0;&#xB1;&#xA0;4.8&#xA0;pmol/L respectively, <italic>P</italic>&#xA0;&lt;&#xA0;0.0001).<xref rid="cen13991-bib-0024" ref-type="ref">24</xref> Conversely, hypotonic saline infusion leads to a prompt suppression of plasma copeptin levels in the same volunteers,<xref rid="cen13991-bib-0024" ref-type="ref">24</xref> as did oral water load in a similar study with 20 healthy volunteers<xref rid="cen13991-bib-0009" ref-type="ref">9</xref> (6.2&#xA0;&#xB1;&#xA0;2.4 to 2.4&#xA0;&#xB1;&#xA0;2.1&#xA0;pmol/L [<italic>P</italic>&#xA0;&lt;&#xA0;0.01], and 3.3&#x2010;2.0&#xA0;pmol/L respectively).</p>
        <p>The prompt response of copeptin secretion upon the nonosmotic stimulus of volume depletion was shown in a baboon model of experimental haemorrhagic shock,<xref rid="cen13991-bib-0025" ref-type="ref">25</xref> where plasma copeptin concentration rapidly increased from median levels of 7.5&#x2010;269&#xA0;pmol/L, with a subsequent decline to 27&#xA0;pmol/L after reperfusion. The much higher increase in copeptin upon hypovolaemic shock highlights the significant difference between the magnitude of osmotic and nonosmotic AVP and copeptin secretion.</p>
        <p>In addition to osmotic and arterial pressure, somatic stress as seen in all states of serious illness is also a major determinant of copeptin regulation. In fact, several observational studies confirmed the predictive character of plasma copeptin as an unspecific stress marker in various states of acute diseases, including ischaemic stroke, myocardial infarction and lower respiratory tract infections with copeptin levels up to 100&#xA0;pmol/L in severely ill patients.<xref rid="cen13991-bib-0026" ref-type="ref">26</xref>, <xref rid="cen13991-bib-0027" ref-type="ref">27</xref>, <xref rid="cen13991-bib-0028" ref-type="ref">28</xref> This stress&#x2010;related increase in copeptin again shows the higher magnitude in increase compared to the &#x201C;classical&#x201D; osmotic stimulus.</p>
        <p>Compared to somatic stress, the influence of psychological stress on copeptin release is rather limited, though existent, as shown by recent studies in medical students tested before and after a written examination (decrease from 3.1&#xA0;pmol/L before the examination to 2.3&#xA0;pmol/L after the examination, <italic>P</italic>&#xA0;&lt;&#xA0;0.001) and upon a psychological stress test (increase in copeptin from 3.7 to 5.1&#xA0;pmol/L, <italic>P</italic>&#xA0;=&#xA0;0.002).<xref rid="cen13991-bib-0029" ref-type="ref">29</xref>, <xref rid="cen13991-bib-0030" ref-type="ref">30</xref> Increased levels of plasma copeptin were also reported in response to physical exercise, but levels did not exceed the 99th percentile of the normal range.<xref rid="cen13991-bib-0031" ref-type="ref">31</xref>, <xref rid="cen13991-bib-0032" ref-type="ref">32</xref>
</p>
        <p>Together, these findings emphasize the importance of avoiding emotional or physical stress levels before taking blood samples for copeptin analysis.</p>
      </sec>
      <sec id="cen13991-sec-0005">
        <label>2.3</label>
        <title>Physiological range of copeptin</title>
        <p>The normal range of plasma copeptin levels has been established in two large clinical trials evaluating healthy volunteers under normo&#x2010;osmotic conditions. In the first study including 359 subjects, plasma copeptin levels ranged from 1.0 to 13.8&#xA0;pmol/L with a median concentration of 4.2&#xA0;pmol/L.<xref rid="cen13991-bib-0013" ref-type="ref">13</xref> The second evaluation with over 700 randomly selected volunteers reported comparable results with plasma copeptin levels ranging from 1.0 to 13.0&#xA0;pmol/L.<xref rid="cen13991-bib-0033" ref-type="ref">33</xref> Both trials reported higher median plasma copeptin levels in men than in women, whereas no correlation with age was shown.<xref rid="cen13991-bib-0013" ref-type="ref">13</xref>, <xref rid="cen13991-bib-0033" ref-type="ref">33</xref> The difference in gender is poorly understood. In an observational study in female volunteers, copeptin levels did not significantly change during the menstrual cycle. However, throughout the menstrual cycle, changes in estradiol were positively related to copeptin, whereas changes in other sex hormones, in markers of subclinical inflammation or in bio impedance analysis&#x2010;estimated body fluid were not.<xref rid="cen13991-bib-0034" ref-type="ref">34</xref> Interestingly, the gender differences are lost upon hypertonic saline infusion.<xref rid="cen13991-bib-0023" ref-type="ref">23</xref>
</p>
        <p>While copeptin levels show no significant variation in response to circadian rhythm<xref rid="cen13991-bib-0035" ref-type="ref">35</xref>, <xref rid="cen13991-bib-0036" ref-type="ref">36</xref> or digestion, levels significantly decreased from 4.9 to 3.2&#xA0;pmol/L after oral fluid intake of as little as 200&#x2010;300&#xA0;mL,<xref rid="cen13991-bib-0037" ref-type="ref">37</xref> which has to be considered for interpretation of values in clinical practice.</p>
      </sec>
      <sec id="cen13991-sec-0006">
        <label>2.4</label>
        <title>Measurement of copeptin</title>
        <p>In contrast to AVP, copeptin can be measured in clinical routine with commercially available assays with high&#x2010;standard technical performance. The two main assays that are currently commercially available and are CE zertified are on one hand the original manual sandwich immunoluminometric assay (LIA)<xref rid="cen13991-bib-0013" ref-type="ref">13</xref> and on the other hand the automated immunofluorescent successor (on the KRYPTOR platform). Correlation between with these two assays is very high. Other commercially available copeptin assays are mostly ELISA assays which, however, do not have CE certification and are not approved for diagnostic purposes. Advantages of copeptin over AVP measurement are that only a small sample volume (50&#xA0;&#x3BC;L of serum or plasma) is required, no extraction step or other pre&#x2010;analytical procedures are needed and that results are usually available in 0.5&#x2010;2.5&#xA0;hours. Copeptin is very stable in plasma or serum ex vivo with &lt;20% loss of recovery for at least 7&#xA0;days at room temperature and for 14&#xA0;days at 4&#xB0;C, which makes the handling of blood samples less complicated.</p>
      </sec>
    </sec>
    <sec id="cen13991-sec-0007">
      <label>3</label>
      <title>THE ROLE OF COPEPTIN IN THE DIFFERENTIAL DIAGNOSIS OF DIABETES INSIPIDUS</title>
      <sec id="cen13991-sec-0008">
        <label>3.1</label>
        <title>Polyuria&#x2010;polydipsia syndrome</title>
        <p>Polyuria&#x2010;polydipsia syndrome is a common problem in clinical practice with the main entities being central or nephrogenic diabetes insipidus and primary polydipsia.<xref rid="cen13991-bib-0038" ref-type="ref">38</xref>
</p>
        <p>While central diabetes insipidus is characterized by a complete (complete central diabetes insipidus) or partial (partial&#xA0;central diabetes insipidus) insufficient vasopressin (AVP) secretion from the pituitary,<xref rid="cen13991-bib-0039" ref-type="ref">39</xref>, <xref rid="cen13991-bib-0040" ref-type="ref">40</xref> nephrogenic diabetes insipidus results from an AVP resistance of the kidneys<xref rid="cen13991-bib-0041" ref-type="ref">41</xref> both leading to hypotonic polyuria with compensatory polydipsia. Central diabetes insipidus can result from various conditions affecting the hypothalamic&#x2010;neurohypophyseal system such as trauma resulting from surgery or accident, local tumours or metastases, inflammatory/autoimmune or granulomatous diseases.<xref rid="cen13991-bib-0001" ref-type="ref">1</xref>, <xref rid="cen13991-bib-0042" ref-type="ref">42</xref> Several reports also described genetic defects in the AVP synthesis leading to inherited forms of central diabetes insipidus.<xref rid="cen13991-bib-0020" ref-type="ref">20</xref>, <xref rid="cen13991-bib-0043" ref-type="ref">43</xref> The most challenging form of central diabetes insipidus involves an impairment of the thirst perception and consecutive hypodipsia, which can result in severe hypernatremia.<xref rid="cen13991-bib-0038" ref-type="ref">38</xref>, <xref rid="cen13991-bib-0044" ref-type="ref">44</xref>
</p>
        <p>Nephrogenic diabetes insipidus results from a lack of aquaporin 2 (AQP2)&#x2010;mediated water reabsorption in the collecting duct. This is either a consequence of gene mutations in the key proteins vasopressin V2 receptor or AQP2, is secondarily triggered by electrolyte disorders or is induced by certain drugs especially lithium.<xref rid="cen13991-bib-0041" ref-type="ref">41</xref>
</p>
        <p>The pathomechanism of primary polydipsia, which is characterized by excessive fluid intake, is less clear. An analysis of 23 patients with profound hyponatraemia due to primary polydipsia revealed an increased prevalence for psychiatric diagnoses such as dependency disorders (43%) and depression (35%).<xref rid="cen13991-bib-0045" ref-type="ref">45</xref> Another prospective study with 156 patients with polyuria&#x2010;polydipsia syndrome however showed a similar rate (around 30%) of psychiatric disorders in patients with primary polydipsia and patients with central diabetes insipidus.<xref rid="cen13991-bib-0046" ref-type="ref">46</xref> As chronic excessive fluid intake in patients with primary polydipsia leads to a down&#x2010;regulation of the AQP2 channels in the kidneys, the renal medullary concentration gradient is reduced, making any diagnostic evaluation of the urine osmolality and urinary output difficult.<xref rid="cen13991-bib-0047" ref-type="ref">47</xref>
</p>
        <p>Differentiation between the three mentioned entities is important since treatment strategies vary and application of the wrong treatment can be dangerous.<xref rid="cen13991-bib-0048" ref-type="ref">48</xref> However, reliable differentiation is often difficult to achieve,<xref rid="cen13991-bib-0049" ref-type="ref">49</xref> especially in patients with primary polydipsia or partial forms of diabetes insipidus.<xref rid="cen13991-bib-0002" ref-type="ref">2</xref>, <xref rid="cen13991-bib-0050" ref-type="ref">50</xref>
</p>
      </sec>
      <sec id="cen13991-sec-0009">
        <label>3.2</label>
        <title>Indirect water deprivation test</title>
        <p>For decades, the standard diagnostic test for the evaluation of polyuria&#x2010;polydipsia syndrome was the indirect water deprivation test.<xref rid="cen13991-bib-0040" ref-type="ref">40</xref> Hereby, patients are required to stop any fluid intake from midnight onwards. During the water deprivation period, urinary excretion and urine osmolality as well as plasma sodium and osmolality are measured regularly. Fluid deprivation is continued for a maximum of 17&#xA0;hours or until a plasma sodium concentration &#x2265;150&#xA0;mmol/L has been reached or until the patient has lost 3%&#x2010;5% of his initial body weight. At this time point, exogenous AVP is administered and the corresponding change in urine osmolality is analysed. Thus, insufficient AVP secretion or effect is indirectly diagnosed by urine osmolality, giving the test the name indirect measurement method. Interpretation of the test results is based on recommendations from Miller et al<xref rid="cen13991-bib-0040" ref-type="ref">40</xref> according to the results of 29 patients with central diabetes insipidus (of whom 11 with a partial form), 2 patients with nephrogenic diabetes insipidus and 5 patients with primary polydipsia. Patients showing a urinary osmolality below 300&#xA0;mosm/kg during the water deprivation test are classified as complete central diabetes insipidus if the urinary osmolality increased &gt;50% after exogenous AVP injection. Patients staying below this cut&#x2010;off are diagnosed with nephrogenic diabetes insipidus. Patients with partial central diabetes insipidus and primary polydipsia are expected to have a urinary osmolality between 300 and 800&#xA0;mosm/kg upon thirsting. An increase in the urinary osmolality of &gt;9% after AVP administration further differentiates patients with partial central diabetes insipidus from patients with primary polydipsia. However, the proposed cut&#x2010;off levels were post hoc derived on a small patient cohort, showed a wide overlap in urinary osmolalities and were never prospectively validated.<xref rid="cen13991-bib-0040" ref-type="ref">40</xref>
</p>
      </sec>
      <sec id="cen13991-sec-0010">
        <label>3.3</label>
        <title>Direct AVP measurements</title>
        <p>Consequently, a recent evaluation of 156 patients with polyuria&#x2010;polydipsia syndrome<xref rid="cen13991-bib-0046" ref-type="ref">46</xref> pointed out the problems with this diagnostic test, by reaching a diagnostic accuracy (the percentage of correctly diagnosed patients) of only 77% (sensitivity 86%, specificity 70%).</p>
        <p>Already in 1981, Zerbe et al<xref rid="cen13991-bib-0051" ref-type="ref">51</xref> described a different approach including measurement of plasma AVP upon osmotic stimulation into the diagnostic evaluation (thus called the direct measurement method). In their work, AVP levels were evaluated in relation to the area of normality describing the physiological relationship between AVP release and plasma osmolality. Plasma AVP levels above the area of normality were defined as nephrogenic diabetes insipidus, levels below as central diabetes insipidus and levels in the normal range were defined as primary polydipsia.<xref rid="cen13991-bib-0043" ref-type="ref">43</xref>, <xref rid="cen13991-bib-0051" ref-type="ref">51</xref> Although the study showed that direct measurement of plasma AVP substantially improved the diagnostic accuracy, it failed to be adopted in clinical practice mainly due to the above&#x2010;mentioned inherent assay problems.<xref rid="cen13991-bib-0002" ref-type="ref">2</xref>, <xref rid="cen13991-bib-0052" ref-type="ref">52</xref>
</p>
      </sec>
      <sec id="cen13991-sec-0011">
        <label>3.4</label>
        <title>Direct copeptin measurements</title>
        <p>With the development of the copeptin assay,<xref rid="cen13991-bib-0009" ref-type="ref">9</xref>, <xref rid="cen13991-bib-0013" ref-type="ref">13</xref>, <xref rid="cen13991-bib-0053" ref-type="ref">53</xref> interest in the direct measurement arose again. In a first study, Fenske et al aimed to increase the diagnostic accuracy of the water deprivation test by combining it with copeptin measurements.<xref rid="cen13991-bib-0050" ref-type="ref">50</xref> In their cohort of 50 patients with polyuria&#x2010;polydipsia syndrome, baseline plasma copeptin levels &gt;20&#xA0;pmol/L diagnosed patients with nephrogenic diabetes insipidus, while levels &lt;2.6&#xA0;pmol/L after an overnight water deprivation test indicated central diabetes insipidus. A ratio of the &#x394;plasma copeptin levels (before and after the water deprivation phase) to the plasma sodium level at the end of the test showed a high diagnostic accuracy of 94% in differentiating patients with central diabetes insipidus from patients with primary polydipsia.<xref rid="cen13991-bib-0050" ref-type="ref">50</xref>
</p>
        <p>In an evaluation of 55 patients with nephrogenic or central diabetes insipidus or primary polydipsia, Timper et al<xref rid="cen13991-bib-0054" ref-type="ref">54</xref> described copeptin further as a promising new tool for the diagnosis of polyuria&#x2010;polydipsia syndrome. This study confirmed in a larger patient number that patients with nephrogenic diabetes insipidus can be easily diagnosed by using a single baseline copeptin level of &gt;21.4&#xA0;pmol/L without prior thirsting. Baseline copeptin values in the other entities (ie, central diabetes insipidus and primary polydipsia) however largely overlapped. Further, the study showed that osmotically stimulated copeptin levels of &gt;4.9&#xA0;pmol/L differentiated patients with central diabetes insipidus from patients with primary polydipsia with a high diagnostic accuracy of 96%. Osmotic stimulation was reached by water deprivation and if needed by additional 3% saline infusion aiming at an increase in plasma sodium levels above 147&#xA0;mmol/L. The evaluation of osmotically stimulated AVP instead of copeptin measurement showed a lower overall diagnostic accuracy of only 80%, and the accuracy was especially low for differentiation between partial central diabetes insipidus and primary polydipsia (44%).</p>
      </sec>
      <sec id="cen13991-sec-0012">
        <label>3.5</label>
        <title>Hypertonic saline&#x2010;stimulated copeptin measurements</title>
        <p>The osmotically stimulated copeptin cut&#x2010;off level was recently validated in an international multicenter trial including 156 patients with diabetes insipidus or primary polydipsia.<xref rid="cen13991-bib-0046" ref-type="ref">46</xref> In contrast to the studies described above, the test protocol was simplified in using only the 3% saline infusion test without prior thirsting. Hypertonic saline was initially given as a bolus dose of 250&#xA0;mL over 10&#x2010;15&#xA0;minutes, followed by a slower infusion rate of 0.15&#xA0;mL/kg/min. Plasma sodium and osmolality were measured every 30&#xA0;minutes, and the infusion was terminated once the plasma sodium was &#x2265;150&#xA0;mmol/L. At this point, copeptin was measured and the patient was asked to drink water at 30&#xA0;mL/kg within 30&#xA0;minutes followed by an intravenous infusion of 5% glucose at 500&#xA0;mL/h for 1&#xA0;hour. Plasma sodium was once more measured after completing the 5% glucose infusion to ensure its return to normal values. The diagnostic accuracy of the 3% saline infusion stimulated copeptin measurements was compared to the indirect water deprivation test according to the protocol of Miller et al.<xref rid="cen13991-bib-0040" ref-type="ref">40</xref> Further end&#x2010;points included the evaluation of copeptin measurements during the water deprivation test.</p>
        <p>Hypertonic saline infusion lead to a correct diagnosis in 97% (95% CI: 92, 99) of the patients using the copeptin cut&#x2010;off level of &gt;4.9&#xA0;pmol/L (Figure <xref rid="cen13991-fig-0003" ref-type="fig">3</xref>), which was clearly superior to the diagnostic accuracy of the indirect water deprivation test of 77% (95%CI: 69, 83; <italic>P</italic>&#xA0;&lt;&#xA0;0.001). The diagnostic accuracy of hypertonic saline&#x2010;stimulated copeptin was similarly accurate in distinguishing patients with partial diabetes insipidus from patients with primary polydipsia with a correct diagnosis in 95%, compared to 73% with the water deprivation test.</p>
        <fig fig-type="Figure" xml:lang="en" id="cen13991-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Stimulated copeptin levels in response to the hypertonic saline infusion and water deprivation test in patients with polyuria&#x2010;polydipsia syndrome. Shown are stimulated copeptin levels in response to the hypertonic saline infusion test (HIS) and water deprivation test (WDT) in patients with polyuria&#x2010;polydipsia syndrome that was caused by complete central diabetes insipidus (DI) or partial central diabetes insipidus as compared with primary polydipsia. The horizontal line in each box represents the median, the lower and upper boundaries of the boxes the interquartile range, the ends of the whisker lines the minimum and maximum values within 1.5 times the interquartile range, and the dots outliers (modified from Ref.<xref rid="cen13991-bib-0046" ref-type="ref">46</xref>)</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="CEN-91-22-g003"/>
        </fig>
        <p>Contrary to the study of Fenske described above, the proposed copeptin&#x2010;sodium ratio did not improve diagnostic accuracy of the water deprivation test,<xref rid="cen13991-bib-0050" ref-type="ref">50</xref> resulting in a diagnostic accuracy of only 44%.<xref rid="cen13991-bib-0046" ref-type="ref">46</xref> The proposed copeptin cut&#x2010;off level of &lt;2.6&#xA0;pmol/L after an overnight water deprivation test to diagnose complete central diabetes insipidus had a diagnostic accuracy of 78%. The fact that the determination of copeptin after water deprivation alone does not lead to an improved diagnostic accuracy is most likely due to the inadequate osmotic stimulation. Indeed, most patients in the study did not reach hyperosmotic plasma sodium levels during the classical water deprivation test.</p>
        <p>Accordingly, osmotic stimulation by hypertonic saline solution is needed to obtain reliable copeptin measurements. It is however important to note that hypertonic saline infusion requires close monitoring of sodium levels to ensure increase in plasma sodium levels into the hyperosmotic range<xref rid="cen13991-bib-0022" ref-type="ref">22</xref>, <xref rid="cen13991-bib-0039" ref-type="ref">39</xref> while preventing osmotic overstimulation.<xref rid="cen13991-bib-0046" ref-type="ref">46</xref> It might therefore be prudent for clinical practice to aim at a plasma sodium level &gt;147&#xA0;mmol/L instead of 150&#xA0;mmol/L. Also, rapid normalization of sodium levels after the osmotic stimulation is crucial to guarantee the safety of the test.<xref rid="cen13991-bib-0046" ref-type="ref">46</xref>
</p>
        <p>Based on these results, the hypertonic saline test plus copeptin measurement might now replace the indirect water deprivation test in the differential diagnosis of polyuria&#x2010;polydipsia syndrome<xref rid="cen13991-bib-0055" ref-type="ref">55</xref>; the recommended new diagnostic workflow algorithm is displayed in Figure <xref rid="cen13991-fig-0004" ref-type="fig">4</xref>. Not included in this algorithm are the special cases of diabetes insipidus patients with osmoreceptor dysfunction where thirst is also impaired, and hypodipsia can result in serious complications associated with hyperosmolality. These patients usually develop hypernatremia as they fail to increase their daily fluid intake and therefore do not require additional osmotic stimulation. Copeptin levels can be measured directly to differentiate between central and nephrogenic diabetes insipidus.</p>
        <fig fig-type="Figure" xml:lang="en" id="cen13991-fig-0004" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <p>New copeptin&#x2010;based diagnostic workflow for the differential diagnosis of polyuria&#x2010;polydipsia syndrome [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://www.wileyonlinelibrary.com">http://www.wileyonlinelibrary.com</ext-link>]</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="CEN-91-22-g004"/>
        </fig>
      </sec>
      <sec id="cen13991-sec-0013">
        <label>3.6</label>
        <title>Prediction of postoperative diabetes insipidus</title>
        <p>Another role of copeptin is its use as a prognostic marker for the development of diabetes insipidus after pituitary surgery. A first proof&#x2010;of&#x2010;concept study in 2007 used the classical insulin tolerance test and showed that copeptin measured during hypoglycaemia is a useful measure to identify patients with complete central diabetes insipidus at 3&#xA0;months after transsphenoidal pituitary surgery.<xref rid="cen13991-bib-0056" ref-type="ref">56</xref> In this study, copeptin levels of patients with intact posterior pituitary showed a maximal increase to 11.1&#xA0;&#xB1;&#xA0;4.6&#xA0;pmol/L, while copeptin levels in patients with central diabetes insipidus remained low upon hypoglycaemia at 3.7&#xA0;&#xB1;&#xA0;0.7&#xA0;pmol/L. A hypoglycaemic stimulated copeptin level &lt;4.75&#xA0;pmol/L had an optimal diagnostic accuracy to detect central diabetes insipidus of 100%.</p>
        <p>Despite its reliable diagnostic performance, the insulin tolerance test is not appropriate in the immediate postoperative recovery phase. Moreover, this test is contraindicated in patients with cardiovascular disease or seizure history. However, surgery&#x2014;itself known as a stressful event stimulating hypothalamic stress hormone release including AVP,<xref rid="cen13991-bib-0057" ref-type="ref">57</xref>&#x2014;can be used as a &#x201C;stress test&#x201D; to assess functionality of AVP and copeptin secretion. In a prospective multicentre trial including 205 patients undergoing pituitary surgery, 24% of patients developed postoperative central diabetes insipidus. Those patients had significantly lower copeptin levels on the first postoperative day compared to patients without postoperative diabetes insipidus. The post hoc&#x2010;derived copeptin cut&#x2010;off level of &lt;2.5&#xA0;pmol/L had a positive predictive value for the development of central diabetes insipidus of 81% and a specificity of 97%, while a level &gt;30&#xA0;pmol/L excluded it with a negative predictive value of 95% and a sensitivity of 94%. Accordingly, copeptin measurement after pituitary surgery is helpful to predict the onset of central diabetes insipidus, allowing earlier targeted therapeutic measures.</p>
        <p>In conclusion, copeptin is a valuable and reliable diagnostic marker in the differential diagnosis of polyuria&#x2010;polydipsia syndrome. In a patient with unclear polyuria&#x2010;polydipsia syndrome, determination of basal copeptin levels is recommended to exclude nephrogenic diabetes insipidus. In patients with high suspicion of complete central diabetes insipidus, an overnight water deprivation test might confirm diagnosis provided urine osmolality remains below 300&#xA0;mosm/kg and plasma sodium levels increase above 147&#xA0;mmol/L. In all other patients, copeptin measurement after osmotic stimulation with 3% saline solution aiming at a plasma sodium level above 147&#xA0;mmol/L is recommended (see diagnostic work flow in Figure <xref rid="cen13991-fig-0004" ref-type="fig">4</xref>).</p>
        <p>The determination of copeptin on the first postoperative day after pituitary surgery is useful to predict the development of central diabetes insipidus.</p>
      </sec>
    </sec>
    <sec id="cen13991-sec-0014">
      <label>4</label>
      <title>THE ROLE OF COPEPTIN IN THE DIAGNOSIS OF SIAD</title>
      <sec id="cen13991-sec-0015">
        <label>4.1</label>
        <title>Differential diagnosis of hyponatraemia</title>
        <p>Hyponatraemia is defined as a plasma sodium level of &lt;135&#xA0;mmol/L and characterized by a relative excess of body water compared to total body sodium.<xref rid="cen13991-bib-0003" ref-type="ref">3</xref> Although often neglected in clinical practice, hyponatraemia is an important condition as it is present in up to 30% of hospitalized patients<xref rid="cen13991-bib-0004" ref-type="ref">4</xref>, <xref rid="cen13991-bib-0058" ref-type="ref">58</xref> and linked to increased morbidity, mortality and length of hospital stay.<xref rid="cen13991-bib-0059" ref-type="ref">59</xref>, <xref rid="cen13991-bib-0060" ref-type="ref">60</xref>, <xref rid="cen13991-bib-0061" ref-type="ref">61</xref> Hyponatraemia is associated with a variety of underlying disorders and may be categorized according to extracellular fluid volume into hypervolemic (eg, heart failure, liver cirrhosis, nephrotic syndrome), hypovolaemic and euvolemic hyponatraemia with SIAD as the most common cause.<xref rid="cen13991-bib-0062" ref-type="ref">62</xref>, <xref rid="cen13991-bib-0063" ref-type="ref">63</xref> Main diagnostic criteria for SIAD include plasma osmolality &lt;275&#xA0;mOsm/kg, urine osmolality &gt;100&#xA0;mOsm/kg and urine sodium concentration &gt;30&#xA0;mmol/L, euvolemia and absence of adrenal, thyroid or renal insufficiency.<xref rid="cen13991-bib-0062" ref-type="ref">62</xref> Hyponatraemia may further be triggered by diuretic use, primary polydipsia or endocrine conditions (adrenal insufficiency, hypothyroidism). Discrimination between these pathophysiological categories is crucial as management differs considerably (eg, fluid restriction in SIAD vs intravenous fluid in hypovolaemia), and delayed treatment may lead to devastating consequences such as brain oedema, seizures and coma/death.<xref rid="cen13991-bib-0064" ref-type="ref">64</xref> Unfortunately, the diagnostic approach to hyponatraemia is complex and time&#x2010;consuming; clinical signs and symptoms are variable and unspecific and fluid status is difficult to assess.<xref rid="cen13991-bib-0065" ref-type="ref">65</xref>, <xref rid="cen13991-bib-0066" ref-type="ref">66</xref> According to current hyponatraemia Clinical Practice Guidelines,<xref rid="cen13991-bib-0062" ref-type="ref">62</xref> laboratory measurements such as urine osmolality and urine sodium as well as the calculation of fractional uric acid excretion are proposed; however, in many cases accurate classification into pathophysiological categories remains cumbersome.</p>
      </sec>
      <sec id="cen13991-sec-0016">
        <label>4.2</label>
        <title>Copeptin in hyponatraemia and SIAD</title>
        <p>From a pathophysiological point of view, the assessment of AVP or copeptin in hyponatraemia seems promising as most hyponatraemia forms are AVP&#x2010;dependent. Copeptin has, therefore, been proposed and evaluated as a readily available and stable diagnostic marker.<xref rid="cen13991-bib-0067" ref-type="ref">67</xref>, <xref rid="cen13991-bib-0068" ref-type="ref">68</xref>, <xref rid="cen13991-bib-0069" ref-type="ref">69</xref> Results from a study involving 106 patients showed no diagnostic utility of copeptin in the differentiation of hyponatraemia, but the ratio of copeptin to urinary sodium helped to discriminate between SIAD and conditions with decreased effective arterial blood volume and, therefore, haemodynamically stimulated AVP release (sensitivity 85%, specificity 87%).<xref rid="cen13991-bib-0068" ref-type="ref">68</xref> According to the largest prospective observational study with copeptin measurements in 298 hypoosmolar hyponatraemic patients at hospital admission, clearly elevated copeptin levels as high as &gt;84&#xA0;pmol/L indicated hypovolaemic hyponatraemia (specificity 90%, sensitivity 23%), whereas low levels &lt;3.9&#xA0;pmol/L pointed to primary polydipsia (specificity 91%, sensitivity, 58%).<xref rid="cen13991-bib-0069" ref-type="ref">69</xref> However, apart from the specificity of highest and lowest values, copeptin measurements were not helpful to differentiate between SIAD and other main causes of hyponatraemia, such as hypovolaemic and hypervolemic or diuretic&#x2010;induced hyponatraemia. Indeed, copeptin levels overlapped widely between those categories and showed also a vast variability within single categories, especially in SIAD (Figure <xref rid="cen13991-fig-0005" ref-type="fig">5</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="cen13991-fig-0005" orientation="portrait" position="float">
          <label>Figure 5</label>
          <caption>
            <p>Plasma copeptin levels in different aetiologies of hyponatraemia (modified from Ref.<xref rid="cen13991-bib-0069" ref-type="ref">69</xref>). Boxplots show median and interquartile range. <sup>&#xA7;</sup>
<italic>P</italic>&#xA0;=&#xA0;&lt;0.0001 compared to patients with PP, *<italic>P</italic>&#xA0;=&#xA0;&lt;0.001 compared to patients with hypervolemic hyponatraemia, **<italic>P</italic>&#xA0;=&#xA0;&lt;0.05 compared to patients with hypovolaemic hyponatraemia, &#xB0;<italic>P</italic>&#xA0;=&#xA0;0.05 compared to patients with hypervolemic hyponatraemia</p>
          </caption>
          <graphic id="nlm-graphic-9" xlink:href="CEN-91-22-g005"/>
        </fig>
      </sec>
      <sec id="cen13991-sec-0017">
        <label>4.3</label>
        <title>Osmolatory defects in SIAD</title>
        <p>Syndrome of inappropriate antidiuresis is generally characterized by water retention and secondary natriuresis, but its pathophysiology is complex and poorly understood.<xref rid="cen13991-bib-0005" ref-type="ref">5</xref> SIAD may arise from a variety of conditions, for example infections, central nervous system disorders, drugs, pain or stress and to an important number also by cancers.<xref rid="cen13991-bib-0070" ref-type="ref">70</xref> Other than implied by the originally introduced term &#x201C;syndrome of inappropriate antidiuretic hormone secretion (SIADH)&#x201D; by Schwartz and Bartter<xref rid="cen13991-bib-0071" ref-type="ref">71</xref> in 1957, this syndrome is not always linked to consistently elevated AVP release. In 1980, Zerbe et al<xref rid="cen13991-bib-0072" ref-type="ref">72</xref> first described four types of SIAD according to different osmoregulatory defects. While the first type is characterized by an autonomous, erratic hypersecretion of AVP, they described a preserved linear correlation between AVP and plasma osmolality, but a low osmotic threshold (reset osmostat) in the second type, a constant nonsuppressible AVP leak in the third and a hypovasopressinemic antidiuresis in the fourth type of SIAD patients. In the latter group, no abnormality in AVP secretion could be established and AVP levels were therefore suppressed in the hyponatraemic state, but yet, these patients were not able to dilute their urine.</p>
        <p>Later, in 2014 Fenske et al<xref rid="cen13991-bib-0073" ref-type="ref">73</xref> analysed serial measurement of copeptin during a hypertonic saline infusion test in SIAD patients. They confirmed the previously suggested subtypes and described a fifth type with linear decrease in copeptin concentrations with increasing plasma osmolality (&#x201C;barostat reset&#x201D;; Figure <xref rid="cen13991-fig-0006" ref-type="fig">6</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="cen13991-fig-0006" orientation="portrait" position="float">
          <label>Figure 6</label>
          <caption>
            <p>Plasma copeptin levels in different subtypes of SIAD (modified from Ref.<xref rid="cen13991-bib-0073" ref-type="ref">73</xref>) [Colour figure can be viewed at <ext-link ext-link-type="uri" xlink:href="http://www.wileyonlinelibrary.com">http://www.wileyonlinelibrary.com</ext-link>]</p>
          </caption>
          <graphic id="nlm-graphic-11" xlink:href="CEN-91-22-g006"/>
        </fig>
        <p>While Zerbe et al could not find an association of one of the osmoregulatory defects and a specific underlying illness, Fenske et al observed that the first type (&#x201C;subtype A&#x201D;) was primarily found in patients with lung cancer. The persistently high copeptin values (&gt;38&#xA0;pmol/L) in these patients may correspond to the long&#x2010;standing idea of autonomous extra&#x2010;hypothalamic paraneoplastic production of AVP (eg, in lung cancer tissue).<xref rid="cen13991-bib-0074" ref-type="ref">74</xref>, <xref rid="cen13991-bib-0075" ref-type="ref">75</xref>, <xref rid="cen13991-bib-0076" ref-type="ref">76</xref> Based on this observation, one can assume that copeptin might provide a good tool to detect underlying malignancies, which are present in up to a third of SIAD patients according to the Hyponatraemia Registry.<xref rid="cen13991-bib-0077" ref-type="ref">77</xref>
</p>
      </sec>
      <sec id="cen13991-sec-0018">
        <label>4.4</label>
        <title>Copeptin in cancer&#x2010;related SIAD</title>
        <p>Our group has recently evaluated data from 146 hospitalized patients with SIAD, of whom 39 were adjudicated to cancer&#x2010;related SIAD (unpublished data). Patients with cancer&#x2010;related SIAD were predominantly male and of younger age and had significantly higher plasma sodium and urine osmolality levels than patients with nonmalignant SIAD. Interestingly, copeptin levels were not higher in patients with cancer&#x2010;related vs cancer&#x2010;unrelated SIAD (unpublished data). Although patients with small cell lung cancer tended to have highest copeptin values compared to other cancer entities, copeptin values were not consistently elevated in this cancer subgroup and varied widely both in patient with cancer&#x2010;related and cancer&#x2010;unrelated SIAD. This can be explained by the fact that hyponatraemia in cancer patients may not only be caused by paraneoplastic AVP secretion, but by any other condition seen in noncancer patients: comorbidities, medication or symptoms as vomiting, nausea, dehydration or stress.<xref rid="cen13991-bib-0078" ref-type="ref">78</xref> Of note, irrespective of SIAD, copeptin is known to be elevated due to stress and acute conditions such a pneumonia,<xref rid="cen13991-bib-0079" ref-type="ref">79</xref> stroke<xref rid="cen13991-bib-0026" ref-type="ref">26</xref> or heart failure.<xref rid="cen13991-bib-0080" ref-type="ref">80</xref> The nonosmotic stress&#x2010;related copeptin stimulus in acute hospitalized hyponatraemic patients may, therefore, confound the osmotic or paraneoplastic impulse.<xref rid="cen13991-bib-0081" ref-type="ref">81</xref>, <xref rid="cen13991-bib-0082" ref-type="ref">82</xref>
</p>
      </sec>
      <sec id="cen13991-sec-0019">
        <label>4.5</label>
        <title>Nephrogenic syndrome of inappropriate antidiuresis</title>
        <p>Finally, the forth osmoregulatory SIAD subtype (&#x201C;subtype D&#x201D;)<xref rid="cen13991-bib-0072" ref-type="ref">72</xref>, <xref rid="cen13991-bib-0073" ref-type="ref">73</xref>&#x2014;characterized by low or undetectable AVP/copeptin values&#x2014;may be linked to the nephrogenic syndrome of inappropriate antidiuresis,<xref rid="cen13991-bib-0083" ref-type="ref">83</xref> although in the study of Fenske et al no gene alteration could be found in the respective patients. This rare syndrome is caused by x&#x2010;linked recessive gain of function variants in the AVPR2 gene, which encodes the vasopressin V2 receptor<xref rid="cen13991-bib-0084" ref-type="ref">84</xref> or as recently suggested also by a mutation in the GNAS gene.<xref rid="cen13991-bib-0085" ref-type="ref">85</xref> In affected male and female patients, the continuous activation of the vasopressin receptor leads to AVP&#x2010;independent antidiureses. Consecutively, AVP/copeptin levels are low or suppressed in these patients.<xref rid="cen13991-bib-0085" ref-type="ref">85</xref>, <xref rid="cen13991-bib-0086" ref-type="ref">86</xref>, <xref rid="cen13991-bib-0087" ref-type="ref">87</xref> Management of this disorder includes fluid restriction and avoidance of potential episodes of fluid overload.</p>
      </sec>
    </sec>
    <sec sec-type="conclusions" id="cen13991-sec-0020">
      <label>5</label>
      <title>CONCLUSIONS</title>
      <p>In conclusion, copeptin is a reliable surrogate parameter of AVP. In contrast to AVP, it is stable and can be measured easily with a sandwich immunoassay in serum or plasma. Copeptin is a promising new parameter clearly simplifying the differential diagnosis of polyuria&#x2010;polydipsia syndrome. Here, high baseline levels unequivocally indicate nephrogenic diabetes insipidus, and hypertonic saline&#x2010;stimulated copeptin levels differentiate between central diabetes insipidus and primary polydipsia with a high sensitivity and specificity. Consequently, hypertonic saline infusion plus copeptin measurement could replace the indirect water deprivation test in the routine evaluation of patients with hypotonic polyuria.</p>
      <p>In contrast, in SIAD, copeptin measurement is of only little diagnostic value. Copeptin levels widely overlap in patients with hyponatraemia and emphasize the heterogeneity of the disease. Additionally, a variety of factors leads to unspecific copeptin elevations in the acute setting further complicating its interpretation. The broad use of copeptin as diagnostic marker in hyponatraemia and specifically to detect cancer&#x2010;related disease in SIAD patients can, therefore, not be recommended. Nevertheless, extreme values point to a specific underlying pathophysiology: copeptin levels above 84&#xA0;pmol/L indicate hypovolaemic hyponatraemia and the need for fluid infusion while low levels &lt;3.9&#xA0;pmol/L are associated with primary polydipsia. Hyponatraemic patients presenting with undetectable copeptin levels and low free water clearance should be investigated for nephrogenic syndrome of inappropriate antidiuresis.</p>
    </sec>
    <sec sec-type="COI-statement" id="cen13991-sec-0021">
      <title>CONFLICT OF INTEREST</title>
      <p>All authors report no conflicts of interest.</p>
    </sec>
  </body>
  <back>
    <ref-list content-type="cited-references" id="cen13991-bibl-0001">
      <title>REFERENCES</title>
      <ref id="cen13991-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0001">
<string-name>
<surname>Verbalis</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Disorders of body water homeostasis</article-title>. <source xml:lang="en">Best Pract Res Clin Endocrinol Metab</source>. <year>2003</year>;<volume>17</volume>(<issue>4</issue>):<fpage>471</fpage>&#x2010;<lpage>503</lpage>.<pub-id pub-id-type="pmid">14687585</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0002">
<string-name>
<surname>Robertson</surname>
<given-names>GL</given-names>
</string-name>. <article-title>Diabetes insipidus</article-title>. <source xml:lang="en">Endocrinol Metab Clin North Am</source>. <year>1995</year>;<volume>24</volume>(<issue>3</issue>):<fpage>549</fpage>&#x2010;<lpage>572</lpage>.<pub-id pub-id-type="pmid">8575409</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0003">
<string-name>
<surname>Kumar</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Berl</surname>
<given-names>T</given-names>
</string-name>. <article-title>Sodium</article-title>. <source xml:lang="en">Lancet</source>. <year>1998</year>;<volume>352</volume>(<issue>9123</issue>):<fpage>220</fpage>&#x2010;<lpage>228</lpage>.<pub-id pub-id-type="pmid">9683227</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0004">
<string-name>
<surname>Upadhyay</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jaber</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Madias</surname>
<given-names>NE</given-names>
</string-name>. <article-title>Incidence and prevalence of hyponatremia</article-title>. <source xml:lang="en">Am J Med</source>. <year>2006</year>;<volume>119</volume>(<issue>7 Suppl 1</issue>):<fpage>S30</fpage>&#x2010;<lpage>S35</lpage>.<pub-id pub-id-type="pmid">16843082</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0005">
<string-name>
<surname>Bartter</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>
<given-names>WB</given-names>
</string-name>. <article-title>The syndrome of inappropriate secretion of antidiuretic hormone</article-title>. <source xml:lang="en">Am J Med</source>. <year>1967</year>;<volume>42</volume>(<issue>5</issue>):<fpage>790</fpage>&#x2010;<lpage>806</lpage>.<pub-id pub-id-type="pmid">5337379</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0006">
<string-name>
<surname>Miller</surname>
<given-names>M</given-names>
</string-name>. <article-title>Syndromes of excess antidiuretic hormone release</article-title>. <source xml:lang="en">Crit Care Clin</source>. <year>2001</year>;<volume>17</volume>(<issue>1</issue>):<fpage>11</fpage>&#x2010;<lpage>23</lpage>, v.<pub-id pub-id-type="pmid">11219224</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0007">
<string-name>
<surname>Kinzie</surname>
<given-names>BJ</given-names>
</string-name>. <article-title>Management of the syndrome of inappropriate secretion of antidiuretic hormone</article-title>. <source xml:lang="en">Clin Pharm</source>. <year>1987</year>;<volume>6</volume>(<issue>8</issue>):<fpage>625</fpage>&#x2010;<lpage>633</lpage>.<pub-id pub-id-type="pmid">3121240</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0008">
<string-name>
<surname>Kluge</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Riedl</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Erhart&#x2010;Hofmann</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hartmann</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Waldhauser</surname>
<given-names>F</given-names>
</string-name>. <article-title>Improved extraction procedure and RIA for determination of arginine8&#x2010;vasopressin in plasma: role of premeasurement sample treatment and reference values in children</article-title>. <source xml:lang="en">Clin Chem</source>. <year>1999</year>;<volume>45</volume>(<issue>1</issue>):<fpage>98</fpage>&#x2010;<lpage>103</lpage>.<pub-id pub-id-type="pmid">9895344</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0009">
<string-name>
<surname>Balanescu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kopp</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gaskill</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Schindler</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rutishauser</surname>
<given-names>J</given-names>
</string-name>. <article-title>Correlation of plasma copeptin and vasopressin concentrations in hypo&#x2010;, iso&#x2010;, and hyperosmolar States</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2011</year>;<volume>96</volume>(<issue>4</issue>):<fpage>1046</fpage>&#x2010;<lpage>1052</lpage>.<pub-id pub-id-type="pmid">21289257</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0010">
<string-name>
<surname>Holwerda</surname>
<given-names>DA</given-names>
</string-name>. <article-title>A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization</article-title>. <source xml:lang="en">Eur J Biochem</source>. <year>1972</year>;<volume>28</volume>(<issue>3</issue>):<fpage>334</fpage>&#x2010;<lpage>339</lpage>.<pub-id pub-id-type="pmid">5079944</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0011">
<string-name>
<surname>Levy</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Chauvet</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Chauvet</surname>
<given-names>J</given-names>
</string-name>., <string-name>
<surname>Acher</surname>
<given-names>R</given-names>
</string-name>. <article-title>Ontogeny of bovine neurohypophysial hormone precursors. II. Foetal copeptin, the third domain of the vasopressin precursor</article-title>. <source xml:lang="en">Int J Pept Protein Res</source>. <year>1986</year>;<volume>27</volume>(<issue>3</issue>):<fpage>320</fpage>&#x2010;<lpage>324</lpage>.<pub-id pub-id-type="pmid">3710692</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0012">
<string-name>
<surname>Land</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Schutz</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Schmale</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Richter</surname>
<given-names>D</given-names>
</string-name>. <article-title>Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin&#x2010;neurophysin II precursor</article-title>. <source xml:lang="en">Nature</source>. <year>1982</year>;<volume>295</volume>(<issue>5847</issue>):<fpage>299</fpage>&#x2010;<lpage>303</lpage>.<pub-id pub-id-type="pmid">6276766</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0013">
<string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Struck</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Alonso</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bergmann</surname>
<given-names>A</given-names>
</string-name>. <article-title>Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin</article-title>. <source xml:lang="en">Clin Chem</source>. <year>2006</year>;<volume>52</volume>(<issue>1</issue>):<fpage>112</fpage>&#x2010;<lpage>119</lpage>.<pub-id pub-id-type="pmid">16269513</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0014">
<string-name>
<surname>Nathanson</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Moyer</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Burgstahler</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>O'Carroll</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Brownstein</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Lolait</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>Mechanisms of subcellular cytosolic Ca2+ signaling evoked by stimulation of the vasopressin V1a receptor</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>1992</year>;<volume>267</volume>(<issue>32</issue>):<fpage>23282</fpage>&#x2010;<lpage>23289</lpage>.<pub-id pub-id-type="pmid">1429675</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0015">
<string-name>
<surname>Baylis</surname>
<given-names>PH</given-names>
</string-name>. <article-title>Osmoregulation and control of vasopressin secretion in healthy humans</article-title>. <source xml:lang="en">Am J Physiol</source>. <year>1987</year>;<volume>253</volume>(<issue>5 Pt 2</issue>):<fpage>R671</fpage>&#x2010;<lpage>R678</lpage>.<pub-id pub-id-type="pmid">3318505</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0016">
<string-name>
<surname>Nagy</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mulchahey</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Smyth</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Neill</surname>
<given-names>JD</given-names>
</string-name>. <article-title>The glycopeptide moiety of vasopressin&#x2010;neurophysin precursor is neurohypophysial prolactin releasing factor</article-title>. <source xml:lang="en">Biochem Biophys Res Comm</source>. <year>1988</year>;<volume>151</volume>(<issue>1</issue>):<fpage>524</fpage>&#x2010;<lpage>529</lpage>.<pub-id pub-id-type="pmid">3126738</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0017">
<string-name>
<surname>Hyde</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>North</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Ben&#x2010;Jonathan</surname>
<given-names>N</given-names>
</string-name>. <article-title>The vasopressin&#x2010;associated glycopeptide is not a prolactin&#x2010;releasing factor: studies with lactating Brattleboro rats</article-title>. <source xml:lang="en">Endocrinology</source>. <year>1989</year>;<volume>125</volume>(<issue>1</issue>):<fpage>35</fpage>&#x2010;<lpage>40</lpage>.<pub-id pub-id-type="pmid">2500328</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0018">
<string-name>
<surname>Barat</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Breslow</surname>
<given-names>E</given-names>
</string-name>. <article-title>Properties of human vasopressin precursor constructs: inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus</article-title>. <source xml:lang="en">Biochemistry</source>. <year>2004</year>;<volume>43</volume>(<issue>25</issue>):<fpage>8191</fpage>&#x2010;<lpage>8203</lpage>.<pub-id pub-id-type="pmid">15209516</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0019">
<string-name>
<surname>Parodi</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Protein glucosylation and its role in protein folding</article-title>. <source xml:lang="en">Annu Rev Biochem</source>. <year>2000</year>;<volume>69</volume>:<fpage>69</fpage>&#x2010;<lpage>93</lpage>.<pub-id pub-id-type="pmid">10966453</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0020">
<string-name>
<surname>Birk</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Friberg</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Prescianotto&#x2010;Baschong</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Spiess</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rutishauser</surname>
<given-names>J</given-names>
</string-name>. <article-title>Dominant pro&#x2010;vasopressin mutants that cause diabetes insipidus form disulfide&#x2010;linked fibrillar aggregates in the endoplasmic reticulum</article-title>. <source xml:lang="en">J Cell Sci</source>. <year>2009</year>;<volume>122</volume>(<issue>Pt 21</issue>):<fpage>3994</fpage>&#x2010;<lpage>4002</lpage>.<pub-id pub-id-type="pmid">19825939</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0021">
<string-name>
<surname>Roussel</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Fezeu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Marre</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2014</year>;<volume>99</volume>(<issue>12</issue>):<fpage>4656</fpage>&#x2010;<lpage>4663</lpage>.<pub-id pub-id-type="pmid">25202818</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0022">
<string-name>
<surname>Robertson</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Shelton</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Athar</surname>
<given-names>S</given-names>
</string-name>. <article-title>The osmoregulation of vasopressin</article-title>. <source xml:lang="en">Kidney Int</source>. <year>1976</year>;<volume>10</volume>(<issue>1</issue>):<fpage>25</fpage>&#x2010;<lpage>37</lpage>.<pub-id pub-id-type="pmid">181630</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0023">
<string-name>
<surname>Fenske</surname>
<given-names>WK</given-names>
</string-name>, <string-name>
<surname>Schnyder</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Release and decay kinetics of copeptin vs AVP in response to osmotic alterations in healthy volunteers</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2018</year>;<volume>103</volume>(<issue>2</issue>):<fpage>505</fpage>&#x2010;<lpage>513</lpage>.<pub-id pub-id-type="pmid">29267966</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0024">
<string-name>
<surname>Szinnai</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Berneis</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Changes in plasma copeptin, the c&#x2010;terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2007</year>;<volume>92</volume>(<issue>10</issue>):<fpage>3973</fpage>&#x2010;<lpage>3978</lpage>.<pub-id pub-id-type="pmid">17635944</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0025">
<string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Struck</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bergmann</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Redl</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Christ&#x2010;Crain</surname>
<given-names>M</given-names>
</string-name>. <article-title>Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock</article-title>. <source xml:lang="en">Shock</source>. <year>2007</year>;<volume>28</volume>(<issue>2</issue>):<fpage>219</fpage>&#x2010;<lpage>226</lpage>.<pub-id pub-id-type="pmid">17515850</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0026">
<string-name>
<surname>Katan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fluri</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, et al. <article-title>Copeptin: a novel, independent prognostic marker in patients with ischemic stroke</article-title>. <source xml:lang="en">Ann Neurol</source>. <year>2009</year>;<volume>66</volume>(<issue>6</issue>):<fpage>799</fpage>&#x2010;<lpage>808</lpage>.<pub-id pub-id-type="pmid">20035506</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0027">
<string-name>
<surname>Reichlin</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hochholzer</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Stelzig</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Incremental value of copeptin for rapid rule out of acute myocardial infarction</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2009</year>;<volume>54</volume>(<issue>1</issue>):<fpage>60</fpage>&#x2010;<lpage>68</lpage>.<pub-id pub-id-type="pmid">19555842</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0028">
<string-name>
<surname>Katan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Christ&#x2010;Crain</surname>
<given-names>M</given-names>
</string-name>. <article-title>The stress hormone copeptin: a new prognostic biomarker in acute illness</article-title>. <source xml:lang="en">Swiss Med Wkly</source>. <year>2010</year>;<volume>140</volume>:<fpage>w13101</fpage>.<pub-id pub-id-type="pmid">20872295</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0029">
<string-name>
<surname>Siegenthaler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Walti</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Urwyler</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Schuetz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Christ&#x2010;Crain</surname>
<given-names>M</given-names>
</string-name>. <article-title>Copeptin concentrations during psychological stress: the PsyCo study</article-title>. <source xml:lang="en">Eur J Endocrinol</source>. <year>2014</year>;<volume>171</volume>(<issue>6</issue>):<fpage>737</fpage>&#x2010;<lpage>742</lpage>.<pub-id pub-id-type="pmid">25249697</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0030">
<string-name>
<surname>Urwyler</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Schuetz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sailer</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Christ&#x2010;Crain</surname>
<given-names>M</given-names>
</string-name>. <article-title>Copeptin as a stress marker prior and after a written examination &#x2013; the CoEXAM study</article-title>. <source xml:lang="en">Stress</source>. <year>2015</year>;<volume>18</volume>(<issue>1</issue>):<fpage>134</fpage>&#x2010;<lpage>137</lpage>.<pub-id pub-id-type="pmid">25472823</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0031">
<string-name>
<surname>Maeder</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Staub</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Brutsche</surname>
<given-names>MH</given-names>
</string-name>, et al. <article-title>Copeptin response to clinical maximal exercise tests</article-title>. <source xml:lang="en">Clin Chem</source>. <year>2010</year>;<volume>56</volume>(<issue>4</issue>):<fpage>674</fpage>&#x2010;<lpage>676</lpage>.<pub-id pub-id-type="pmid">20110449</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0032">
<string-name>
<surname>Hew&#x2010;Butler</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hoffman</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Stuempfle</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Rogers</surname>
<given-names>IR</given-names>
</string-name>, <string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Verbalis</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Changes in copeptin and bioactive vasopressin in runners with and without hyponatremia</article-title>. <source xml:lang="en">Clin J Sport Med</source>. <year>2011</year>;<volume>21</volume>(<issue>3</issue>):<fpage>211</fpage>&#x2010;<lpage>217</lpage>.<pub-id pub-id-type="pmid">21519298</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0033">
        <label>33</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0033">
<string-name>
<surname>Bhandari</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Loke</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Squire</surname>
<given-names>IB</given-names>
</string-name>, <string-name>
<surname>Struck</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ng</surname>
<given-names>LL</given-names>
</string-name>. <article-title>Gender and renal function influence plasma levels of copeptin in healthy individuals</article-title>. <source xml:lang="en">Clin Sci (Lond)</source>. <year>2009</year>;<volume>116</volume>(<issue>3</issue>):<fpage>257</fpage>&#x2010;<lpage>263</lpage>.<pub-id pub-id-type="pmid">18647134</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0034">
        <label>34</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0034">
<string-name>
<surname>Puder</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Blum</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Mueller</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>De Geyter</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dye</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Keller</surname>
<given-names>U</given-names>
</string-name>. <article-title>Menstrual cycle symptoms are associated with changes in low&#x2010;grade inflammation</article-title>. <source xml:lang="en">Eur J Clin Invest</source>. <year>2006</year>;<volume>36</volume>(<issue>1</issue>):<fpage>58</fpage>&#x2010;<lpage>64</lpage>.<pub-id pub-id-type="pmid">16403011</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0035">
        <label>35</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0035">
<string-name>
<surname>Darzy</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Dixit</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Shalet</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Brabant</surname>
<given-names>G</given-names>
</string-name>. <article-title>Circadian secretion pattern of copeptin, the C&#x2010;terminal vasopressin precursor fragment</article-title>. <source xml:lang="en">Clin Chem</source>. <year>2010</year>;<volume>56</volume>(<issue>7</issue>):<fpage>1190</fpage>&#x2010;<lpage>1191</lpage>.<pub-id pub-id-type="pmid">20413431</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0036">
        <label>36</label>
        <mixed-citation publication-type="miscellaneous" id="cen13991-cit-0036">
<string-name>
<surname>Beglinger</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Drewe</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Christ&#x2010;Crain</surname>
<given-names>M</given-names>
</string-name>.<article-title>The circadian rhythm of Copeptin, the C&#x2010;terminal portion of Arginin Vasopressin</article-title>. Poster Presentation, SGED Congress Nov 17&#x2013;18, 2016, Bern, Switzerland. 2016.</mixed-citation>
      </ref>
      <ref id="cen13991-bib-0037">
        <label>37</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0037">
<string-name>
<surname>Walti</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Siegenthaler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Christ&#x2010;Crain</surname>
<given-names>M</given-names>
</string-name>. <article-title>Copeptin levels are independent of ingested nutrient type after standardised meal administration&#x2013;the CoMEAL study</article-title>. <source xml:lang="en">Biomarkers</source>. <year>2014</year>;<volume>19</volume>(<issue>7</issue>):<fpage>557</fpage>&#x2010;<lpage>562</lpage>.<pub-id pub-id-type="pmid">25224842</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0038">
        <label>38</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0038">
<string-name>
<surname>Christ&#x2010;Crain</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fenske</surname>
<given-names>W</given-names>
</string-name>. <article-title>Copeptin in the diagnosis of vasopressin&#x2010;dependent disorders of fluid homeostasis</article-title>. <source xml:lang="en">Nat Rev Endocrinol</source>. <year>2016</year>;<volume>12</volume>(<issue>3</issue>):<fpage>168</fpage>&#x2010;<lpage>176</lpage>.<pub-id pub-id-type="pmid">26794439</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0039">
        <label>39</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0039">
<string-name>
<surname>Robertson</surname>
<given-names>GL</given-names>
</string-name>. <article-title>The regulation of vasopressin function in health and disease</article-title>. <source xml:lang="en">Recent Prog Horm Res</source>. <year>1976</year>;<volume>33</volume>:<fpage>333</fpage>&#x2010;<lpage>385</lpage>.<pub-id pub-id-type="pmid">801194</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0040">
        <label>40</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0040">
<string-name>
<surname>Miller</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dalakos</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Moses</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Fellerman</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Streeten</surname>
<given-names>DH</given-names>
</string-name>. <article-title>Recognition of partial defects in antidiuretic hormone secretion</article-title>. <source xml:lang="en">Ann Intern Med</source>. <year>1970</year>;<volume>73</volume>(<issue>5</issue>):<fpage>721</fpage>&#x2010;<lpage>729</lpage>.<pub-id pub-id-type="pmid">5476203</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0041">
        <label>41</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0041">
<string-name>
<surname>Bockenhauer</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bichet</surname>
<given-names>DG</given-names>
</string-name>. <article-title>Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus</article-title>. <source xml:lang="en">Nat Rev Nephrol</source>. <year>2015</year>;<volume>11</volume>(<issue>10</issue>):<fpage>576</fpage>&#x2010;<lpage>588</lpage>.<pub-id pub-id-type="pmid">26077742</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0042">
        <label>42</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0042">
<string-name>
<surname>Robertson</surname>
<given-names>GL</given-names>
</string-name>. <article-title>Differential diagnosis of polyuria</article-title>. <source xml:lang="en">Annu Rev Med</source>. <year>1988</year>;<volume>39</volume>:<fpage>425</fpage>&#x2010;<lpage>442</lpage>.<pub-id pub-id-type="pmid">3285784</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0043">
        <label>43</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0043">
<string-name>
<surname>Babey</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kopp</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>GL</given-names>
</string-name>. <article-title>Familial forms of diabetes insipidus: clinical and molecular characteristics</article-title>. <source xml:lang="en">Nat Rev Endocrinol</source>. <year>2011</year>;<volume>7</volume>(<issue>12</issue>):<fpage>701</fpage>&#x2010;<lpage>714</lpage>.<pub-id pub-id-type="pmid">21727914</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0044">
        <label>44</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0044">
<string-name>
<surname>Thompson</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Baylis</surname>
<given-names>PH</given-names>
</string-name>. <article-title>Thirst in diabetes insipidus: clinical relevance of quantitative assessment</article-title>. <source xml:lang="en">Q J Med</source>. <year>1987</year>;<volume>65</volume>(<issue>246</issue>):<fpage>853</fpage>&#x2010;<lpage>862</lpage>.<pub-id pub-id-type="pmid">3449889</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0045">
        <label>45</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0045">
<string-name>
<surname>Sailer</surname>
<given-names>CO</given-names>
</string-name>, <string-name>
<surname>Winzeler</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Nigro</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Characteristics and outcomes of patients with profound hyponatraemia due to primary polydipsia</article-title>. <source xml:lang="en">Clin Endocrinol (Oxf)</source>. <year>2017</year>;<volume>87</volume>(<issue>5</issue>):<fpage>492</fpage>&#x2010;<lpage>499</lpage>.<pub-id pub-id-type="pmid">28556237</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0046">
        <label>46</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0046">
<string-name>
<surname>Fenske</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Refardt</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Chifu</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>A copeptin&#x2010;based approach in the diagnosis of diabetes insipidus</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2018</year>;<volume>379</volume>(<issue>5</issue>):<fpage>428</fpage>&#x2010;<lpage>439</lpage>.<pub-id pub-id-type="pmid">30067922</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0047">
        <label>47</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0047">
<string-name>
<surname>Epstein</surname>
<given-names>FH</given-names>
</string-name>, <string-name>
<surname>Kleeman</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Hendrikx</surname>
<given-names>A</given-names>
</string-name>. <article-title>The influence of bodily hydration on the renal concentrating process</article-title>. <source xml:lang="en">J Clin Invest</source>. <year>1957</year>;<volume>36</volume>(<issue>5</issue>):<fpage>629</fpage>&#x2010;<lpage>634</lpage>.<pub-id pub-id-type="pmid">13428850</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0048">
        <label>48</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0048">
<string-name>
<surname>Fenske</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Allolio</surname>
<given-names>B</given-names>
</string-name>. <article-title>Clinical review: current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2012</year>;<volume>97</volume>(<issue>10</issue>):<fpage>3426</fpage>&#x2010;<lpage>3437</lpage>.<pub-id pub-id-type="pmid">22855338</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0049">
        <label>49</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0049">
<string-name>
<surname>Carter</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Robbins</surname>
<given-names>J</given-names>
</string-name>. <article-title>The use of hypertonic saline infusions in the differential diagnosis of diabetes insipidus and psychogenic polydipsia</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>1947</year>;<volume>7</volume>(<issue>11</issue>):<fpage>753</fpage>&#x2010;<lpage>766</lpage>.<pub-id pub-id-type="pmid">20272266</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0050">
        <label>50</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0050">
<string-name>
<surname>Fenske</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Quinkler</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lorenz</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Copeptin in the differential diagnosis of the polydipsia&#x2010;polyuria syndrome&#x2013;revisiting the direct and indirect water deprivation tests</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2011</year>;<volume>96</volume>(<issue>5</issue>):<fpage>1506</fpage>&#x2010;<lpage>1515</lpage>.<pub-id pub-id-type="pmid">21367924</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0051">
        <label>51</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0051">
<string-name>
<surname>Zerbe</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>GL</given-names>
</string-name>. <article-title>A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>1981</year>;<volume>305</volume>(<issue>26</issue>):<fpage>1539</fpage>&#x2010;<lpage>1546</lpage>.<pub-id pub-id-type="pmid">7311993</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0052">
        <label>52</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0052">
<string-name>
<surname>Milles</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Spruce</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Baylis</surname>
<given-names>PH</given-names>
</string-name>. <article-title>A comparison of diagnostic methods to differentiate diabetes insipidus from primary polyuria: a review of 21 patients</article-title>. <source xml:lang="en">Acta Endocrinol (Copenh)</source>. <year>1983</year>;<volume>104</volume>(<issue>4</issue>):<fpage>410</fpage>&#x2010;<lpage>416</lpage>.<pub-id pub-id-type="pmid">6659843</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0053">
        <label>53</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0053">
<string-name>
<surname>Fenske</surname>
<given-names>WK</given-names>
</string-name>, <string-name>
<surname>Schnyder</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Release and decay kinetics of copeptin versus AVP in response to osmotic alterations in healthy volunteers</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2018</year>;<volume>103</volume>(<issue>2</issue>):<fpage>505</fpage>&#x2010;<lpage>513</lpage>.<pub-id pub-id-type="pmid">29267966</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0054">
        <label>54</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0054">
<string-name>
<surname>Timper</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fenske</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Kuhn</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria&#x2010;polydipsia syndrome: a prospective multicenter study</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2015</year>;<volume>100</volume>(<issue>6</issue>):<fpage>2268</fpage>&#x2010;<lpage>2274</lpage>.<pub-id pub-id-type="pmid">25768671</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0055">
        <label>55</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0055">
<string-name>
<surname>Rosen</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Ingelfinger</surname>
<given-names>JR</given-names>
</string-name>. <article-title>A reliable diagnostic test for hypotonic polyuria</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2018</year>;<volume>379</volume>(<issue>5</issue>):<fpage>483</fpage>&#x2010;<lpage>484</lpage>.<pub-id pub-id-type="pmid">30067935</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0056">
        <label>56</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0056">
<string-name>
<surname>Katan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Dixit</surname>
<given-names>KC</given-names>
</string-name>, et al. <article-title>Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2007</year>;<volume>92</volume>(<issue>7</issue>):<fpage>2640</fpage>&#x2010;<lpage>2643</lpage>.<pub-id pub-id-type="pmid">17426098</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0057">
        <label>57</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0057">
<string-name>
<surname>Widmer</surname>
<given-names>IE</given-names>
</string-name>, <string-name>
<surname>Puder</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Konig</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Cortisol response in relation to the severity of stress and illness</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2005</year>;<volume>90</volume>(<issue>8</issue>):<fpage>4579</fpage>&#x2010;<lpage>4586</lpage>.<pub-id pub-id-type="pmid">15886236</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0058">
        <label>58</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0058">
<string-name>
<surname>Upadhyay</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jaber</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Madias</surname>
<given-names>NE</given-names>
</string-name>. <article-title>Epidemiology of hyponatremia</article-title>. <source xml:lang="en">Semin Nephrol</source>. <year>2009</year>;<volume>29</volume>(<issue>3</issue>):<fpage>227</fpage>&#x2010;<lpage>238</lpage>.<pub-id pub-id-type="pmid">19523571</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0059">
        <label>59</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0059">
<string-name>
<surname>Waikar</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Mount</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Curhan</surname>
<given-names>GC</given-names>
</string-name>. <article-title>Mortality after hospitalization with mild, moderate, and severe hyponatremia</article-title>. <source xml:lang="en">Am J Med</source>. <year>2009</year>;<volume>122</volume>(<issue>9</issue>):<fpage>857</fpage>&#x2010;<lpage>865</lpage>.<pub-id pub-id-type="pmid">19699382</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0060">
        <label>60</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0060">
<string-name>
<surname>Winzeler</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Jeanloz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nigro</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Long&#x2010;term outcome of profound hyponatremia: a prospective 12 months follow&#x2010;up study</article-title>. <source xml:lang="en">Eur J Endocrinol</source>. <year>2016</year>;<volume>175</volume>(<issue>6</issue>):<fpage>499</fpage>&#x2010;<lpage>507</lpage>.<pub-id pub-id-type="pmid">27585594</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0061">
        <label>61</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0061">
<string-name>
<surname>Holland&#x2010;Bill</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Christiansen</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Heide&#x2010;Jorgensen</surname>
<given-names>U</given-names>
</string-name>, et al. <article-title>Hyponatremia and mortality risk: a Danish cohort study of 279 508 acutely hospitalized patients</article-title>. <source xml:lang="en">Eur J Endocrinol</source>. <year>2015</year>;<volume>173</volume>(<issue>1</issue>):<fpage>71</fpage>&#x2010;<lpage>81</lpage>.<pub-id pub-id-type="pmid">26036812</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0062">
        <label>62</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0062">
<string-name>
<surname>Spasovski</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Vanholder</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Allolio</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Clinical practice guideline on diagnosis and treatment of hyponatraemia</article-title>. <source xml:lang="en">Eur J Endocrinol</source>. <year>2014</year>;<volume>170</volume>(<issue>3</issue>):<fpage>G1</fpage>&#x2010;<lpage>G47</lpage>.<pub-id pub-id-type="pmid">24569125</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0063">
        <label>63</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0063">
<string-name>
<surname>Ellison</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Berl</surname>
<given-names>T</given-names>
</string-name>. <article-title>Clinical practice. The syndrome of inappropriate antidiuresis</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2007</year>;<volume>356</volume>(<issue>20</issue>):<fpage>2064</fpage>&#x2010;<lpage>2072</lpage>.<pub-id pub-id-type="pmid">17507705</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0064">
        <label>64</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0064">
<string-name>
<surname>Verbalis</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Goldsmith</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Greenberg</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations</article-title>. <source xml:lang="en">Am J Med</source>. <year>2013</year>;<volume>126</volume>(<issue>10 Suppl 1</issue>):<fpage>S1</fpage>&#x2010;<lpage>S42</lpage>.</mixed-citation>
      </ref>
      <ref id="cen13991-bib-0065">
        <label>65</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0065">
<string-name>
<surname>Chung</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Kluge</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schrier</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Clinical assessment of extracellular fluid volume in hyponatremia</article-title>. <source xml:lang="en">Am J Med</source>. <year>1987</year>;<volume>83</volume>(<issue>5</issue>):<fpage>905</fpage>&#x2010;<lpage>908</lpage>.<pub-id pub-id-type="pmid">3674097</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0066">
        <label>66</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0066">
<string-name>
<surname>Fenske</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Maier</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Blechschmidt</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Allolio</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>St&#xF6;rk</surname>
<given-names>S</given-names>
</string-name>. <article-title>Utility and limitations of the traditional diagnostic approach to hyponatremia: a diagnostic study</article-title>. <source xml:lang="en">Am J Med</source>. <year>2010</year>;<volume>123</volume>(<issue>7</issue>):<fpage>652</fpage>&#x2010;<lpage>657</lpage>.<pub-id pub-id-type="pmid">20609688</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0067">
        <label>67</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0067">
<string-name>
<surname>Boursier</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Alm&#xE9;ras</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Buthiau</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>CT&#x2010;pro&#x2010;AVP as a tool for assessment of intravascular volume depletion in severe hyponatremia</article-title>. <source xml:lang="en">Clin Biochem</source>. <year>2015</year>;<volume>48</volume>(<issue>10&#x2010;11</issue>):<fpage>640</fpage>&#x2010;<lpage>645</lpage>.<pub-id pub-id-type="pmid">25828045</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0068">
        <label>68</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0068">
<string-name>
<surname>Fenske</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>St&#xF6;rk</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Blechschmidt</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Maier</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Allolio</surname>
<given-names>B</given-names>
</string-name>. <article-title>Copeptin in the differential diagnosis of hyponatremia</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2009</year>;<volume>94</volume>(<issue>1</issue>):<fpage>123</fpage>&#x2010;<lpage>129</lpage>.<pub-id pub-id-type="pmid">18984663</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0069">
        <label>69</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0069">
<string-name>
<surname>Nigro</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Winzeler</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Suter&#x2010;Widmer</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: 'The Co&#x2010;MED Study'</article-title>. <source xml:lang="en">Clin Endocrinol (Oxf)</source>. <year>2017</year>;<volume>86</volume>(<issue>3</issue>):<fpage>456</fpage>&#x2010;<lpage>462</lpage>.<pub-id pub-id-type="pmid">27658031</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0070">
        <label>70</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0070">
<string-name>
<surname>Verbalis</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Greenberg</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Burst</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Diagnosing and treating the syndrome of inappropriate antidiuretic hormone secretion</article-title>. <source xml:lang="en">Am J Med</source>. <year>2016</year>;<volume>129</volume>(<issue>5</issue>):<fpage>537</fpage>.e9&#x2010;537.e23.</mixed-citation>
      </ref>
      <ref id="cen13991-bib-0071">
        <label>71</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0071">
<string-name>
<surname>Schwartz</surname>
<given-names>WB</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Curelop</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bartter</surname>
<given-names>FC</given-names>
</string-name>. <article-title>A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone</article-title>. <source xml:lang="en">Am J Med</source>. <year>1957</year>;<volume>23</volume>(<issue>4</issue>):<fpage>529</fpage>&#x2010;<lpage>542</lpage>.<pub-id pub-id-type="pmid">13469824</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0072">
        <label>72</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0072">
<string-name>
<surname>Zerbe</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Stropes</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>G</given-names>
</string-name>. <article-title>Vasopressin function in the syndrome of inappropriate antidiuresis</article-title>. <source xml:lang="en">Annu Rev Med</source>. <year>1980</year>;<volume>31</volume>:<fpage>315</fpage>&#x2010;<lpage>327</lpage>.<pub-id pub-id-type="pmid">6772090</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0073">
        <label>73</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0073">
<string-name>
<surname>Fenske</surname>
<given-names>WK</given-names>
</string-name>, <string-name>
<surname>Christ&#x2010;Crain</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Horning</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>A copeptin&#x2010;based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis</article-title>. <source xml:lang="en">J Am Soc Nephrol</source>. <year>2014</year>;<volume>25</volume>(<issue>10</issue>):<fpage>2376</fpage>&#x2010;<lpage>2383</lpage>.<pub-id pub-id-type="pmid">24722436</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0074">
        <label>74</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0074">
<string-name>
<surname>Hirata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Matsukura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Imura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yakura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ihjima</surname>
<given-names>S</given-names>
</string-name>. <article-title>Two cases of multiple hormone&#x2010;producing small cell carcinoma of the lung: coexistence of tumor ADH, ACTH, and beta&#x2010;MSH</article-title>. <source xml:lang="en">Cancer</source>. <year>1976</year>;<volume>38</volume>(<issue>6</issue>):<fpage>2575</fpage>&#x2010;<lpage>2582</lpage>.<pub-id pub-id-type="pmid">187319</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0075">
        <label>75</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0075">
<string-name>
<surname>List</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Hainsworth</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>BW</given-names>
</string-name>, <string-name>
<surname>Hande</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Greco</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>DH</given-names>
</string-name>. <article-title>The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small&#x2010;cell lung cancer</article-title>. <source xml:lang="en">J Clin Oncol</source>. <year>1986</year>;<volume>4</volume>(<issue>8</issue>):<fpage>1191</fpage>&#x2010;<lpage>1198</lpage>.<pub-id pub-id-type="pmid">3016206</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0076">
        <label>76</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0076">
<string-name>
<surname>S&#xF8;rensen</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Hansen</surname>
<given-names>HH</given-names>
</string-name>. <article-title>Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease</article-title>. <source xml:lang="en">J Intern Med</source>. <year>1995</year>;<volume>238</volume>(<issue>2</issue>):<fpage>97</fpage>&#x2010;<lpage>110</lpage>.<pub-id pub-id-type="pmid">7629492</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0077">
        <label>77</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0077">
<string-name>
<surname>Burst</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Grundmann</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kubacki</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study</article-title>. <source xml:lang="en">Support Care Cancer</source>. <year>2017</year>;<volume>25</volume>(<issue>7</issue>):<fpage>2275</fpage>&#x2010;<lpage>2283</lpage>.<pub-id pub-id-type="pmid">28255808</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0078">
        <label>78</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0078">
<string-name>
<surname>Fiordoliva</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Meletani</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Baleani</surname>
<given-names>MG</given-names>
</string-name>, et al. <article-title>Managing hyponatremia in lung cancer: latest evidence and clinical implications</article-title>. <source xml:lang="en">Ther Adv Med Oncol</source>. <year>2017</year>;<volume>9</volume>(<issue>11</issue>):<fpage>711</fpage>&#x2010;<lpage>719</lpage>.<pub-id pub-id-type="pmid">29344107</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0079">
        <label>79</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0079">
<string-name>
<surname>Schuetz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wolbers</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Christ&#x2010;Crain</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Prohormones for prediction of adverse medical outcome in community&#x2010;acquired pneumonia and lower respiratory tract infections</article-title>. <source xml:lang="en">Crit Care</source>. <year>2010</year>;<volume>14</volume>(<issue>3</issue>):<fpage>R106</fpage>.<pub-id pub-id-type="pmid">20529344</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0080">
        <label>80</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0080">
<string-name>
<surname>Schurtz</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lamblin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bauters</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lemesle</surname>
<given-names>G</given-names>
</string-name>. <article-title>Copeptin in acute coronary syndromes and heart failure management: state of the art and future directions</article-title>. <source xml:lang="en">Arch Cardiovasc Dis</source>. <year>2015</year>;<volume>108</volume>(<issue>6&#x2010;7</issue>):<fpage>398</fpage>&#x2010;<lpage>407</lpage>.<pub-id pub-id-type="pmid">26071835</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0081">
        <label>81</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0081">
<string-name>
<surname>Nigro</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>M&#xFC;ller</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Morgenthaler</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseases</article-title>. <source xml:lang="en">Swiss Med Wkly</source>. <year>2011</year>;<volume>141</volume>:<fpage>w13270</fpage>.<pub-id pub-id-type="pmid">21990032</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0082">
        <label>82</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0082">
<string-name>
<surname>Jochberger</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Morgenthaler</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Mayr</surname>
<given-names>VD</given-names>
</string-name>, et al. <article-title>Copeptin and arginine vasopressin concentrations in critically ill patients</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2006</year>;<volume>91</volume>(<issue>11</issue>):<fpage>4381</fpage>&#x2010;<lpage>4386</lpage>.<pub-id pub-id-type="pmid">16940457</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0083">
        <label>83</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0083">
<string-name>
<surname>Feldman</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Rosenthal</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Vargas</surname>
<given-names>GA</given-names>
</string-name>, et al. <article-title>Nephrogenic syndrome of inappropriate antidiuresis</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2005</year>;<volume>352</volume>(<issue>18</issue>):<fpage>1884</fpage>&#x2010;<lpage>1890</lpage>.<pub-id pub-id-type="pmid">15872203</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0084">
        <label>84</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0084">
<string-name>
<surname>Decaux</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Vandergheynst</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Bouko</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Parma</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Vassart</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Vilain</surname>
<given-names>C</given-names>
</string-name>. <article-title>Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree</article-title>. <source xml:lang="en">J Am Soc Nephrol</source>. <year>2007</year>;<volume>18</volume>(<issue>2</issue>):<fpage>606</fpage>&#x2010;<lpage>612</lpage>.<pub-id pub-id-type="pmid">17229917</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0085">
        <label>85</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0085">
<string-name>
<surname>Biebermann</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kleinau</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Schnabel</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>A new multisystem disorder caused by the g&#x3B1;s mutation p.F376V</article-title>. <source xml:lang="en">J Clin Endocrinol Metab</source>. <year>2019</year>;<volume>104</volume>(<issue>4</issue>):<fpage>1079</fpage>&#x2010;<lpage>1089</lpage>.<pub-id pub-id-type="pmid">30312418</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0086">
        <label>86</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0086">
<string-name>
<surname>Powlson</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Challis</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Halsall</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Schoenmakers</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gurnell</surname>
<given-names>M</given-names>
</string-name>. <article-title>Nephrogenic syndrome of inappropriate antidiuresis secondary to an activating mutation in the arginine vasopressin receptor AVPR2</article-title>. <source xml:lang="en">Clin Endocrinol (Oxf)</source>. <year>2016</year>;<volume>85</volume>(<issue>2</issue>):<fpage>306</fpage>&#x2010;<lpage>312</lpage>.<pub-id pub-id-type="pmid">26715131</pub-id></mixed-citation>
      </ref>
      <ref id="cen13991-bib-0087">
        <label>87</label>
        <mixed-citation publication-type="journal" id="cen13991-cit-0087">
<string-name>
<surname>Hague</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Casey</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bruty</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Adult female with symptomatic AVPR2&#x2010;related nephrogenic syndrome of inappropriate antidiuresis (NSIAD)</article-title>. <source xml:lang="en">Endocrinol Diabetes Metab Case Rep</source>. <year>2018</year>;<volume>2018</volume>: 17-0139. <pub-id pub-id-type="doi">10.1530/EDM-17-0139</pub-id>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
